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RESUMO 
 
A anemia é uma complicação comum da doença renal crónica (DRC), cuja principal 
causa é a produção insuficiente de eritropoietina (EPO) pelos rins. A introdução dos 
agentes estimuladores da eritropoiese (AEE) revolucionou o tratamento da anemia da 
DRC; porém, alguns doentes não respondem adequadamente a esta terapia, necessitando 
de doses mais altas para atingir os níveis alvo de hemoglobina. Vários ensaios clínicos 
evidenciaram um aumento de eventos cardiovasculares e de mortalidade em doentes 
tratados com AEE, particularmente nos não respondedores, permanecendo por esclarecer 
as causas e os mecanismos subjacentes. Vários efeitos pleiotrópicos, para além da correção 
da anemia, têm sido atribuídos à EPO e aos AEE, tais como renoproteção e propriedades 
anti-inflamatórias; contudo, para obter estes efeitos são necessárias doses mais elevadas, 
cujos riscos-benefícios não foram ainda suficientemente estudados e definidos. 
O nosso trabalho teve como objectivos i) estudar o desenvolvimento da anemia, a 
função e lesão renal, a pressão arterial, o metabolismo do ferro e a relação entre as 
diferentes alterações, usando como modelo animal de insuficiência renal crónica (IRC) o 
rato, submetido a nefrectomia cirúrgica de 5/6; ii) avaliar o impacto da terapêutica com 
eritropoietina humana recombinante (rHuEPO), tratando os animais com IRC, durante 3 
semanas, com doses usadas para corrigir a anemia nos doentes com DRC (100 e 200 
UI/peso (Kg)/semana), e com doses mais altas (400 e 600 UI/peso (Kg)/semana), usadas 
no tratamento de doentes não respondedores; iii) analisar os efeitos das mesmas doses de 
rHuEPO, per se, usando ratos saudáveis, sem IRC.   
Os ratos com IRC não tratados desenvolveram anemia, hipertensão, inflamação 
(sistémica e renal) e lesões renais severas. O tratamento com rHuEPO nos animais com 
IRC corrigiu a anemia de forma dose-dependente. As doses mais baixas (grupos IRC100 e 
IRC200) melhoraram as lesões renais glomerulares e tubulointersticiais (apesar de ainda 
presentes), e reduziram os marcadores inflamatórios no tecido renal, mas sem impacto na 
inflamação sistémica (valores de PCR). As doses mais altas (IRC400 e IRC600) 
melhoraram substancialmente todas as lesões renais e a inflamação (renal e sistémica); 
todavia, a taxa de filtração glomerular manteve-se inalterada. Observou-se uma redução 
da pressão arterial em todos os animais tratados com rHuEPO, apesar de se ter verificado 
um aumento dose-dependente. Em ratos saudáveis, o tratamento com rHuEPO induziu 
um aumento dos eritrócitos, dose-dependente, aumentando a viscosidade sanguínea. O 
aumento da pressão arterial induzida pelo tratamento com rHuEPO pode resultar de uma 
ação direta desta nos vasos renais e/ou da hiperviscosidade sanguínea devido à 
eritrocitose, acompanhada por uma redução da atividade da enzima monóxido de azoto 
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sintetase endotelial. Nos grupos com pressão arterial mais elevada foram observadas 
lesões renais vasculares e tubulointersticiais. 
Apesar do contexto inflamatório, não foram observadas alterações nos marcadores 
séricos do metabolismo do ferro. A hipóxia resultante da anemia no grupo não tratado e a 
eritropoiese estimulada com a dose mais baixa (IRC100) parecem determinantes na 
repressão da transcrição da hepcidina. As doses mais altas (IRC200 e IRC400) induziram 
um estímulo eritropoiético maior, aumentando a absorção de ferro de forma a 
disponibilizar ferro suficiente para a eritropoiese, determinando a inibição da síntese de 
hepcidina. A dose mais elevada (IRC600) promoveu um estímulo eritropoiético e uma 
absorção de ferro ainda superiores, induzindo acumulação de ferro hepático capaz de 
ativar a síntese de hepcidina através da via BMP6/SMAD. Nos ratos saudáveis, 
contrastando com os resultados obtidos nos animais com IRC, as doses mais altas não 
estimularam a produção de hepcidina; em vez disso, as doses mais altas reprimiram a 
síntese de hepcidina, apesar do aumento da absorção de ferro, sugerindo uma supremacia 
da eritropoiese sobre o ferro na regulação da hepcidina. 
Finalmente, após uma correção inicial da anemia, um grupo de ratos tratados com 
rHuEPO (200 UI/peso (Kg)/semana) deixou subitamente de responder ao tratamento, 
desenvolvendo anemia. Nestes animais, observou-se um aumento dos níveis séricos de 
PCR e dos marcadores renais de inflamação (NF-κB, IL-1β and IL-6), contribuindo para a 
inibição da eritropoiese e da síntese renal de EPO. Além disso, observou-se um aumento 
dos marcadores de fibrose (CTGF e TGF-β1) no rim, contribuindo para fibrose renal. 
Em conclusão, os resultados sugerem que um tratamento de curta duração com 
doses altas, para ultrapassar um episódio de resistência à terapia com rHuEPO, pode 
apresentar benefícios, por reduzir a inflamação; contudo, o efeito pro-hipertensor durante 
um tratamento de longa duração, particularmente com doses altas, deve ser devidamente 
monitorizado, para evitar um impacto cardiorrenal deletério. A correção da anemia com 
doses de rHuEPO mais elevadas, ao estimular a eritropoiese e a absorção de ferro, pode 
aumentar os níveis de ferro armazenados, induzindo a síntese de hepcidina, contribuindo 
assim para o desenvolvimento de resistência à terapia. A resistência à rHuEPO associada à 
inflamação agrava a anemia, favorecendo a hipóxia e a fibrose renal, que exacerbam ainda 
mais a resposta inflamatória, num ciclo vicioso que conduz a progressão da doença renal. 
 
 
Palavras-chave: anemia; doença renal crónica; eritropoietina; hepcidina; 
hipertensão 
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ABSTRACT 
 
Anemia is a common complication in chronic kidney disease (CKD) patients and its 
main cause is the insufficient production of erythropoietin (EPO) by the failing kidneys. 
The introduction of erythropoiesis-stimulating agents (ESA) revolutionized the treatment 
of anemia in CKD; however, some patients do not respond properly to ESA therapy 
requiring higher doses to achieve target hemoglobin (Hb) levels. Several clinical studies 
reported an increase in cardiovascular events and mortality in patients treated with ESA, 
especially in hyporesponsive patients, whose specific causes and mechanisms remain to be 
elucidated.  Several pleiotropic effects, beyond anemia correction, have been attributed to 
EPO and ESA, such as renoprotection and anti-inflammatory properties, but to attain 
those effects higher ESA doses are needed, whose risk-benefits are still undisclosed, 
requiring further clarification.  
 Our work aimed i) to characterize anemia development, renal function and damage, 
blood pressure, iron metabolism and the crosstalk between the induced disturbances, 
using the remnant kidney rat model of chronic renal failure (CRF) induced by 5/6 surgical 
nephrectomy; ii) to evaluate the impact of different recombinant human erythropoietin 
(rHuEPO) therapy, by treating the CRF animals, during 3 weeks, with standard rHuEPO 
doses, usually used to correct anemia in CKD patients (100 and 200 IU/Kg body weigh 
[BW]/week), and with higher doses (400 and 600 IU/Kg BW/week), used in the 
treatment of hyporesponsive patients; iii) to dissect the effects of these rHuEPO doses, per 
se, using normal rats, without CRF. 
We found that the untreated CRF group developed anemia, hypertension, 
inflammation (systemic and renal) and severe renal lesions. The use of rHuEPO in the 
CRF rats was able to correct the anemia in a dose-dependent manner. The lower doses 
tested (CRF100 and CRF200 groups) were able to ameliorate (but still present) 
glomerular and tubulointerstitial renal lesions, to reduce renal tissue inflammatory 
markers, without impact on systemic inflammation (CRP levels). The higher rHuEPO 
doses (CRF400 and CRF600 groups) markedly improved all renal lesions and 
inflammation (renal and systemic); however, glomerular filtration rate did not change. 
Blood pressure was reduced in all rHuEPO treated groups, even though a dose-dependent 
raise was found. In normal rats, rHuEPO treatment was able to induce a dose-dependent 
increment in erythrocytes, leading to increased blood viscosity. Thus, the rHuEPO-
induced blood pressure raise might result from a direct effect on the renal vessels and/or 
from blood hyperviscosity associated with erythrocytosis, accompanied by a reduced 
activity of endothelial nitric oxide synthase. Vascular and tubulointerstitial renal lesions 
were presented by the groups with the highest blood pressure.  
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Despite the inflammatory state, no significant changes in serum iron markers were 
observed in untreated CRF rats. The hypoxia associated to anemia in the CRF group and 
the stimulated erythropoiesis with the lowest rHuEPO dose (CRF100) seems to prevail in 
the down-regulation of hepcidin mRNA levels. Higher rHuEPO doses (CRF200 and 
CRF400) induced a higher erythropoietic stimulus, increasing iron absorption to maintain 
iron availability for erythropoiesis, thus causing hepcidin synthesis repression. The 
highest rHuEPO dose (CRF600) endorsed an even higher erythropoietic stimulus and iron 
absorption, leading to liver iron accumulation, which is able to trigger hepcidin 
transcription through the BMP6/SMAD pathway. In healthy rats, contrasting with the 
results obtained in the CRF animals, higher rHuEPO doses were unable to induce an 
increase in hepcidin synthesis; instead, we found a down-regulation of hepcidin 
transcription with the highest doses, despite the increased iron absorption, suggesting the 
supremacy of erythropoiesis over iron in the regulation of hepcidin.   
Finally, after an initial correction of anemia, a group of rats receiving rHuEPO 
therapy (200IU/Kg BW/week), presented a sudden hyporesponse to treatment, 
developing anemia. In these animals, serum CRP levels and renal inflammatory markers 
(NF-κB, IL-1β and IL-6) increased, contributing to suppress erythropoiesis and renal EPO 
synthesis. Furthermore, kidney fibrosis markers (CTGF and TGF-β1) were overexpressed, 
contributing to renal fibrosis. 
In conclusion, our data suggest that a short-term treatment with high doses, used to 
overcome an episode of hyporesponse to rHuEPO, can present benefits by reducing 
inflammation, without worsening of renal lesions; however, the pro-hypertensive effect 
during a long-term treatment, particularly with higher rHuEPO doses, should be carefully 
managed in order to avoid a negative cardiorenal impact. Anemia correction with high 
rHuEPO doses, by favoring erythropoiesis and iron absorption, can increase iron stores, 
inducing hepcidin synthesis, which might contribute to hyporesponsiveness to rHuEPO 
therapy. This condition is associated with inflammation, aggravating anemia and favoring 
hypoxia and renal fibrosis, which further enhance the inflammatory response in a vicious 
cycle that promotes renal disease progression. 
 
Keywords: anemia, chronic kidney disease, erythropoietin, hepcidin, hypertension
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1. CHRONIC KIDNEY DISEASE 
 
1.1. Definition and classification 
Chronic kidney disease (CKD) is a pathological condition that results from a gradual, 
permanent loss of kidney function over time, usually, months to years. According to the 
National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) 
guidelines, the diagnosis of CKD should be based on the presence of kidney damage or 
reduction of kidney function (evaluated by glomerular filtration rate – GFR), allowing to 
classify the disease in 5 stages (Table 1), with increasing severity [1].  
 
Table 1 – Stages of chronic renal disease severity 
Stage GFR Description 
1 ≥90 Kidney damage (protein in the urine) and normal GFR 
2 60 - 89 Kidney damage and mild decrease in GFR 
3 30 - 59 Moderate decrease in GFR 
4 15 - 29 Severe decrease in GFR 
5 <15 Kidney failure (dialysis or kidney transplant needed) 
Abbreviations: GFR – Glomerular Filtration Rate (mL/min/1.73m2). Stage 3 can be subdivided in 3a (GRF 45–
59, mildly to moderately decreased) and 3b (GFR 30–44, moderately to severely decreased). Adapted from the 
National Kidney Foundation (2002) [1]. 
 
CKD is a complex pathology and, in the recent years, some updates to better classify 
CKD have been made. The recent Kidney Disease Improving Global Outcomes (KDIGO) 
guidelines for “Evaluation and Management of Chronic Kidney Disease” introduced 
albuminuria categories as a further criteria to CKD staging (Table 2) and risk prediction 
(Figure 1) [2].  
 
Table 2 – Albuminuria categories in chronic kidney disease 
Abbreviations: ACR - albumin-to-creatinine ratio; AER - albumin excretion rate. Adapted from KDIGO Group 
(2012) [2]. 
 
Category 
AER 
(mg/24h) 
ACR 
Description 
(mg/mmol) (mg/g) 
A1 < 30 < 3 < 30 Normal to mildly increased 
A2 30 – 300 3 – 30 30 - 300 Moderately increased 
A3 > 300 > 30 > 300 Severely increased 
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CKD is confirmed if in a period superior to 3 months there is a decrease in kidney 
function (GFR < 60 mL/min/1.73m2) or markers of kidney damage (albuminuria with 
albumin to creatinine ratio > 30 mg/g) are present [2]. The progressive decline in kidney 
function can lead to costly renal replacement therapy that includes dialysis [hemodialysis 
(HD) and peritoneal dialysis] or kidney transplantation. 
 
 
Figure 1 – Risk of chronic kidney disease (CKD) by glomerular filtration rate (GFR) and 
albuminuria categories.  
*If no other markers of kidney disease, no CKD; GFR (mL/min/1.73m2). Adapted from KDIGO Group (2012) 
[2]. 
 
1.2. Epidemiology 
According to data reported by Jha et al. (2013) [3] the incidence and prevalence of 
end-stage renal disease (ESRD) (Figure 2) is increasing worldwide and the aging of 
population contributes to this fact.  According to the 2013 Global Burden of Disease Study 
[4], between 1990 and 2013 the mortality due to CKD increased 36.9% worldwide, with 
regional differences. The incidence of ESRD in developed countries appears to be slowing, 
while in developing countries is increasing [5]. In 1990, CKD was ranked 36th in the top 50 
causes of global years of life lost (annual age-standardized death rate 11.6 per 100 000), 
but rose to 19th in 2013 (annual age-standardized death rate 15.8 per 100 000) [4].  
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Figure 2 – Incidence (A) and prevalence (B) of end-stage renal disease in different 
countries.  
Adapted from Jha et al. (2013) [3]. 
 
In Portugal, the incidence and prevalence of CKD is extremely high when compared 
to other European countries (Figure 2). The 2013 Global Burden of Disease Study showed 
that, in Portugal, CKD is in the top 10 causes of potential life lost due to premature 
mortality and loss of years of productive life due to disability [6]. Data from the 
“Sociedade Portuguesa de Nefrologia” [7] showed that the incidence (Figure 3) and the 
prevalence of patients in dialysis therapy increased between 1997 and 2014; in addition, 
due to increased life expectancy, the majority of incident patients are older than 65 years.  
A 
B 
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Figure 3 – Annual incidence of dialysis patients in Portugal between 1997 and 2014. 
Adapted from “Sociedade Portuguesa de Nefrologia” (2015) [7]. 
 
1.3. Etiology and risk factors 
According to the location of the pathological-anatomical findings within the kidney, 
CKD can be classified in several categories (Table 3). CKD can result from primary 
diseases of the kidneys, such as glomerulonephritis, fibromuscular or renal dysplasia [8]. 
However, the two main causes of CKD in developed countries are diabetes [mainly type 2 
diabetes mellitus] and hypertension [9], as occurs in Portugal (Figure 4), accounting for 
the majority of deaths in CKD patients [4]. Other causes include inherited kidney diseases, 
such as polycystic kidney disease, kidney malformations, and acquired kidney diseases, 
associated with acute kidney injury, recurrent urinary infections, regular use of analgesics 
(e.g., acetaminophen and ibuprofen) over long periods of time, some nephrotoxic 
antibiotics (e.g., aminoglycosides), human immunodeficiency virus infection, sickle cell 
disease, kidney stones and lupus [8-10]. In developing countries, the most common causes 
of CKD are chronic glomerulonephritis, infections and exposure to drugs and toxins [3, 7]. 
Several risk factors can contribute to the development and progression of CKD, 
including age, obesity, African American ancestry, familiar history, and kidney transplant, 
among others [11-13]. 
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Table 3 – Classification of chronic kidney disease based on the presence or absence of 
systemic disease and location within the kidney 
Diseases 
Primary kidney  
diseases 
Systemic diseases  
affecting the kidney 
Glomerular  
Glomerulonephritis, 
glomerulosclerosis,  
membranous nephropathy 
Obesity, metabolic syndrome, 
diabetes, systemic autoimmune 
diseases, systemic infections, drugs, 
neoplasias 
Vascular  Fibromuscular dysplasia 
Hypertension, atherosclerosis, 
ischaemia, systemic vasculitis, 
thrombotic microangiopathy, and 
systemic sclerosis 
Tubulointerstitial  Urinary-tract infections, 
stones, obstruction 
Systemic infections, sarcoidosis, 
drugs, urate, environmental toxins 
(eg, lead, aristolochic acid), myeloma 
Cystic and 
congenital 
Renal dysplasia, 
medullary cystic disease, 
podocytopathies 
Autosomal-dominant polycystic 
kidney disease, Alport syndrome, 
Fabry disease 
Adapted from Eckdart et al. (2013) [9]. 
 
 
 
Figure 4 – Etiology of incident dialysis chronic kidney disease patients (n=2446) in 
Portugal (2014).  
Adapted from “Sociedade Portuguesa de Nefrologia” (2015) [7]. 
 
1.4. Pathophysiology 
CKD can present as the initial cause, glomerular, tubulointerstitial and vascular 
diseases (Table 3). Irrespective of the initial origin, the histopathological analysis of renal 
tissue shows that in the final stage of CKD, glomerulosclerosis, tubular atrophy, 
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tubulointerstitial fibrosis and interstitial inflammatory infiltrate are present in renal 
biopsies [14-16]. 
Human studies and the use of animal models have deeply contributed to improve 
the knowledge on CKD progression [17, 18]. The loss of nephrons (the functional unit of 
the kidney) is the underlying cause for progressive reduction in renal function. The initial 
loss of some nephrons is compensated by the remaining nephrons via tissue hypertrophy 
and hyperfiltration, in order to maintain normal GFR. However, this compensatory 
mechanism appears to be deleterious for the remaining nephrons, as a progressive 
deterioration of renal function is observed. Several mechanisms have been proposed to 
explain the loss of nephrons and progressive CKD (Figure 5).   
 Glomerular diseases can have many underlying causes as dysregulated, 
degenerative and inflammatory mechanisms, but all of them will eventually affect 
podocytes [19]. These cells have major roles in the selective permeability of the glomerular 
filtration barrier [20] and in the production of vascular endothelial growth factor (VEGF) 
[21]. The continuous loss or alteration in podocytes will lead to endothelial cell damage, 
collapse of glomerular capillaries and proteinuria. The glomerular injury is accompanied 
by a reduction in glomerular blood flow, which leads to a reduction in blood flow into 
peritubular capillaries, leading to hypoxia and consequent tubulointerstitial injury and 
renal fibrosis that is considered a final common pathway in CKD [19]. The impact of 
proteinuria in tubulointerstitial injury and in the progressive renal damage is not well 
established [22, 23]. In the presence of proteinuria the tubules have to increase 
reabsorption, with consequent increase in metabolic demands that could lead to hypoxia 
[24]. The presence of inflammatory cytokines and pro-fibrotic factors in the filtrate may 
activate tubular cells to produce more of inflammatory and pro-fibrotic factors [25]. In 
fact, after an initial injury in the tubules, there is an attempt to correct and repair the 
injury with recruitment and activation of several cells (macrophages, fibroblasts, 
leukocytes, epithelial tubular cells) that might release cytokines and growth factors. The 
continuous activation of this system will also lead to excessive extracellular matrix (ECM) 
accumulation and to increase release of pro-inflammatory cytokines and pro-fibrotic 
factors, culminating in the formation of scar tissue or fibrosis [25]. The initial stage of 
tubular injury is characterized by tubular atrophy (loss of brush border and epithelial 
simplification), associated with diminished transport functions [26]. The progression of 
tubular atrophy culminates in apoptosis or necrosis of tubular cells [24]. It has been 
shown that tubulointerstitial lesions, mainly tubular atrophy, correlate better with CKD 
progression than glomerular lesions [26]. However, due to the higher tubulointerstitial 
area (about 80%) compared to the glomerular area, a misleading analysis can 
underestimate the importance of glomerular pathology [26]. 
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Figure 5 – Schematic diagram of consequences and progression of glomerular and 
tubular injuries. 
Adapted from Hodgkins et al. (2012) [24]. 
 
1.5. Complications 
The progressive evolution of CKD is associated with several complications, as 
anemia, worsening hypertension, development and/or progression of cardiovascular 
disease (CVD), bone disease, hyperkalemia, volume overload, metabolic acidosis, and 
neurological disturbances, among others.  
Hypertension is simultaneously a cause and a complication CKD, and is found in 
about 80% of CKD patients, increasing its prevalence with decreased renal function [27]. 
Abnormal sodium homeostasis and increased activity of the renin-angiotensin-
aldosterone system (RAAS) are the main causes of hypertension worsening in CKD 
patients [27]. 
A systematic analysis for the global burden of diseases, from 1990 to 2013, showed 
that CVD account for almost a third of all deaths [4], and within CKD patients the 
mortality rate due to CVD was even higher, especially for ESRD patients [28, 29]. Several 
risk factors, divided in traditional and non-traditional (Table 4), can contribute to the 
development and/or progression of CVD in CKD patients.  
Many patients with CKD present traditional risk factors (old age, diabetes, 
hypertension, dyslipidemia and obesity) that, however, do not entirely explain the high 
CVD rate in CKD patients. Anemia, inflammation, abnormal calcium and phosphate 
metabolism, increased lipoprotein (a), and malnutrition, among others, are the better 
known non-traditional risk factors for CVD in CKD patients [10, 30]. The increased risk of 
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cardiovascular events in patients with CKD seems to result from the conjugation of both 
traditional and non-traditional risk factors, confirming the very complex pathogenesis of 
CVD in these patients.  
 
Table 4 – Traditional and non-traditional risk factors for cardiovascular disease in 
chronic kidney disease patients 
Traditional risk factors Non-traditional risk factors 
Age 
Male gender 
Hypertension 
↑ LDLc 
↓ HDLc 
↓ TG 
Diabetes 
Smoking 
Physical inactivity 
Menopause 
Family history of CVD 
Left ventricular hypertrophy 
Sleep disturbances 
Anemia 
RDW 
ESA 
Albuminuria 
↑ Homocysteine 
↑ Lipoprotein(a)  
↑Lipoprotein remnants 
Abnormal calcium/phosphate metabolism 
Extracellular fluid volume overload 
Electrolyte imbalance 
Oxidative stress 
Inflammation (↑ CRP) 
Malnutrition 
Thrombogenic factors 
Altered nitric oxide/endothelin balance 
Abbreviations: ↑ - increased; ↓ - decreased; apo (a) – Apolipoprotein (a); CRP – C-reactive protein; CVD – 
Cardiovascular disease; ESA – Erythropoiesis-stimulating agents; HDLc - High density lipoprotein 
cholesterol; LDLc - Low density lipoprotein cholesterol; RDW - Red cell distribution width ; TG - 
Triglycerides. Adapted from Weiner (2007) [10], Gargiulo et al. (2015) [30] and Faria et al. (2013)[31].  
 
Mineral and bone disorders are frequent in CKD patients, due to 
hyperphosphatemia, hypocalcemia, secondary hyperparathyroidism and vitamin D 
deficiency that can lead to renal osteodystrophy, increasing the risk of bone fractures [32].  
Neurological complications, resulting from stroke, white matter diseases, 
intracerebral microbleeds and cognitive impairment, have increased prevalence in CKD 
patients, even in mild stages of the disease [33]. The incidence of stroke increases in CKD 
patients, with a higher incidence in ESRD patients [34]. The increased prevalence of 
neurological complications may be linked to the traditional and non-traditional risk 
factors for CVD observed in CKD patients (Table 4). 
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2. ANEMIA OF CHRONIC KIDNEY DISEASE 
 
2.1. Definition and diagnosis 
Anemia is a common complication of CKD that often develops early in the course of 
the disease, increasing its frequency and severity with the decline of renal function. The 
incidence of anemia is less than 2% in CKD stages 1 and 2, about 5% in CKD stage 3, 44% 
in CKD stage 4 and more than 70% in the ESRD [35]. This condition is associated with a 
decreased quality of life [36, 37], increased hospitalization [38, 39], progression of renal 
dysfunction [22, 40, 41], cardiovascular complications [42, 43] and mortality [44-46]. 
The World Health Organization [47] and KDIGO guidelines [48] define anemia as 
hemoglobin (Hb) concentration below established cut-off levels of less than 12 g/dL for 
women and less than 13 g/dL for an adult men (Table 5). However, the European Best 
Practice Guidelines (EBPG) for the management of anemia in patients with CKD 
recommends that a diagnosis of anemia in these patients should be considered when Hb 
concentration falls below 11.5 g/dL in women, 13.5 g/dL in adult men and 12.0 g/dL in 
men older than age 70 [49]. 
 
Table 5 – Cut-off levels of hemoglobin concentration to define anemia 
Age or gender  Hemoglobin (g/dL) 
Children 6 months to 59 months 11.0 
Children 5–11 years 11.5 
Children 12–14 years 12.0 
Non-pregnant women (>15 years) 12.0 
Pregnant women 11.0 
Men (> 15 years) 13.0 
Adapted from World Health Organization (2001) [47]. 
 
The diagnosis of CKD anemia should consider the degree and severity of anemia and 
the type of kidney disease [49]. The parameters that are, usually, used in the clinical 
assessment of anemia in CKD patients include the complete blood cell count, reticulocyte 
count, serum ferritin, transferrin saturation (TSAT) and, more recently, the percentage of 
hypochromic red blood cells (RBC) and reticulocyte Hb content.  
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The complete blood cell count provides information about the severity and type of 
anemia, adequacy of nutrients and bone marrow function, and includes the evaluation of 
Hb concentration, hematocrit (Ht), RBC count, the RBC indices [mean cell volume (MCV), 
mean cell Hb (MCH) and mean cell Hb concentration (MCHC)], total and differential 
white blood cell (WBC) count, and platelet count [50]. Usually, the CKD anemia is 
normocytic (normal MCV: 80-95 fL) and normochromic (normal MCHC: 31.5-34.5 g/dL 
and MCH: 27-32 pg). However, in the presence of iron deficiency a microcytic anemia 
develops (low MCV) and, in case of folate or vitamin B12 deficiencies, a macrocytic anemia 
is observed (high MCV). The WBC and platelet counts helps to distinguish between 
anemia and pancytopenia (a drop in RBC, granulocytes and platelets), which may reflect 
ineffective hematopoiesis or bone marrow failure. The anemia associated with hemolysis 
or hemorrhage usually present neutrophil and platelet counts raised; in case of associated  
infections the leucocyte count is also often raised [50]. 
The reticulocyte count (percentage and absolute) and the reticulocyte production 
index (RPI) are inexpensive and useful to assess the erythropoietic activity. Reticulocytes, 
the cells released into the circulation that will mature into RBC, are released one day prior 
to maturation. In a healthy condition, 0.5-2.5% of the circulating RBC are reticulocytes, 
but in anemia, when the bone marrow is stimulated, more reticulocytes are released into 
circulation [51]. To face the increased demand in reticulocytes, they are released from the 
bone marrow in a more immature state, needing, therefore, a longer period in circulation, 
until they mature into RBC. In case of anemia, the percentage of reticulocytes increases 
due to a higher production and to a longer period in circulation, needed for their 
maturation into RBC. Thus, the activity of bone marrow is, more correctly, assessed by 
calculating the RPI (reticulocyte %/maturation index)*(Ht/normal Ht), as this index 
corrects for the effect of the premature release of reticulocytes from bone marrow and the 
severity of the anemia, as worsening of anemia leads to an earlier release of the 
reticulocytes. In an anemic patient a RPI higher than 3 indicates a normal proliferative 
response to anemia, whereas a RPI lower than 2 indicates hypoproliferation of bone 
marrow. 
Anemia of CKD is, usually, hypoproliferative with a low erythropoietic activity, due 
to insufficient renal EPO production. Thus, the EPO deficit leads to a reduced reticulocyte 
production. 
 The studies on iron status reflect the level of iron in tissue stores and its availability 
for erythropoiesis, through the analysis of serum ferritin, TSAT, percentage of 
hypochromic RBC and reticulocyte Hb content. These tests will be discussed in another 
chapter (2.2.2 Iron deficiency). 
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2.2. Etiology 
 The main cause for anemia in CKD patients is EPO deficit, due to decreased EPO 
production from the failing kidneys, but other factors can also contribute to the 
development or worsening of CKD anemia, such as iron deficiency, inflammation, and 
uremic toxins, among others.  
 
2.2.1. Inadequate erythropoietin production 
 EPO is a glycoprotein presenting several functions, such as hormone, cytokine and 
growth factor. EPO acts on target cells that express the EPO receptors (EPOR), through 
multiple pathways, to control cell proliferation, differentiation and death. EPO is the 
hormone that promotes erythroid differentiation during erythropoiesis. In the bone 
marrow, EPO binds to receptors in the early hematopoietic progenitor burst-forming unit-
erythroid (BFU-E) cells that differentiate into colony-forming unit-erythroid cells (CFU-
E), increasing the EPOR expression, as these cells need EPO for survival [52]. Continued 
stimulation with EPO triggers differentiation into erythroblasts, which will enucleate to 
form reticulocytes that mature into RBC after a few days (Figure 6). These two late cell 
stages (reticulocytes and RBC) do not express EPOR and, therefore, they are not 
responsive to EPO. The absence of EPO leads to pre-programmed apoptosis of the 
erythroid cells [52].  
 
 
Figure 6 – Erythropoietin in erythropoiesis.  
Progenitor cells burst-forming unit-erythroid (BFU-E) and colony-forming unit-erythroid cells (CFU-E) are 
responsive to erythropoietin (EPO) stimulation and differentiate in the progenitors of red blood cells (RBC). 
EPO stimulation continues until progenitors differentiate into erythroblasts. Reticulocytes and mature RBC 
are no longer responsive to EPO.   
  
 During fetal life the majority of EPO is produced by the liver, but after birth there is 
a switch, and in the adulthood 90% of EPO is produced by the kidney, whereas the liver is 
a secondary site of production [52]. The kidney cells responsible for EPO production are 
still a matter of debate, but several studies showed that renal EPO-producing cells (REPC) 
comprise the peritubular fibroblast-like interstitial cells in the inner cortex and in the 
outer medulla [53, 54], as well as proximal and distal convoluted tubules and cortical 
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collecting ducts [55]. REPC are sensitive to changes in oxygen (O2) tension, and in 
conditions of hypoxia the kidney responds increasing the number of REPC capable of 
producing EPO, as tubular cells and renal microvascular endothelial cells, creating a 
regulatory feedback mechanism [56]. The EPO gene is regulated by hypoxia through a 
family of heterodimeric transcription factors, known as the hypoxia-inducible factor (HIF) 
system [56-58]. This HIF system comprises O2-dependent HIF-1α, HIF-2α (also known as 
endothelial PAS domain-containing protein 1) and HIF-3α subunits, and the constitutively 
expressed HIF-1β and HIF-2β subunits (also known as aryl hydrocarbon receptor nuclear 
translocator). Under normoxia, the HIF-α subunits are hydroxylated, in specific proline 
residues, by prolyl-4-hydroxylase (PHD) proteins. This functions as a signal for the von 
Hippel–Lindau tumor suppressor protein (VHL) to work as a substrate for an ubiquitin 
ligase complement that targets the HIF-α subunits for rapid ubiquitination and 
proteasomal degradation (Figure 7). However, under hypoxic conditions, as the PHD 
proteins are inhibited, the HIF-α is not target by VHL protein for degradation and 
accumulates.   
HIF-α subunit translocates to the nucleus, binds to the HIF-β subunit, forming a 
complex that activates the transcription of several genes (Figure 7), including the EPO 
gene [56, 57]. Another point of HIF-α control is the hydroxylation of an asparagine residue 
by the factor-inhibiting-HIF (FIH) in the presence of O2 that impairs the association of 
HIF complex with the transcriptional co-activator CBP/p300; however, in hypoxic 
conditions this hydroxylation is inhibited, as FIH action requires O2, and the recruitment 
of CBP/p300 is facilitated, allowing increased levels of transcription (Figure 7) [59]. 
As EPO is not stored, the mRNA levels reflect the EPO production. Although HIF-1α 
and HIF-2α share the regulation of many genes, recent studies showed that HIF-2α is the 
main regulator of EPO synthesis in the kidney [60, 61]. In CKD, the kidney capacity to 
produce EPO will depend on the severity of the disease [62, 63]. Indeed, it was reported 
that patients with GFR >30 mL/min/1.73m2 retain a physiologic response to anemia, 
showed by the normal or even elevated serum EPO levels [64, 65]; however, serum EPO 
levels may not be sufficient for the degree of anemia, as anemic patients with normal renal 
function may present a 10 to 100 fold increase in serum EPO levels compared to the 
normal range [66, 67]. In this sense, CKD anemia may be characterized by a relative EPO 
deficiency rather than an absolute lack. 
The kidney is the major site of EPO production in the adults; however, it is possible 
that in conditions of kidney injury the liver increases its production. In a study using a 
PHD inhibitor, ESRD patients presented an increase in EPO levels similar to healthy 
volunteers, suggesting that extrarenal sites can be responsible for a marked rise in plasma 
EPO [68]. It was also reported that patients with anemia can switch EPO production from
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Figure 7 – Schematic representation of hypoxia inducible system.  
Proteasomal degradation of hypoxia-inducible factor α (HIF-α) by the von Hippel–Lindau tumor suppressor 
protein (VHL) requires hydroxylation (OH) by oxygen (O2) and iron (Fe) dependent prolyl-4-hydroxylase 
(PHD) proteins. Under hypoxia, HIF-α is not degraded and translocates to the nucleus where it forms a 
heterodimer with HIF-β, activating the transcription of several genes. Adapted from Smith et al. (2008) [69]. 
 
the kidney to the liver [70], and that can be showed by glycoform analysis of EPO, as the 
posttranslational EPO glycosylation is specific to the synthesizing cells, giving rise to 
different EPO glycoforms, that can be used to localize EPO synthesis [70, 71]. As occurs in 
the kidney, HIF-2α mediates EPO production in the liver [72, 73]. Hepatocytes, Ito-cells 
and nonparenchymal cells appear to be the hepatic cells responsible for EPO production, 
increasing the amount of EPO produced by each cell, in contrast to the kidney that 
increases REPC number [74-77]. EPO was also found to be expressed in the brain, spleen, 
lung and testis, although its contribution to serum EPO levels is not clear; EPO expressed 
in these organs seems to act only at local level [78].  
 
2.2.2. Iron deficiency 
Iron is an important element for the erythropoietic process, as it is essential for Hb 
synthesis. Iron is widely distributed in the organism and is needed for the synthesis of 
several biological compounds. It is a component of myoglobin, enzymes, cytochromes and 
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it is important in cellular immune responses. It has been described that iron deficiency 
leads to a reduced proliferation and function of lymphocytes and natural killer cells and to 
a diminished neutrophil respiratory burst [79]. 
The iron in the organism comes from the diet and can be recycled from the internal 
iron turnover (Figure 8). A normal diet provides 15-20 mg of iron, of which only about 1-2 
mg is mostly absorbed in duodenum, through the apical surface of the enterocytes. Dietary 
iron is provided mainly in the non-heme form (Fe3+) that has to undergo reduction to Fe2+, 
by the duodenal cytochrome B (DcytB), before enter in the enterocytes, through the 
divalent metal iron transporter 1 (DMT1). The heme iron present in the diet seems to be 
promptly absorbed through the membrane protein – heme carrier protein 1 (HCP-1), and 
released in the enterocyte by the heme-oxigenase-1 (HO-1) [79, 80].  
According to the iron requirements, the iron will stay sequestered in the enterocyte 
in the form of ferritin and lost with the senescence of the enterocyte, or will move to the 
basolateral membrane, where it is effluxed through the only known iron exporter - 
ferroportin (FPN). Iron is oxidized by hephaestin, before it binds to plasma transferrin 
(Tf), the glycoprotein responsible for iron transport to target cells [79, 80]. TfR mediate 
the cellular uptake of Tf bound iron (Tf-Fe) from plasma. There are two types of TfR, TfR1, 
which is expressed ubiquitously, and TfR2, mainly present in hepatocytes and erythroid 
cells, with a lower affinity for Tf-Fe than TfR1 [81].  
Tf-Fe is transported to its target cells, such as erythroid, immune and hepatic cells, 
where it can be used or stored in cytosol, as ferritin, or in the lysosomes, after ferritin 
breakdown, as hemosiderin [79]. The liver is the major organ for iron storage; however, 
macrophages can also store iron, as they are responsible for the phagocytosis of senescent 
erythrocytes in the reticulo-endothelial system [79], and are, actually the main iron 
storage to be used in erythropoiesis. 
The major regulator of body iron homeostasis is hepcidin, a peptide synthesized by 
the liver that regulates iron absorption and mobilization from stores. The binding of 
hepcidin to FPN in the membrane of enterocytes, hepatocytes and macrophages, induces 
its internalization and degradation, thereby, inhibiting iron absorption and mobilization 
[82]. Hepcidin, the central player of iron metabolism, is synthesized in the liver as a 
prepropeptide (84 amino acids) that undergoes a cleavage, mediated by furin, producing 
pro-hepcidin (60 amino acids), which is then processed to produce the mature form – 
hepcidin (25 amino acids) [83].  
Hepcidin can be regulated by several factors (Figure 8). Inflammation, TSAT and 
liver iron are inducers of hepcidin synthesis, whereas erythropoiesis and hypoxia are 
inhibitors of hepcidin synthesis. 
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Figure 8 – Iron absorption and regulation of iron metabolism.  
Diet iron is present as either heme iron (Fe2+) or non-heme iron (Fe3+). Non-heme iron (Fe3+) must be reduced to Fe2+, by  the duodenal cytochrome B (DcytB), to be 
transported by the divalent metal iron transporter 1 (DMT1). Once inside the enterocyte, the newly absorbed iron enters the intracellular iron pool. If the iron is not 
required by the body, it is loaded onto the iron storage protein ferritin. Iron required by the body is transferred across the basolateral membrane by ferroportin (FPN). 
The export of iron also requires the ferroxidase hephaestin (HEPH). Iron is transported by transferrin (Tf) to the local where it is needed, such as into the bone marrow to 
be used in erythropoiesis. The senescent erythrocytes are phagocyted by macrophages, recycling iron. Hepcidin, the main regulator of iron metabolism (by blocking FPN 
action), is synthesized by the liver and is regulated by several stimulator (+) and inhibitor (−) factors. Increased transferrin saturation (TSAT) displaces hemochromatosis 
(HFE) protein from Tf receptor 1 (TfR1) to TfR2, forming a complex that recruits hemojuvelin (HJV), inducing hepcidin synthesis through bone morphogenetic protein 6 
(BMP6) and BMP receptor (BMPr). Interleukin (IL)-6 through its receptor (IL6-r) can induce hepcidin synthesis.  Anemia, increased erythropoiesis, erythropoietin and 
hypoxia (probably through hypoxia inducible factor [HIF]) are factors responsible for hepcidin inhibition. Adapted from Ribeiro et al. (2015) [84]. 
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Several tests can be used to assess iron deficiency. Plasma/serum ferritin 
concentration is the only blood marker to assess iron stores; a value lower than 30 ng/mL 
in men or 15 ng/mL in women is consistent with absolute iron deficiency. On the other 
hand, ferritin levels higher than 300 ng/mL, along with anemia, indicate a functional iron 
deficiency, as frequently occurs in CKD patients [49]. TSAT is a measure of circulating 
iron, available for delivery into the bone marrow; a value lower than 20% indicates iron 
deficiency [49]. It is important to distinguish between absolute and functional iron 
deficiency. Low levels of iron, ferritin and TSAT reflect absolute iron deficiency, which is 
responsive to iron therapy. A functional iron deficiency presents with high levels of 
ferritin, low iron and low/normal levels of TSAT that, usually, results from an 
inflammatory state. C-reactive protein (CRP) is widely used to assess inflammation, and 
present concentrations higher than 3 mg/L in inflammatory conditions [49]. Due to the 
limitations of ferritin and TSAT analysis, as they are influenced by inflammation and 
general nutritional status [85], other parameters that are included in the EBPG guidelines 
can also be useful to assess iron status [49]. The value of serum soluble TfR (sTfR) reflects 
the number of erythroblasts in the bone marrow and/or the need for iron. Indeed, under 
conditions of iron deficiency, the number of erythroblasts will increase in the bone 
marrow, as well as the number of membrane TfR in the erythroblasts. Some of the TfR are 
released along cell maturation into the circulation, where they can be evaluated. Higher 
levels of sTfR usually indicate iron deficiency or deficient iron mobilization; in the anemia 
of chronic disease or anemia of inflammation, the levels of sTfR are within normal range 
or high. This parameter is very useful as it is less affected by inflammation. The availability 
of iron for erythropoiesis can also be assessed by the percentage of hypochromic RBC and 
reticulocyte Hb content. The percentage of hypochromic RBC increases in case of absolute 
or functional iron deficiency [86], and is affected by erythropoietic activity [87]. The 
reticulocyte Hb content, measuring the amount of Hb in reticulocytes, increases in the 
case of absolute or functional iron deficiency [85], and is influenced by MCV [88]. 
Iron deficiency is a common factor for CKD anemia, mainly in HD patients, that lose 
about 1–2 g of iron per year. The high frequency of blood analysis, the surgical procedures 
for vascular access, the blood loss into the hemodialyser (and tubes) during the dialysis 
procedure, and the presence of inflammation contribute to iron deficiency. Moreover, in 
CKD patients, iron homeostasis may be disturbed at several points of its cycle, including 
absorption, release from its storages and utilization. For instance, high hepcidin levels that 
are common in CKD patients [31, 89], can contribute to iron deficiency, due to its effect on 
iron absorption and mobilization from stores. Inflammation, also common in CKD 
patients [31, 90], is one of the major contributors for functional iron deficiency, due to its 
stimulatory effect on hepcidin synthesis (Figure 9A). Hepcidin was first reported by its 
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antifungal and antimicrobial properties [91] and was considered an acute-phase protein 
[92]. The best characterized cytokine responsible for inducing hepcidin synthesis is 
interleukin-6 (IL-6) [93], although other cytokines have been later reported as hepcidin 
synthesis stimulators [94, 95]. IL-6 mediated hepcidin activation occurs through the 
activation of the signal transducer and activator of transcription 3 (STAT3) pathway [96, 
97]. Recently, it was reported that activin B, also increased in inflammatory states, can 
induce hepcidin synthesis through the son of mothers against decapentaplegic (SMAD) 
1/5/9 pathway, independently of IL-6 pathway [98].  
Iron is a strong inducer of hepcidin synthesis (Figure 9B). TSAT is a sensor for 
circulating iron and, therefore, controls iron systemic homeostasis. In normal serum iron 
levels (normal TSAT), diferric Tf competes with hemochromatosis (HFE) protein for 
binding to TfR1; in conditions associated with increased iron (increased TSAT), more HFE 
will be available to bind to TfR2; this complex, TfR2-HFE, recruits hemojuvelin (HJV) an 
important co-factor for bone morphogenetic protein 6 (BMP6) [99, 100]. The BMP6-HJV 
complex activates the BMP receptor that will induce the phosphorylation of SMAD1/5/9 
proteins, which recruits SMAD4, forming a complex that translocates to the nucleus, 
triggering hepcidin synthesis [101]. It was suggested that the complex TfR2-HFE can also 
induce hepcidin synthesis through the extracellular signal-regulated kinase/mitogen-
activated protein kinase (ERK/MAPK) pathway and furin [102], but this pathway was not 
proved to occur in vivo [103].  
Other proteins are involved in the fine-tuning of hepcidin expression. Neogenin 
appears to present two distinct functions, as it acts as a HJV stabilizer, enhancing BMP 
signaling [104, 105], and interacts with matriptase-2 to promote HJV cleavage [105]. 
Matriptase-2 is a recognized negative modulator of hepcidin synthesis; due to its activity 
as a membrane serine protease, it cleaves HJV that is released in a soluble form, blunting 
the BMP pathway [106, 107]. The regulation of matriptase-2 is still under study but several 
stabilizers and inducers have been reported, such as low intracellular iron [108], HIF 
system [109], and (indirectly) circulating iron and BMP6 to control iron overload [110]. 
Hepatocyte growth factor activator inhibitor type 2 [111] and inflammation (through 
STAT5) [112] modulates matriptase-2 inhibition. SMAD7 emerged as an inhibitor of 
hepcidin synthesis by its interaction with SMAD4, thus blunting the SMAD pathway 
activation [113]. Recently, endofin responsible for the recruitment of the SMAD proteins 
to BMP receptors was identified as another protein involved in the regulation of hepcidin 
synthesis [114].  
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Figure 9 – Regulation of hepcidin expression.  
A) Regulation of hepcidin by inflammation. Interleukin-6 (IL-6) activates the janus kinase/signal transducer 
and activator of transcription 3 (JAK/STAT3) pathway, whereas activin B activates the son of mothers against 
decapentaplegic (SMAD) pathway, both inducing hepcidin synthesis. B) Regulation of hepcidin by transferrin. 
Increased transferrin saturation displaces hemochromatosis (HFE) protein from transferrin receptor 1 (TfR1) 
to TfR2, forming a complex that recruits hemojuvelin (HJV) and neogenin (Neo), activating the bone 
morphogenetic (BMP)-SMAD pathway inducing hepcidin transcription. The TfR2-HFE complex can possibly 
also act through the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) 
pathway. Matriptase-2 (TMPRSS6) promotes cleavage of HJV, releasing a soluble form (sHJV) that blunts the 
BMP-SMAD pathway. SMAD7 inhibits the SMAD pathway by interacting with SAMD4. Adapted from Zhao et 
al. (2013) [115] and Hentze et al. (2010) [116].  
 
Liver iron stores are also modulators of hepcidin synthesis, responsible for cellular 
iron homeostasis [117]. Liver iron appears to induce directly BMP6 expression and 
activation of the SMAD1/5/9 pathway [103]; however, the mechanism by which hepatic 
iron levels regulate BMP6 remains to be elucidated. 
When blood O2 saturation decreases and hypoxia occurs, erythropoiesis is 
stimulated and the iron demand for erythropoiesis in the bone marrow increases. Thus, it 
is necessary to increase iron absorption and the mobilization of iron stores. Both 
erythropoiesis and hypoxia down-regulate hepcidin expression [118, 119]. Although, 
intense studies have been made in this field, the exact mechanisms by which 
erythropoiesis and hypoxia inhibit hepcidin are poorly understood. 
Enhanced erythropoiesis is accompanied by an increase in serum EPO levels and 
bone marrow erythropoietic activity. It was reported that EPO can directly suppress 
hepcidin synthesis [120], but several studies in vivo showed that EPO inhibition of 
hepcidin occurs indirectly by erythropoiesis [121-124]. The most accepted mechanism is 
that bone marrow releases factors produced during erythropoiesis that control hepcidin 
synthesis. Several candidates have been proposed, as growth differentiation factor 15 [125, 
126], twisted gastrulation 1 [127] and, more recently, erythroferrone [128, 129]; however, 
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the exact factor(s) and mechanism(s) is still unclear. Increased erythropoietic activity, as 
occurs in response to anemia, is accompanied by HIF system stimulation, due to hypoxia. 
The effect of the HIF system on hepcidin synthesis also appears to occur indirectly via 
erythropoiesis, but no consensus is still available [130-132]. It was also reported that, in 
hepatocytes, hypoxia inhibits hepcidin synthesis by reducing SMAD4 protein [133] and, as 
already referred, matriptase-2 (hepcidin negative modulator) can be regulated by the HIF 
system [109, 134]. Furin, that is responsible for hepcidin cleavage, also appears to act on 
HJV in a HIF-dependent manner [135]. In addition, the HIF system is also responsible for 
the expression of several fundamental elements in iron cycling, such as Tf, TfR1, 
hephaestin, DMT1, DcytB and HO-1 [136-138].  
 
2.2.3. Inflammation 
 Inflammation modulates not only hepcidin synthesis, contributing to functional 
iron deficiency, but also affect EPO synthesis and erythropoiesis [51]. Inflammation starts 
early in the progress of renal disease [139] and is often observed in HD patients [27, 90]. 
The etiology of inflammation in these patients is multifactorial and includes intercurrent 
clinical events, comorbidities, renal disease and dialysis [140, 141]. The inflammatory state 
can be evidenced by the rise in several pro-inflammatory markers, such as IL-6, IL-1β, 
tumor necrosis factor alpha (TNF-α) and interferon-gamma (IFN-γ), and by the rise in the 
acute phase reactant CRP.  
 Inflammation contributes to CKD anemia through several ways. It can directly 
suppress erythropoiesis, due to the inhibitory effect of IL-1β, TNF-α and IFN-γ on BFU-E 
and CFU-E stages in bone marrow [142-145]. IL-6 can impair erythroid production by 
inducing mitochondrial dysfunction in maturing erythroid cells, which leads to impaired 
Hb synthesis and erythroid maturation [146]. The bone marrow macrophages can be 
stimulated to increase local pro-inflammatory cytokines, amplifying the effects of systemic 
inflammation [147]. Inflammation can also influence EPO production [148-150]. It was 
recently reported that HIF system can also be affected by inflammation, through the 
induction of the aryl hydrocarbon receptor that competes with HIF-2α for binding with 
HIF-β [151]. Reduced RBC lifespan is also a consequence of inflammation due to increased 
phosphatidylserine exposure, increased phosphorylation of membrane protein Band 3 and 
reduced deformability, all markers for RBC phagocytosis by macrophages [152].  
 
2.2.4. Uremic toxins 
In CKD, the progressive loss of glomerular filtration capacity of potentially toxic 
compounds leads to the accumulation of uremic solutes in the blood stream that are 
known as uremic toxins, biologically or biochemically active. The European Uremic Toxin 
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(EUTox) Work Group [153] listed more than 100 different uremic retention solutes, 
classified in three major groups (Table 6), according to their physical-chemical 
characteristics that may influence solute removal by dialysis or related strategies [154]. 
Uremic toxins can induce anemia by reducing the RBC lifespan or by causing 
hypoproliferation of red cell progenitors in the bone marrow, through an inhibitory effect. 
Uremia associated to inflammation and oxidative stress are responsible for an 
acceleration of functional changes and disruption of the RBC membrane [155]. This can 
lead to a mechanism known as eryptosis (suicidal death of erythrocytes), whose features 
are cell shrinkage, membrane blebbing and exposure of phosphatidylserine, a signal for 
recognition by macrophages and subsequent elimination of these RBC from circulation 
[152]. It has been reported that uremic toxins increase O2 consumption and aggravate 
local hypoxia in renal tubular cells through a mechanism involving the development of 
oxidative stress, triggering disturbances in the O2 sensing system and in EPO production 
[156]. 
 
Table 6 – Classification of uremic retention solutes 
Classification Characteristics Examples 
Small water-
soluble molecules 
MW <500 Da 
easily removed by any dialysis strategy 
Urea, 
creatinine 
Middle molecules 
MW >500 Da 
only removed  through large-pored  membranes 
β2-M, TNF-α,  
IL-1β, IL-6 
Protein-bound 
molecules 
Any MW 
difficult to remove with any dialysis strategy 
Homocysteine, 
indoles 
Abbreviations: β2-M - β2-Microglobulin; Da – Daltons; IL- Interleukin; MW – Molecular weight; TNF – 
Tumor necrosis factor. Adapted from Vanholder et al. (2003) [154]. 
 
2.2.5. Others 
 Chronic blood loss occurs is dialysis patients, especially in those on HD, due to 
uremic platelet dysfunction [157], blood retained and lost within the dialysis circuit, blood 
drawn for laboratory monitoring studies, and to bleeding events [49]. Blood loss results in 
iron loss that may lead to depletion of iron and development of iron deficient anemia. 
Malnutrition, aluminum accumulation, deficiency in folic acid or vitamin B12, and 
some drugs, such as angiotensin-converting-enzyme (ACE) inhibitors, can also contribute 
to anemia in CKD patients [49].  
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2.3. Anemia and progression of renal disease 
Anemia is associated with the progression of renal dysfunction [22, 40, 41] and the 
use of animal models have been helpful to elucidate the underlying mechanisms. As above 
mentioned, the main cause of anemia is the inadequate EPO production by the kidneys. It 
is proposed that after an injury REPC can suffer a transdifferentiation, called epithelial to 
mesenchymal transition (EMT), into myofibroblasts, thus, losing their capacity to 
synthesise EPO [158]. The increase in myofibroblasts, responsible for collagen synthesis, 
leads to excessive ECM deposition. These cells seem to derive from several cells, as 
fibroblasts, pericytes, tubular epithelial cells (such as endothelial cells), and bone marrow 
derived cells (fibrocytes and mesenchymal stem cells), although its origin is still debatable 
[53, 159, 160]. Transforming growth factor beta (TGF-β), a recognized pro-fibrotic factor, 
appears to be central for fibroblast activation, proliferation and transdifferentiation, 
contributing to ECM deposition [161]. TGF-β presents immunomodulatory effects on 
macrophages and monocyte recruitment, leading to the production of inflammatory 
cytokines [162]. Initially, in renal injuries, M2-type macrophages are recruited to promote 
tissue remodelling; however, if this process is continuous more  inflammatory monocytes 
are recruited that will differentiate into M1-type macrophages, which  produce pro-
inflammatory cytokines (such as TNF-α, IFN-γ, IL-1β and IL-6) and induce apoptosis 
[163]. The release of these pro-inflammatory cytokines leads to the activation of the 
nuclear factor kappa B (NF-κB) pathway, thus, amplifying the inflammatory process [162]. 
The initial response occurs as an attempt to reduce/overcome renal injury. When not 
achieved, the continuous activation and excessive ECM accumulation contribute to the 
formation of scar tissue and renal fibrosis, creating a vicious cycle that will lead to 
decreasing EPO production, development of anemia and tissue hypoxia. 
Tissue hypoxia is amplified according to the severity of anemia that will reduce O2 
availability to the organs. Within the kidney, the hypoxic environment leads to the 
activation of the HIF system, promoting the transcription of several target genes. 
Although HIF-1α and HIF-2α share the activation of several genes, HIF-2α is the main 
regulator of EPO gene, whereas HIF-1α is responsible for regulating glycolytic enzyme 
genes, as well as the genes involved in renal fibrosis [164]. Renal biopsies from CKD 
patients showed increased expression of HIF-1α in tubular epithelial cells that correlates 
to the stage of renal disease [164]. Connective tissue growth factor (CTGF) is directly 
regulated by HIF-1α and is a potent pro-fibrotic factor, as it potentiates TGF-β signaling 
[164] and appears to promote EMT [165]. HIF-1α was also associated to the EMT process 
[166]. It was reported that in CKD HIF-α activation presents dynamic changes, being 
activated in early CKD stages and suppressed in the middle and end-stage of CKD [167]. In 
a study using a PHD inhibitor, the early activation of the HIF system, triggering mainly 
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the up-regulation of the HIF-1α subunit, was associated with renal fibrosis and 
exacerbated renal dysfunction; the activation of the HIF system by the PHD inhibitor in a 
more advanced stage, where HIF-2α was also up-regulated induced VEGF and EPO 
production [63]. Inflammation and hypoxia are closely linked as tissue hypoxia induces 
inflammation, and vice-versa, through a NF-κB-dependent pathway that induces HIF-1α 
up-regulation [168]. The initial up-regulation of HIF-1α promotes injury repair, but the 
continuous activation contributes to worsening of tissue hypoxia and progression of renal 
disease [169].   
  
2.4. Treatment 
 The correction of anemia should be based on the diagnosis and identification of  
correctable causes [48]. In patients with a known inflammatory state (including bacterial 
and viral infections) the reduction of inflammation can be associated with Hb increase 
[48].  
The use of RBC transfusion is an option for CKD chronic anemia correction [48], but 
the risk of transfusion reactions (immunological sensitization), transmission of infectious 
agents and iron overload are limitations for the use of this treatment [170].  
The standard treatment for CKD anemia is based on pharmaceutical intervention by 
the use of erythropoiesis-stimulating agents (ESA) and/or iron supplementation, in order 
to maintain Hb concentration in the range of 10-11.5 g/dL [48]. ESA therapy will be 
discussed in the next chapter. The current guidelines refer that CKD patients with absolute 
iron deficiency should start a trial using oral supplementation, when TSAT is lower than 
30% and ferritin levels lower than 500 ng/mL. In case of functional iron deficiency, 
normal TSAT and ferritin higher than 300 ng/mL, iron supplementation is also 
recommended, in order to maintain iron available for an adequate erythropoiesis; 
however, the upper safe serum ferritin level was not defined. The decision for oral or 
intravenous (IV) iron treatment should balance the benefits and risks for the patient 
(Figure 10).  
Oral iron formulations (Table 7) are less expensive; however, the gastrointestinal 
side effects experienced by some patients (about 30%) may reduce the effect and the 
adherence to treatment [171, 172]. Some studies in anemic non-dialysis (ND)-CKD 
patients reported that IV iron therapy increases both Hb and ferritin, while oral iron 
therapy increases Hb without increasing iron stores [171, 172]. Moreover, most of the 
clinical studies evaluating oral and IV administration reported that IV iron therapy leads 
to a higher increase in Hb than oral iron therapy [172, 173].  
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Figure 10 – Iron deficiency and treatment of anemia in chronic kidney disease patients. 
Iron deficiency can be absolute or functional according to transferrin saturation (TSAT) and ferritin values. 
Oral or intravenous (IV) iron can be used to correct iron deficiency depending on patient characteristics. 
Adapted from Ribeiro et al. (2015) [84]. 
 
Table 7 - Iron supplements approved for chronic kidney disease anemia treatment 
Oral Intravenous 
Ferrous sulfate 
Ferrous gluconate 
Ferrous fumarate 
 
Iron sucrose 
Ferumoxytol 
Ferric carboxymaltose 
Iron dextran 
Adapted from Ribeiro et al. (2015) [84]. 
 
IV iron therapy is better tolerated than oral iron therapy [171, 172], has more 
adherence and efficacy, but requires the existence of an IV access. It has been associated 
with hypersensitivity reactions that, although very rare, can be life-threatening [174]. The 
major risk factors for these hypersensitivity reactions include a previous reaction to an 
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iron infusion, a fast iron infusion rate, multiple drug allergies, severe atopy and systemic 
inflammatory diseases [174].  
IV iron therapy is preferred for patients under HD, as they have a vascular access 
already available that can be used for iron infusion. In ND-CKD patients, oral iron may be 
preferred to preserve IV accesses. However, there is no consensus for the use of oral rather 
than IV iron as first line treatment in ND-CKD patients. Several studies have been 
performed [171, 173, 175, 176] to further clarify the efficacy and safety of oral versus IV 
iron supplementation in ND-CKD patients. Stoves et al. (2001) [175] in a follow-up study 
along 6 months of ND-CKD patients, found that the Hb response and ESA requirements 
with IV iron (iron sucrose) or with oral iron (ferrous sulfate) supplementation were 
similar. In accordance, Charytan et al. (2005) [171] and Agarwal et al. (2006) [177] 
reported that both IV and oral iron therapies in ND-CKD patients resulted in similar Hb 
responses, but IV iron therapy showed better results in replacing iron stores. Conversely, 
Qunibi et al. (2011) [172], Van Wyck et al. (2005) [173] and the recently FIND-CKD study 
(2014) [176] found that IV iron is superior to oral iron therapy, as ND-CKD patients under 
IV iron therapy showed higher Hb levels and iron stores, as well as a higher improvement 
in their quality of life.  
The efficacy of oral iron therapy can be compromised in CKD, as these patients 
usually present a low to mild degree of inflammation, which leads to an increase in 
hepcidin levels [31, 89]. This increase in hepcidin, by reducing gastrointestinal iron 
absorption and decreasing iron release from body storage sites, inhibits the use of iron for 
erythropoiesis and leads to an increase in ferritin, also functioning as an acute phase 
protein. 
The optimization of iron delivery, given the complications associated with IV iron 
therapy, and the reduced oral iron adherence and efficacy, is a current challenge to search 
and develop better iron formulations (Table 7). 
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3. ERYTHROPOIESIS-STIMULATING AGENTS 
 
3.1. Pharmacology 
Purification of human EPO from the urine of patients with aplastic anemia [178] 
allowed its characterization, and the isolation and cloning of the human genomic DNA 
encoding for EPO [179]. EPO is a glycoprotein of 166 amino acids with a molecular weight 
(MW) of 34 kDa and 30% carbohydrate, containing sialic acid and N-acetylglucosamine. 
The glycosylation of EPO is important for its in vivo activity and stability [180]. 
After cloning the EPO gene, the modern technology of DNA recombination allowed 
the production of recombinant human erythropoietin (rHuEPO). rHuEPO synthesized by 
(Chinese) hamster ovary cell lines is highly glycosylated, but the carbohydrate structure is 
similar to human EPO. rHuEPO presents a MW of 30 kDa and contains approximately 
39% carbohydrate [181], but this does not affect its activity [182].  
Epoetin beta and epoetin alpha were the first rHuEPO approved for anemia 
treatment (Table 8). These isoforms present some differences, but with no effect on its 
clinical efficacy [183].   
The pattern of glycosylation affects the half-life of rHuEPO; based on that, other 
ESA appeared, with similar actions, but differing in their half-life, which determines the 
frequency and route of administration (usually, the IV administration is more convenient 
for HD patients) leading to the division in “short-acting” and “long-acting” ESA (Table 8).  
Darbepoetin alpha presents two additional N-linked carbohydrate chains compared 
to EPO, which increase its half-life, allowing its administration only once per week [184]. 
In 2007, methoxy polyethylene glycol-epoetin beta, a continuous EPO receptor activator 
was introduced, presenting a half-life of about 130 h, which reduced its administration for 
once per month [185]. Peginesatide, with a longer half-life, is a pegylated homodimeric 
peptide with no sequence homology to EPO [186]; it was the first synthetic peptide 
approved by the Food and Drug Administration (FDA) for the treatment of CKD anemia, 
in 2012; however, due to serious hypersensitivity associated reactions, the product was 
removed from the market in 2013. Due to expire of several patents, ESA biosimilars (Table 
8) have been approved by the European Medicines Agency (EMA), presenting therapeutic 
profiles similar to those of epoetin beta and alpha [184]. 
The need for better formulations and other strategies for drug delivery are growing 
fields in the treatment of anemia (Table 9). EPO fusions proteins - Fc-EPO, CTNO 528 – 
can be administered as an aerosol [187], and other delivery systems are under 
investigation, such as ultrasound-mediated transdermal uptake and via liposomes (orally) 
[188]. The HIF stabilizers have the advantage that can be administered orally. Several HIF 
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Table 8 – Approved erythropoiesis-stimulating agents  
ESA 
Approval 
Structure Half-life 
Freq. 
adm. 
Therapeutic 
area FDA EMA§ 
Short-acting 
Epoetin beta  1989 
Identical aa 
and 
carbohydrate 
composition 
to EPO 
 
IV 4-12h 
SC 12-28h 
3 x/w 
Anemia, CKD, 
cancer, blood 
transfusions 
Epoetin alpha 1989 1989 
IV ≈5h 
SC ≈24h 
3 x/w 
Anemia, CKD 
Cancer 
Epoetin zeta*  2007 
IV ≈5h 
SC ≈24h 
3 x/w 
Anemia, CKD, 
cancer, blood 
transfusions 
Epoetin theta*  2009 
IV ≈4h 
SC ≈34h 
3 x/w 
Anemia, CKD 
Cancer 
Long-acting 
Darbepoetin 
alpha 
2001 2001 
2 additional 
N-linked 
carbohydrate 
chains 
compared to 
EPO 
IV ≈21h 
SC ≈73h 
1 x/w 
Anemia, CKD 
Cancer 
Methoxy 
polyethylene 
glycol-epoetin 
beta 
2007 2007 
Continuous 
EPO receptor 
activator 
IV ≈134h 
SC ≈139h 
1 x/m Anemia, CKD 
*Biosimilars; §From 1995 to 2009, the European Medicines Agency was known as European Agency for the 
Evaluation of Medicinal (EMEA) Products. Abbreviations: aa – amino acid;  CKD – Chronic kidney disease; 
EMA – European Medicines Agency; EPO – Erythropoietin; ESA – Erythropoiesis-stimulating agents; FDA – 
Food and Drug Administration; Freq. adm. – Frequency of administration; IV – Intravenous; m – month; SC 
– Subcutaneous; w – week. Adapted from Ribeiro et al. (2013) [189]. 
 
stabilizers are under clinical trials, mainly PHD inhibitors [190]. However, there are some 
concerns about the tumorigenicity of these agents [191], as they present the disadvantage 
of up-regulate other HIF-sensitive genes, besides the EPO gene. Therefore, the current 
attempt is to find agents able to up-regulate only erythropoiesis genes. The most attractive 
area on this field is the EPO gene therapy, which could allow the generation of lower and 
continuous levels of EPO [192]. Several strategies have been studied [193, 194], but their 
application in humans needs more studies to evaluate the safety profile of these agents. 
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Table 9 – Erythropoiesis agents under study 
Protein-based ESA therapy EPO fusion proteins 
Small-molecule ESA 
Peptide-based 
Non-peptide based 
Other strategies 
HIF stabilizers 
GATA inhibitors 
HCP inhibitors 
EPO gene therapy 
Abbreviations: EPO – Erythropoietin; HIF – Hypoxia inducible factors; HCP – Hemopoietic cell phospathase. 
Adapted from Ribeiro et al. (2013) [195] 
 
In healthy humans, rHuEPO treatment increases Hb concentration and, thus, 
arterial oxygen content, by depressing plasma volume and increasing RBC mass [196]. The 
reduction of plasma volume may result from the reduced reabsorption of water and 
sodium in the proximal renal tubules promoted by rHuEPO and, probably, through a 
mechanism involving the reduction of the RAAS activity [197].  
The mechanisms for ESA clearance are not well elucidated, but several pathways can 
be involved. Clearance by hepatic and kidney pathways are considered [198], but the 
presence of liver or kidney disease appears to unaffected ESA clearance [199, 200], 
suggesting the presence of other mechanism, as receptor-mediated endocytosis of EPO via 
EPOR followed by degradation in lysosomes, with a major role for the bone-marrow [201, 
202].  
EPO and ESA stimulate erythropoiesis by binding to EPOR homodimers, present in 
the membrane of erythroid progenitors. EPO binding triggers a conformational change 
that stimulates auto-phosphorylation of janus kinase 2 (JAK2), which phosphorylates 
tyrosine residues on the EPOR intracellular domains, activating cytoplasmic signaling 
proteins, such as STAT5, AKT and ERK1/2 pathways, responsible for cellular 
differentiation and proliferation and for anti-apoptotic effects (Figure 11) [58]. 
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Figure 11 – Signaling pathways stimulated by the linkage of erythropoietin to 
erythropoietin receptor.  
Erythropoietin (EPO) and erythropoiesis-stimulating agents binding to EPO receptor (EPOR) triggers the 
activation of several signaling pathways, such as the signal transducer and activator of transcription [STAT5],  
AKT and extracellular signal-regulated kinase [ERK1/2]),  in order to promote proliferation and 
differentiation of erythroid cells and reduce erythroid progenitor’s apoptosis. Adapted from Elliot et al. (2014) 
[203]. 
 
3.2. Clinical benefits 
The introduction of ESA revolutionized the treatment of anemia in patients with 
CKD, as they have beneficial effects by correcting anemia and their associated symptoms 
(fatigue, dizziness, shortness of breath, among others) improving patients’ quality of life 
[37, 204, 205]. ESA also reduced the need for RBC transfusions, thereby reducing 
transfusion reactions (immunological sensitization), transmission of infectious agents and 
iron overload [170]. 
The correction of anemia with ESA is also associated with an improvement on heart 
failure symptoms and left ventricular hypertrophy (LVH), both in pre-dialysis and dialysis 
patients [206-208]. LVH is present in many patients with CKD, even in the earlier stages 
of the disease (75% of patients who start HD have LVH), and may lead to heart failure, 
cardiac arrhythmia or both, that are considered major causes of cardiac-related deaths in 
this population [206, 209]. LVH is a physiological adaption that results from long-term 
increase of myocardial work due to high-pressure or volume overload, which can lead to 
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major cardiac events. Volume overload can result from anemia, as hypoxia and the 
decreased blood viscosity contribute to decrease peripheral resistance, and from increased 
venous return, both of which increase cardiac output [209]. 
The effects of ESA on the progression of renal function are controversial. Some 
studies showed that following ESA initiation and correction of anemia renal function 
declines at a slower rate, delaying the dialysis initiation in pre-dialysis patients [210-212], 
while other studies reported that ESA do not significantly affect renal function [213, 214]. 
Therefore, the use of CKD animal models treated with ESA to study the impact of this 
therapy on renal disease progression would be important.  
 
3.3. Non-hematopoietic actions 
ESA are designed to correct anemia, but some evidences showed that ESA (and 
EPO) present actions beyond hematopoiesis. The non-hematopoietic actions appear to 
result from the existence of another EPOR receptor (Figure 12), a heterodimeric receptor 
constituted by an EPOR homodimer complexed with CD131, the common beta receptor 
(βCR) that is involved in granulocyte macrophage colony-stimulating factor, IL-3 and IL-5 
signaling [215]. The two EPOR present different affinities for EPO, as in erythroid cells 
picomolar concentrations of EPO are sufficient to trigger EPOR homodimer activation, 
whereas on other cells and tissues high local EPO concentrations are needed to activate 
EPOR heterodimer [216]. This heterodimer EPOR were detected in several cells and 
tissues, such as brain (neurons, astrocytes and microglia), kidney, female reproductive 
system, vascular endothelial cells, cardiomyocytes, lymphocytes and monocytes, among 
others [217]. 
Several pleiotropic effects have been attributed to EPO and ESA, such as 
cytoprotective, anti-apoptotic, anti-inflammatory and angiogenic properties (Figure 12).  
EPO and ESA reduce the production of pro-inflammatory cytokines (such as TNF-α, 
IL-6 and IL-1β) and nitric oxide (NO), via inducible NO synthase (NOS) through the 
inhibition of NF-κB pathway [218]. Immunomodulator effects of ESA have been described 
on dendritic cells, therefore presenting effects in innate immunity [219]. 
EPO seems to be important for the neural development, as it stimulates the 
differentiation of neural progenitor cells, but it also promotes angiogenesis and reduces 
inflammation, oxidative stress and neuronal apoptosis in some conditions, including in 
hypoxia-ischemia, stroke and glutamate neurotoxicity [220]. EPO also increases the 
number of functionally active endothelial progenitor cells, enhancing angiogenesis, and 
seems to be dependent on functional endothelial NOS (eNOS) [221].  
Several studies showed that EPO/ESA present tissue protective properties. 
Cardioprotection occurs by the inhibition of cardiomyocyte apoptosis, reduction of 
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inflammation and oxidative stress, and induction of angiogenesis [222]. In acute lung 
injury, EPO/ESA present beneficial effects by modulating apoptosis, inflammation, 
peroxidation, and by inducing angiogenesis [223].  
 
 
 
Figure 12 – Signaling pathways activated in hematopoietic (red) and non-hematopoietic 
(blue) cells.  
In hematopoietic cells, erythropoietin (EPO) and erythropoiesis-stimulating agents (ESA) activate the EPO 
receptor (EPOR) homodimer triggering erythropoiesis, whereas in non-hematopoietic cells, EPO and ESA 
activate several pathways responsible for tissue protection through the EPOR and common beta receptor 
(βCR). Adapted from Ogunshola et al. (2013) [217]. 
 
The slowing of renal dysfunction observed in some patients may result from the 
renoprotection afforded by ESA therapy. Several studies on acute kidney injury (AKI) 
reported that a single dose of rHuEPO reduces kidney dysfunction through an anti-
apoptotic mechanism, and increased NO production, but only in intact vessels [224]. ESA 
therapy also exert renoprotective effects by reducing pro-inflammatory cytokines (IL-1β 
and TNF-α), acute phase proteins (CRP), pro-fibrotic factors (TGF-β), and oxidative stress 
[225]. However, it appears that this renoprotection is achieved only with low doses of ESA 
(non-hematopoietic doses), as high doses cause an increase in hematocrit that is 
accompanied with changes in hemorheology, activation of thrombocytes and increased 
platelet adhesion to injured endothelium [224]. 
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Several EPO variants that present the protective effects of EPO in non-
hematopoietic tissues, but no hematopoietic activity, have been extensively used to study 
these pleiotropic effects, namely in animal models, to evaluate putative neuroprotection  
[226-228]. 
 
3.4. Risks 
 Hypertension is a common side effect associated with ESA therapy [229, 230]. ESA 
can be responsible for de novo or exacerbated hypertension; however, the underlying 
mechanisms are not fully understood. ESA can induce an increase in blood pressure by 
hemodynamic alterations, resulting from anemia correction, which is associated with 
increased RBC mass, hematocrit and, consequently, blood viscosity. These changes 
increase peripheral vascular resistance, thus, contributing to blood pressure rise [231]. 
ESA can also act directly on vascular smooth muscle cells (VSMC), promoting its 
proliferation, which induces hyperplasia of the vascular wall, contributing to increase 
peripheral vascular resistance and to alterations in renal vessels [232, 233]. ESA appears 
also to act directly on endothelial cells, stimulating its proliferation and promoting 
endothelial dysfunction by inducing endothelin-1 expression, a potent vasoconstrictor, 
and reducing NO synthesis, an important vasodilator [234-237]. Oxidative stress and 
production of asymmetrical dimethylarginine (ADMA), an inhibitor of eNOS, can also 
underlie ESA-induced hypertension [238, 239]. ESA also impair the balance between 
other vasoactive factors, inducing thromboxane A2 (TXA2) and prostaglandin 2α 
expression (vasoconstrictors), and reducing the production of the vasodilator prostacyclin 
[240]. The effects on the RAA axis are less clear, as ESA appear to reduce plasma renin 
levels [196], but an apparent hypersensitivity to angiotensin II has been reported in HD 
patients [241]. An increase in noradrenaline (another vasoactive substance) concentration 
and hypersensitivity may also contribute to  hypertension during ESA therapy [241]. 
 Thrombotic events have been associated with ESA therapy [242, 243], as it affects 
thrombopoiesis and platelet function. ESA have the capacity of stimulating 
thrombopoiesis (increasing platelet count) and platelet reactivity (especially on the newly 
synthesized ones) promoting a prothrombotic effect [244]. Activated platelets synthesize 
TXA2, a potent platelet activator, prothrombotic factor and vasoconstrictor, and high 
levels were found after ESA treatment, as well as increased E-selectin levels [245]. Some 
other hemostatic disturbances have been described, as an increased expression of P 
selectin, von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1), 
which may increase the risk of thrombosis and thromboembolism, as occlusion of the 
vascular access [240]. 
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 In the treatment of anemia secondary to chemotherapy in adult cancer patients 
with non-myeloid malignancies (Table 8), some evidences indicate that ESA can accelerate 
tumor growth, by promoting angiogenesis; the anti-apoptotic pleiotropic effect of ESA can 
also contribute to tumor progression [246]. 
A rare but serious complication associated with ESA treatment is pure red blood 
cell aplasia (PRCA), an immunogenic side-effect that results from the production of anti-
rHuEPO antibodies, directed against the protein moiety of the molecule [247-249]. The 
method used to produce ESA may not eliminate impurities or aggregated protein that may 
trigger the immune response in patients [249]. 
Despite all the benefits associated with ESA therapy, some adverse effects have been 
associated with this therapy. As described above, some effects of EPO and ESA are beyond 
the correction of anemia, and seem to be achieved by the use of increasing ESA doses, 
needed to trigger the activation of EPOR heterodimer. The current KDIGO guidelines [48] 
are in line with this, by recommending a more conservative increase in ESA dose used in 
CKD patients. 
 
3.5. Hyporesponsiveness 
The majority of CKD patients respond adequately to ESA, but 5-10% of them do 
not respond properly to this therapy [50]. According to the KDIGO guidelines [48], CKD 
patients can present initial or acquired ESA hyporesponsiveness: primary 
hyporesponsiveness is present when a patient has no increase in Hb concentration after 
one month of treatment with adequate weight-based ESA dose, whereas acquired ESA 
resistance exists, if after treatment with stable ESA dose used to maintain Hb 
concentration, a patient requires 2 consecutive increases (up to 50% beyond the stable 
dose) in ESA dose.  
Hyporesponsiveness (also widely referred as resistance) to ESA therapy is 
associated with a poor outcome, progression of renal disease, sudden death, infectious 
complications and all-cause mortality, mainly in dialysis patients [250-254]. Several 
causes are associated with poor response to ESA therapy, including iron deficiency, 
inflammation, malnutrition, hyperparathyroidism, among others [255-258]. ESA 
hyporesponsiveness is typically a transient condition, and correction of its treatable causes  
(Table 10) is usually sufficient to overcome this state, but careful monitoring of these 
patients should be continued [48]. 
Higher doses of ESA are needed to correct anemia in African-American patients 
compared to Caucasians subjects, due to the highest prevalence of sickle cell disease and 
of other hemoglobinopathies in that population [259]. Age and gender can also influence 
response to ESA therapy. Children and older age patients frequently need higher ESA dose 
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to achieve target Hb values [255, 260]. Female patients often need to use higher ESA dose, 
due to menstrual blood loss. In males, the androgenic stimulation of erythropoiesis 
through the production of hematopoietic growth factors improves iron bioavailability, 
and, thus, erythropoiesis [260]. In this sense, low testosterone levels in males with CKD 
may favor anemia and ESA resistance [261]. 
 
Table 10 – Potentially correctable and non-correctable factors involved in erythropoiesis-
stimulating agents response 
Easily correctable Potentially correctable Impossible to correct 
Absolute iron deficiency Infection/Inflammation Hemoglobinopathies 
Vitamin B12  deficiency Underdialysis Bone marrow disorders 
Folate deficiency Hemolysis  
Hypothyroidism Bleeding  
ACE inhibitor/ARB Hyperparathyroidism  
Non-adherence Pure red cell aplasia  
 Malignancy  
 Malnutrition  
Abbreviations: ACE - Angiotensin-converting-enzyme; ARB – Angiotensin-receptor blocker. Adapted from 
KDIGO group (2012) [48].  
 
3.5.1. Iron deficiency/overload 
Iron deficiency is present in about 60% of patients with creatinine clearance <60 
mL/min [262]. In CKD patients this condition may be due to increased iron demand to the 
bone marrow induced by ESA to sustain erythropoiesis; in HD patients the chronic blood 
loss is another factor contributing to iron deficiency. Supplementation with iron (oral or 
IV) can overcome absolute iron deficiency. Functional iron deficiency is also a frequent 
entity in CKD patients, mainly in those on dialysis, and in ESA resistance, due to iron 
restriction to erythropoiesis, by impaired iron release from iron stores [263] that, usually, 
can be corrected by IV iron supplementation [264, 265]. Hepcidin levels, particularly 
increased in HD patients [31, 266], are associated with functional iron deficiency [263], 
and could be clinically useful to assess iron status [267]. As already referred, hepcidin can 
be increased by inflammation [93], a common feature in CKD patients [31, 90], but it can 
be also increased due to reduced urinary excretion. Hepcidin is also found in urine 
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indicating that the kidney may play a role in the excretion of this peptide [91] and, 
therefore, the blood hepcidin levels might be influenced by residual kidney function [268]. 
In the recent years, the proportion of patients with serum ferritin values ≥800 
ng/mL has increased [269] and several studies reported tissue iron accumulation (liver 
and spleen) in CKD patients [270-273], which may contribute to increase hepcidin 
synthesis and further aggravate ESA hyporesponsiveness. The effects of iron overload will 
be discussed in another chapter (4.1. Iron therapy). 
 
3.5.2. Inflammation 
 CKD is considered a pro-inflammatory state, mainly due to increased uremic toxins 
that induce the production of inflammatory cytokines; however, other causes can also 
contribute to inflammation, such as active infections, vascular access for HD procedure 
and surgery-evoked inflammation (vascular surgery included). In this sense, the use of 
dialysis catheter is associated with higher inflammatory features, compared with the use of 
arteriovenous fistula [31, 260]. 
 Elevated pro-inflammatory cytokines are associated with enhanced oxidative 
stress, responsible for alterations in RBC membrane and activation of macrophages, 
increasing erythrocyte damage and reducing its lifespan [274]. Uremic toxins and pro-
inflammatory cytokines also inhibit bone marrow erythropoiesis, as already referred 
above, and may favor ESA hyporesponsiveness. A weak response to ESA also appears to be 
associated with enhanced T cell capacity to express IFN-γ, TNF-α, IL-10, and IL-13 [90, 
275]. Inflammation also induces hepcidin synthesis limiting iron availability for 
erythropoiesis. 
In patients with iron replete stores, inflammation is the best predictor of ESA 
response, and IL-6 and CRP appear to be the best markers [250, 276-278]. Neutrophil 
count is increased in poor responders to ESA therapy, and positive correlations were 
found  between CRP and elastase, and between elastase and rHuEPO doses, suggesting 
that elastase, a neutrophil protease released by degranulation, could be a good marker of 
resistance to ESA therapy in CKD patients under HD [279]. 
 
3.5.3. Malnutrition 
Low body mass index, low levels of total cholesterol and triglycerides are related to 
poor outcomes in dialysis patients, increasing the risk of mortality [31, 280]. This 
phenomenon is called “reverse epidemiology” as the reduction in these factors is 
associated with a lower CVD risk in the general population. CKD patients present a 
malnutrition-inflammatory complex; thus, when they present a decreased nutritional 
reserve, their capacity to overcome inflammation seems to be reduced. A reduced protein-
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calorie intake, chronic acidosis and failure of the vascular access, all contributing to 
requirement of higher ESA dose to correct anemia [281], may also underlie this reverse 
epidemiology. 
 
3.5.4. Secondary hyperparathyroidism 
The parathyroid hormone (PTH) is considered by EUTox Work Group as an uremic 
toxin with some biological effects [153]. Secondary hyperparathyroidism is a condition 
that results from the dysregulation of calcium and phosphorus homeostasis in the kidney. 
It seems that PTH could be a marker of hyporesponse to ESA in dialysis patients [282, 
283], considering that PTH causes bone marrow fibrosis, presents an inhibitory effect on 
BFU-E, interferes with endogenous EPO and increases osmotic fragility of erythrocytes, 
thus, interfering with RBC production and removal [284-286]. 
 
3.5.5. Aluminium toxicity 
Despite the recent progresses in the dialysis procedures, some patients still present 
high levels of aluminium [260]. Usually, high levels of aluminium cause a microcytic, 
hypochromic or normochromic anemia that is hyporesponsive to ESA therapy, as it 
interferes with the enzymes necessary for heme synthesis. The sources for the increase in 
plasma aluminium levels seem to be the water used for dialysis, IV medications and 
infections [287, 288].  
 
3.5.6. Inadequate dialysis 
The intensity or adequacy of dialysis is a factor that can modulate the response to 
ESA therapy. Inadequate dialysis is associated with the need for higher ESA doses. Some 
studies showed that convective treatments present benefits in ESA response, as compared 
with other treatments [289]. High flux HD and online hemodiafiltration improve the 
response to ESA, as compared to low flux HD, probably due to a better removal of middle 
and large molecules that impair erythropoiesis [289]; however, some studies failed to 
reach to the same conclusions [290, 291]. 
 
3.5.7. Vitamins deficiency 
The deficiency of folate or vitamin B12 is not very common in dialysis patients, but 
as these nutrients are water soluble and can be easily loss during dialysis, they can become 
a cause of ESA hyporesponse, especially in patients with malnutrition. The 
supplementation of these nutrients seems to overcome ESA hyporesponsiveness [260].  
Vitamin D deficiency is now a recognized cause for ESA resistance in some patients 
due to reduced kidney capacity to synthesize the active form of vitamin D. It is known that 
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vitamin D is important for bone mineral metabolism, but the link between vitamin D and 
ESA response seems to result from a direct stimulatory action on erythroid progenitors or 
the modulation of innate and adaptive immunity, controlling the expression of 
inflammatory cytokines and, therefore, reducing the effects of inflammation [292]. 
 
3.5.8. Drugs 
ACE inhibitors and angiotensin-receptor blockers, used to treat hypertension, can be 
associated with ESA hyporesponsiveness due to their effects on angiotensin II. They can 
act through several mechanisms, not well understood, including inhibition of angiotensin-
induced EPO release and increment in plasma levels of N-acetyl-serylaspartyl-lysil-proline 
that impairs the recruitment of pluripotent hemopoietic stem cells [260].  
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4. CONTROVERSIES IN THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY 
DISEASE 
 
4.1. Iron therapy 
One of the concerns in IV iron therapy is that the used iron dose overwhelms the 
binding capacity of Tf, leading to an increase in non-Tf bound iron (NTBI). Moreover, as 
Tf levels are usually reduced in CKD patients, this effect might be enhanced [31, 89]. The 
presence of NTBI can lead to the development of oxidative stress, increasing the pro-
oxidant state of these patients. In the case of co-existence of inflammation and CVD, the 
oxidative stress may be even more enhanced. It has been also suggested that NTBI might 
be a source for iron deposition in organs [293]. 
The Dialysis Outcomes and Practice Patterns Study (DOPPS) [269] showed that the 
number of HD patients with IV iron supplementation increased in most countries; and 
even more important, the doses prescribed to these patients also increased in the past 10-
15 years. Overall, the mean serum ferritin has increased overtime, and the proportion of 
patients with serum ferritin values ≥800 ng/mL has also increased [269]. 
The recent KDIGO Controversies Conference on Iron Management in CKD (San 
Francisco, 2014) recognized the entity of iron overload in HD patients. Actually, there are 
several studies (Table 11) reporting tissue iron accumulation in HD patients treated with 
ESA and IV iron. Canavese et al. [270] found that 70% of HD patients present mild-to-
severe hepatic iron overload, although the same percentage of patients presented serum 
ferritin values below 500 ng/mL. Ferrari et al. [271] reported that 60% of HD patients 
present liver iron concentration >60 µmol/g (above the normal upper limit of 30 µmol/g) 
and 13% had liver iron concentrations >130 µmol/g, which is usually found in patients 
with hemochromatosis; they also found that liver iron accumulation was correlated with 
cumulative iron dose, but no correlation was observed with ferritin or TSAT. Recently, two 
other studies found similar results [272, 273]. Ghoti et al. [272] reported that 90% of HD 
patients present mild to severe hepatic iron deposition and also iron deposition in the 
spleen. In the other study [273], 84% of the HD patients had hepatic iron overload, among 
which 30% presented severe iron overload; moreover, liver iron content correlated with 
infused iron. 
In spite of the widespread use of IV iron supplementation in HD patients, the safest 
dosing strategy is still poorly clarified, as well as its relation with serum ferritin levels, iron 
overload and mortality risk. Actually, only few studies addressed these questions, and 
presented controversial results (Table 11). Feldman et al. [294] found that HD patients 
receiving more than 1000 mg of IV iron in a period of 6 months presented a higher risk of 
death and hospitalization, compared to patients with no iron supplementation. In a 
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follow-up study of 2 years, the same group evaluated the effect of each 6 months of iron 
exposure and did not find any association between the iron administrated and mortality, 
but found an association between iron dose and mortality at 12 to 18 months of treatment, 
for iron doses higher than 1800 mg [295]. In the first study of this group [294], only 17% 
of the HD patients received iron dosing above 1000 mg, whereas in the second study [295] 
this number rose to 48%. These authors also found an association between mortality and 
ferritin levels >800 ng/mL in the 6 months prior to death, but this finding could result 
from confounding factors, such as inflammation and malnutrition [295]. 
Another observational study evaluating HD patients for a period of 2 years showed 
that serum ferritin levels in the range of 200-1200 ng/mL, TSAT between 30 and 50% and 
IV iron dose <400 mg by month were associated with improved survival, suggesting that 
the association of high ferritin levels and mortality could also result from confounding 
factors [296].  
A recent study [297] evaluated the effect of a bolus of IV iron (consecutive doses 
≥100 mg exceeding 600 mg during one month) versus maintenance of IV iron therapy (all 
other iron doses during the month), and also the effect of high (>200 mg over 1 month) 
versus low dose of IV iron (≤200 mg over 1 month); after 1 month of iron exposure, the 
patients were studied for a follow-up period of 3 months; no significant associations of 
bolus versus maintenance dose or of high versus low dose IV iron with increased short 
term cardiovascular morbidity and mortality were found. Zitt et al. [298] found that 
increasing ferritin concentrations (>800 ng/mL) in patients with normal CRP 
concentrations were associated with decreasing mortality, whereas in patients with high 
CRP values (>5 mg/dL) the increasing ferritin concentration was linked with increased 
mortality, suggesting that serum ferritin levels above 800 ng/mL are associated with 
increased mortality in the case of concomitant inflammation. A 2-year follow-up study, by 
our group [31], found that HD patients present several changes in iron metabolism 
(increased TSAT, ferritin and hepcidin and a decrease in iron and Tf) and in inflammatory 
markers (increased IL-6 and CRP). Patients who died during this follow-up period showed 
significantly lower values for Tf and TSAT and increased levels of IL-6 and CRP. In the 
adjusted survival regression model, CRP was found to be a significant predictor of 
mortality.  
The recently published observational DOPPS study [299] showed that HD patients 
receiving, along 4 months, 300 mg/month or even a higher dose of IV iron 
supplementation, compared with patients supplemented with 100-199 mg/month, 
presented increased hospitalization risk, all-cause mortality and cardiovascular mortality, 
regardless of serum ferritin or CRP concentrations. 
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Table 11 – Studies evaluating iron overload and mortality risk associated with intravenous iron therapy in dialysis patients 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CRP — C reactive protein; HD — hemodialysis; IV — intravenous; mo — month; w — week. Adapted from Ribeiro et al. (2015) [84].
 
Year Patients Iron dose/follow-up time Outcome Ref. 
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2012 HD patients 
(n=119) 
100 mg of iron sucrose 
(2-3x/w - induction phase; 1x/w every 4 w - maintenance phase) 
60 mo follow-up 
• 84 % of patients with hepatic iron deposition, 30% of them with severe iron overload 
• Iron liver content correlates with infused iron 
[273] 
2012 HD patients 
(n=21) 
100 mg (ferric saccharate) 1-3x/w 
12 mo follow-up 
• 90% of patients with mild-to-severe hepatic iron deposition 
• 95% of patients with splenic iron deposition 
• 14% patients with pancreatic iron deposition 
[272] 
2011 CKD patients 
(n=25) 
50 to 200 mg/mo for 12 mo • Liver iron concentration: 60% of patients > 60 umol/g; 13% of patients > 130 umol/g 
(reference value 30 umol/g) 
[271] 
2004 HD patients 
(n=40) 
31.25 mg ferric gluconate complex 
10 patients: maintenance iron at least 6 mo 
30 patients: without iron therapy at least 2 mo (after ferritin >500 ug/L) 
• 70% of patients with mild-to-severe hepatic iron overload 
• 70% of patients with ferritin < 500 ng/mL 
[270] 
M
o
r
t
a
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2015 HD patients 
(n=32 435) 
4 month-follow up of IV iron dose: < 300 mg/mo versus ≥ 300 mg/mo • ↑ mortality among patients with higher doses of IV iron (≥ 300 mg/mo over 4 months), 
regardless serum ferritin or CRP values 
[299] 
2014 dialysis patients 
(n=235) 
7.6 years-follow up with continuous maintenance iron therapy once/w in 
varying doses: 12.5 mg (minimum dose) to 62.5 mg (maximum dose) 
• ↑ mortality with  ferritin levels > 800 ng/mL in case of concomitant inflammation (CRP 
> 0.5 mg/dL) 
[298] 
2013 HD patients 
(n=117 050) 
3 mo-follow up after 1 mo exposure to: 
high dose (> 200 mg) versus low dose (1-200 mg) 
bolus (consecutive doses ≥ 100 mg exceeding 600 mg during one month) 
versus maintenance dose 
• no significant associations of bolus versus maintenance dose or high dose versus low 
dose IV iron with increased short-term cardiovascular morbidity and mortality  
[297] 
2005 HD patients 
(n=58 058) 
Iron gluconate effect in a 2 year-follow up, with different iron dose 
categories: 0 mg/mo; 1 to 199.9 mg/mo; 200 to 399.9 mg/mo; > 400 
mg/mo 
• ferritin 200-1200 ng/mL, TSAT 30-50% and IV iron dose < 400 mg/mo associated 
with improved survival 
[296] 
2004 HD patients 
(n= 27 280) 
Effect of iron administration in a 2 year follow-up, with iron doses 
categories at each 6 mo: >0 to 700 mg; > 700 to 100 mg; > 1000 to 1800 
mg; > 1800mg 
• no association between iron administrated and mortality 
• association between iron dose and mortality at 12 to 18 months of treatment, for doses 
> 1800 mg 
• association between mortality and ferritin > 800 ng/mL in the 6 months prior to death 
[295] 
2002 HD patients  
(n= 10 169) 
number of 100-mg vials of iron during 6 mo • ↑ risk of death and hospitalization with IV iron > 1000 mg [294] 
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Considering the controversial data in literature, there is a clear need to develop 
clinical trials with longer follow-up periods of HD patients to evaluate the effect of long-
term cumulative IV iron doses and the impact of serum ferritin levels on all-cause and 
cardiovascular mortality. In accordance, a clinical trial, “The Proactive IV irOn Therapy 
for HaemodiALysis patients (PIVOTAL)”, has recently started (2013), and the aim is to 
compare the effect of IV iron high-dose versus low-dose regimen on all-cause mortality, 
and to evaluate the incidence of non-fatal cardiovascular endpoints, in HD patients along 
2-3 year follow-up [300]. Another aim of this study is to compare the effect of the two 
regimens on ESA dose requirements, RBC transfusions, complications of HD treatment, 
and quality of life of the patients. 
Iron toxicity is also a concern surrounding iron therapy. Data in literature strongly 
suggest the risk of tissue iron overload in HD patients, although the underlying 
pathophysiological mechanisms are less clear, especially in the case of IV administration 
of iron. As referred, the infusion of iron may overwhelm the capacity of the iron binding 
proteins, allowing iron to become free in circulation and/or to increase iron stores. It is 
known that free iron can react with hydrogen peroxide leading to the production of 
hydroxyl radicals that are able to trigger oxidative modifications in lipids, proteins and 
DNA. Indeed, the literature supports that after IV iron injection in HD patients a transient 
increase in oxidative stress occurs, as shown by the increase in plasma lipid peroxidation 
[301] and oxidative modification of proteins [302]. Actually, different markers of oxidative 
stress are significantly increased in CKD patients [303, 304] and are involved in the 
progression of renal disease [305]. 
Several diseases have been associated with oxidative stress, such as CVD [306, 307], 
which are the major cause of death in HD patients. It has been hypothesized that the 
oxidative stress induced by IV iron infusion could favor atherosclerosis and endothelial 
cell damage [308, 309]. NTBI might be important for extrahepatic iron deposition and 
toxicity, namely, in the kidney. Progressive tubulointerstitial damage and renal fibrosis are 
common pathways in the development of CKD and iron deposition could favor these 
lesions. Indeed, iron accumulation is observed in the proximal tubule in human CKD 
[310], as well as in rats with nephropathy [311-313], and seems to be associated with the 
progression of CKD [311]. In a study by our group, using a rat model of nephrectomy, we 
found iron deposition in tubules, along with extensive tubulointerstitial lesions, after 9 
weeks of nephrectomy [313].  
An association of iron therapy with infection has been inconsistently reported in 
literature. One study observed a significantly higher rate of bacterial infection with higher 
IV iron saccharate dose, but not with higher frequency of dosing administration [314]. A 
one year follow-up study of HD patients examined the relationship between iron stores, IV 
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iron dosing and bacteremia risk, and found that patients with higher iron stores had a 
significantly higher risk of bacteremia; however, they did not find an IV iron dose-
response relationship [315]. Brewster et al. [316] reported that IV iron did not significantly 
increase the rate of microorganism growth within catheters or the development of blood 
infections with iron supplementation. After the recent changes in the pattern of IV iron 
treatment [48], Bansal et al. [317] in a 2 year follow-up study of HD patients treated with 
IV iron found no increase in the incidence of infectious complications. In a retrospective 
cohort study of HD patients, those receiving bolus versus maintenance iron therapy were 
at increased risk of infection-related hospitalization [297]. Recently, Kuragano et al. [318] 
found that patients with a higher ferritin level had a higher risk of infectious disease than 
those with lower ferritin level. They also found that the risk of infection and 
hospitalization were significantly higher among patients who were treated with high 
weekly doses of IV iron, compared with no iron. An observational study that included 14 
078 patients reported the possibility of infection-related mortality with higher iron doses 
[319]. 
The type of IV iron formulation might also have an impact in the rate of infection, as 
suggested by Sirken et al.[320] that found a higher bacteremia rate with iron sucrose than 
with ferric gluconate; however, a relationship between IV iron dose and bacteremia was 
not supported. Randomized clinical trials are needed to assess the effect of cumulative IV 
iron doses and the risk of infection-related mortality. 
 
 
4.2. High hemoglobin target or high erythropoiesis-stimulating 
agents dose 
Despite all the benefits of ESA therapy some concerns have been raised, due to 
studies reporting a high incidence of cardiovascular events and mortality in CKD patients 
treated with ESA [243, 321], though no difference on mortality risk was observed for the 
different ESA available [322-324]. 
Since the introduction of ESA therapy a demand exists to define the better Hb target 
associated with lower cardiovascular risk. Indeed, recent studies reported increased 
cardiovascular risk and death in patients treated with high ESA doses to achieve higher Hb 
levels. This led to the controversy surrounding increased risk: if higher doses of ESA or 
higher levels of Hb. Only four studies assessed properly the effect of higher Hb levels on 
the increased risk of cardiovascular events and/or death. 
The Normal Hematocrit Trial [325] included patients under HD with congestive 
heart failure or ischemic heart disease. HD patients were randomized to receive epoetin 
alpha aiming to achieve and maintain a target Ht of 42% (high-Ht group) or 30% (normal-
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Ht group). Primary end points were the length of time to death or to first nonfatal 
myocardial infarction. The study was interrupted due to the increased number of deaths 
observed in the high-Ht group and that were nearing the boundary of statistical 
significance. An increased incidence rate of vascular access thrombosis was also reported 
in the high-Ht group. The study failed to reach statistical difference between the two 
groups, however, it was concluded that a target Ht of 42% is not recommended in HD 
patients. 
In 2006, the Cardiovascular Risk Reduction by Early Anemia Treatment with 
Epoetin Beta (CREATE) [326] included pre-dialysis patients in stage 3 or 4 with mild-to-
moderate anemia, randomly assigned to normalization of Hb values (13.0-15.0 g/dL) or to 
a partial correction of anemia (10.5-11.5 g/dL), in order to investigate the effect of Hb 
correction on complications from cardiovascular causes. The primary endpoint was the 
time to first cardiovascular event; secondary objectives included the investigation of the 
effects of these treatments on the left ventricular mass index, the progression of CKD and 
the quality of life. A significant difference in the risk for a first cardiovascular event 
between the two groups was not found. However, this study reported a higher incidence of 
hypertension and headaches, and a higher risk for starting dialysis in the group aiming to 
normalize Hb values. On the other hand, it was reported significant benefits on the quality 
of life for the patients with higher Hb targets. It was concluded that in pre-dialysis patients 
with mild-to-moderate anemia, the normalization of Hb levels to 13.0-15.0 g/dL does not 
reduce cardiovascular events. 
 The Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) 
study [327], published in the same year of the CREATE study, included ND-CKD patients 
and the effect of raising Hb concentration with epoetin alpha to a target Hb value of 13.5 
g/dL (high-Hb group) or 11.3 g/dL (low-Hb group) was compared. The primary end point 
was the time of death, myocardial infarction, hospitalization due to congestive heart 
failure (excluding renal replacement therapy), or stroke. An increased risk for the primary 
end point was found in the high-Hb group, as compared with the low-Hb group. Death 
and hospitalization due to congestive heart failure accounted for 74.8% of the events. An 
increased rate of thrombotic events was also reported in the group aiming high-Hb levels. 
Patients in the high-Hb group had a higher (but not significant) rate of both progression 
and hospitalization to renal replacement therapy. The study found no apparent additional 
benefit in quality of life. In conclusion, it was recommended the use of a target Hb level of 
11.0-12.0 g/dL rather than a level of 11.0-13.0 g/dL to correct anemia in these patients, 
because of the increased risk, increased costs, and no quality-of-life benefit. 
Considering the results of these two studies (CHOIR and CREATE), in 2007, the 
FDA launched a safety advisory, recommending that patients should not exceed the Hb 
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level of 12 g/dL [328]. At the same time, the NKF KDOQI made an update on its 
guidelines, recommending that the selected Hb target should generally be in the range of 
11.0-12.0 g/dL, but should not be higher than 13.0 g/dL [329]. In 2010, the ERBP Work 
Group published the recommendation that “Hb values of 11-12 g/dL should be generally 
sought in the CKD population without intentionally exceeding 13 g/dL” [330]. 
In 2011, the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) 
was published [42]. In this clinical trial patients with type 2 diabetes mellitus, CKD and 
anemia were enrolled and were randomized to receive darbepoetin-alfa (in order to 
achieve a target Hb of 13.0 g/dL) or placebo (in this group was prescribed blinded “rescue” 
darbepoetin for Hb level <9.0 g/dL). The primary end point was time to death or 
hospitalization due to myocardial ischemia. A significantly higher rate of strokes in 
patients treated with darbepoetin was observed. A higher rate of both thromboembolism 
and cancer-related deaths among patients with a history of cancer in the treatment group 
was also reported. 
After the TREAT study was published, FDA introduced warnings in the ESA label 
giving the recommendations “for more conservative dosing of ESA in patients with CKD to 
improve the safe use of these drugs” [331]. This led to the revision of the anemia treatment 
guidelines and, in 2012, the KDIGO guidelines reaffirmed the use of more conservative 
doses [48], that was further translated to the ERBP guidelines [332]. 
Several potential harmful mechanisms for higher Hb targets have been proposed, as 
increased blood viscosity and hemoconcentration, the increased blood pressure, the toxic 
effect of iron and non-physiological doses of ESA, which contribute to ESA toxicity. The 
rise in Ht results in a higher viscosity and, consequently, higher risk of thromboembolism. 
It also favors platelet activation by increasing the interaction between the endothelial cells 
and platelets in blood vessels. Hemoconcentration is a phenomenon observed in HD 
patients after a dialysis session that results from the removal of large amounts of fluids 
[333].  
In conjugation with the optimal Hb target and ESA dose, Hb variability must be 
taken into account, as it was noted that during the treatment of HD patients with ESA the 
level of Hb has a large fluctuation; that is, the Hb level tends to rise or fall in a cyclic 
pattern, which is different for each patient [334]. Some studies showed an association 
between Hb variability and increased risk of death, mainly due to cardiovascular events, 
infection, and hospitalization [318, 335-337]. Hb variability represents an important 
physiological stress, as the ESA treatment involves short, intermittent burst of plasma 
EPO availability that do not coincide, either temporally or in magnitude, with its 
physiological action. Under physiological conditions EPO levels are maintained in a 
narrow range (through several mechanisms), in order to support a constant oxygen supply 
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to the organs. The impact of Hb variability on the organism is not fully understood, but 
the myocardium may be one of the most affected organs, as it has to compensate with an 
increased output and cardiomyocytes proliferation during the periods of reduced oxygen 
availability, that occur when Hb reaches lower levels, before the new ESA administration 
[334, 335]. 
Nevertheless, the debate about the cause of this increased risk with higher doses of 
ESA or higher levels of Hb remains controversial. Naturally occurring Hb levels >12 g/dl 
does not associate with increased mortality among HD patients, suggesting that high Hb 
are not always harmful in CKD patients [338]. In a meta-regression analysis it was 
reported that in CKD patients, higher ESA dose might be associated with all-cause 
mortality and cardiovascular complications independent of Hb level [339]. A secondary 
analysis of the CHOIR study showed that high-dose of ESA was associated with a 
significant increase  hazard of a primary end point [340]; however, it is also true that the 
patients that require higher ESA dose were those that present the inability to achieve the 
target Hb, which could be related to CKD and anemia complications, such as 
inflammation and malnutrition [341]. Indeed, a secondary analysis to the TREAT study 
showed that in diabetic CKD patients, both lower baseline GFR and higher CRP levels are 
associated with higher cardiovascular and non-cardiovascular mortality rates, particularly 
from sudden death and infection [342]. We cannot also forget that higher ESA doses are 
associated with some risks, as above mentioned, in agreement with the report of 
Koulouridis et al. (2013) [339], where mean ESA dose was associated with increased rate 
of hypertension, stroke, and thrombotic events, including dialysis vascular access-related 
thrombotic events. To address if high ESA doses are associated with increased mortality 
risk an ongoing trial has been designed. The Clinical Evaluation of the DOSe of 
Erythropoietins (C.E. DOSE) trial has been designed to identify the potential benefits and 
harms of different fixed doses of ESA in HD patients that were randomized 1:1 to 4000 
IU/week versus 18000 IU/week of IV epoietin alfa or beta, or of any other ESA in 
equivalent doses. The primary outcome was death, non-fatal stroke, non-fatal myocardial 
infarction and hospitalization for cardiovascular causes, but no results were yet published 
[343]. 
 
 | 47  
 
 
  
AIMS  
  
 
 
  
AIMS 
 
 | 49  
 
Anemia is a common complication in CKD patients, mainly due to the reduced 
capacity of the failing kidneys to synthesize EPO, an essential hormone for erythropoiesis. 
The correction of anemia is achieved by the use of ESA; however, some patients do not 
respond properly to ESA therapy, developing hyporesponsiveness, with several potential 
underlying causes, such as inflammation and iron disturbances. ESA hyporesponsiveness 
is usually associated with poorer outcome, progression of renal disease and increased 
mortality. To overcome this resistance higher doses of ESA are usually needed; however, 
recent studies reported an increased risk for cardiovascular events and mortality rate in 
patients treated with higher ESA doses, whose specific causes and mechanisms remain to 
be elucidated.  
In this sense, the main aims of this research project were: 
 
1. To prepare a critical up-to-date revision regarding the benefits and risks of ESA and 
iron therapy in CKD patients. 
 
Book chapter - rhEPO for the treatment of erythropoietin resistant anemia in 
hemodialysis patients - Risks and Benefits - Appendix I 
 
Review article - Iron therapy in chronic kidney disease: recent changes, benefits 
and risks - Appendix II 
 
2. To use the remnant kidney rat model of chronic renal failure (CRF) induced by 5/6 
surgical nephrectomy, to characterize anemia development, renal function and damage, 
blood pressure, iron metabolism and the crosstalk between the induced disturbances  
 
Paper I - Renal risk-benefit determinants of recombinant human erythropoietin 
therapy in the remnant kidney rat model – hypertension, anemia, inflammation and 
drug dose 
 
3. To evaluate the impact of different rHuEPO doses on anemia correction, renal 
damage/disease progression, inflammation, iron disturbances and blood pressure. In 
this sense, CRF animals were treated during 3 weeks with standard rHuEPO doses, 
usually used to correct anemia in CKD patients (100 and 200 IU/Kg body weigh 
[BW]/week), and with higher doses (400 and 600 IU/Kg BW/week), used in the 
treatment of hyporesponsive patients. 
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Paper I and Paper II - Liver iron is a major regulator of hepcidin gene expression 
via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with 
high rHuEPO doses 
 
4. To dissect the pathological and molecular mechanisms underlying rHuEPO 
hyporesponsiveness in this animal model, focusing on anemia, iron metabolism, renal 
damage, hypoxia, inflammation and fibrosis. 
 
Paper III - Pathological and molecular mechanisms underlying resistance to 
recombinant human erythropoietin therapy in the remnant kidney rat model of 
chronic kidney disease associated anemia 
 
5. To clarify the effect of rHuEPO therapy, per se (in normal rats, without CRF), on 
erythropoiesis, renal function and damage, blood pressure and iron metabolism. 
 
Paper IV - Impaired renal endothelial nitric oxide synthase and reticulocyte 
production as modulators of hypertension induced by recombinant human 
erythropoietin in the rat 
 
Paper V - Recombinant human erythropoietin-induced erythropoiesis regulates 
hepcidin expression over iron status in the rat 
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Paper I 
 
Renal risk-benefit determinants of recombinant human erythropoietin 
therapy in the remnant kidney rat model – hypertension, anemia, 
inflammation and drug dose 
 
Sandra Ribeiro, Patrícia Garrido, João Fernandes, Helena Vala, Petronila Rocha-
Pereira, Elísio Costa, Luís Belo, Flávio Reis and Alice Santos-Silva 
 
Clin Exp Pharmacol Physiol 2016 doi: 10.1111/1440-1681.12541 
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Renal risk-benefit determinants of recombinant human erythropoietin therapy in the 
remnant kidney rat model – hypertension, anaemia, inflammation and drug dose 
 
Sandra Ribeiro,* Patrícia Garrido,†,‡ João Fernandes,†,‡ Helena Vala,§ Petronila Rocha-
Pereira,¶ Elísio Costa,* Luís Belo,* Flávio Reis†,‡ and Alice Santos-Silva*1 
 
*Research Unit on Applied Molecular Biosciences (UCIBIO), REQUIMTE, Department of Biological Sciences, 
Laboratory of Biochemistry, Faculty of Pharmacy, University of Porto, Porto, †Laboratory of Pharmacology & 
Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, and  
‡Centre for Neuroscience and Cell Biology - Institute for Biomedical Imaging and Life Sciences (CNC.IBILI) Research 
Unit, University of Coimbra, Coimbra, §Centre for Studies in Education, Technologies and Health (CI&DETS), CITAB, 
Agrarian School of Viseu, Polytechnic Institute of Viseu, Viseu, and  ¶Health Sciences Research Centre, Faculty of 
Health Sciences, University of Beira Interior, Covilhã, Portugal 
 
SUMMARY 
Clinical studies showed that high doses of recombinant human erythropoietin (rHuEPO) used to correct 
anaemia in chronic kidney disease (CKD) hyporesponsive patients may lead to deleterious effects.  The aim 
of this study was to analyze the effects of rHuEPO in doses usually used to correct CKD-anaemia (100, 200 
IU/kg body weight [BW] per week) and in higher doses used in the treatment of hyporesponsive patients 
(400, 600 IU/kg BW per week), focusing on renal damage, hypoxia, inflammation and fibrosis. Male Wistar 
rats with chronic renal failure (CRF) induced by 5/6 nephrectomy were treated with rHuEPO or with vehicle, 
over a 3-week period. Haematological, biochemical and renal function analyses were performed. Kidney and 
liver mRNA levels were evaluated by quantitative real-time polymerase chain reaction (qPCR) and protein 
expression by Western blot and immunohistochemistry. Kidney histopathological evaluations were also 
performed. The CRF group developed anaemia, hypertension and a high score of renal histopathologic 
lesions. Correction of anaemia was achieved with all rHuEPO doses, with improvement in hypertension, 
renal function and renal lesions. In addition, the higher rHuEPO doses also improved inflammation. Blood 
pressure was reduced in all rHuEPO-treated groups, compared to the CRF group, but increased in a dose-
dependent manner. The current study showed that rHuEPO treatment corrected anaemia and improved 
urinary albumin excretion, particularly at lower doses. In addition, it is suggested that a short-term treatment 
with high doses, used to overcome an episode of hyporesponsiveness to rHuEPO therapy, can present 
benefits by reducing inflammation, without worsening of renal lesions; however, the pro-hypertensive effect 
should be considered, and carefully managed to avoid a negative cardiorenal impact. 
 
Key words: anaemia, CKD, high rHuEPO doses, hypertension, hyporesponsiveness, inflammation. 
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INTRODUCTION 
Chronic kidney disease (CKD) is a worldwide 
health problem with increasing incidence and 
prevalence rates.1 Loss of renal function is 
associated with inflammation,2 compromising 
oxygen (O2) availability and worsening hypoxia-
induced anaemia, a common complication in CKD 
patients. Renal hypoxia promotes fibrosis by 
stimulating renal cells to produce extracellular 
matrix, thus contributing to renal disease 
progression.  
Anaemia occurrence and severity increases with 
the progression of renal disease.3 Although it is 
accepted that anaemia of CKD patients is mainly 
due to the reduced erythropoietin (EPO) production 
by the failing kidneys,2 the ability of the kidney to 
synthesize EPO, as well as the liver contribution to 
EPO production, remains to be clarified. 
Erythropoiesis-stimulating agents (ESA) are the 
cornerstone therapy to anaemia correction, 
improving  CKD patients’ quality of life.4 While 
some authors claim that  ESA treatment delays renal 
disease progression,5, 6 others reported that ESA 
therapy does not significantly slow renal function 
decline.7, 8 Preclinical data from animal models of 
CKD treated with ESA also showed controversial 
results; in fact, while some studies reported the 
ability to correct anaemia without a positive impact 
on renal disease progression,9, 10 others  described 
ample beneficial effects.11, 12 This controversy is 
most probably due to non-standardized protocols, 
with different ESA doses and/or  duration of 
treatments. 
Tissue-protective effects attributed to EPO are 
mediated by a heterodimer receptor, consisting of 
EPO receptor (EPOR) and CD131 (beta common 
receptor), that needs higher doses to be activated.13, 
14
 It is well known that there is a marked variability 
in CKD patients’ response to ESA treatment; with 
5–10% becoming resistant to  therapy.15 To 
overcome this hyporesponse, higher doses of ESA 
are needed for   anaemia correction; however, these 
patients present higher rates  of cardiovascular 
events and mortality.16–18 These adverse effects have 
been associated with the increase in haemoglobin 
(Hb) concentrations and/or ESA doses used to 
achieve target Hb levels. Recently, the post hoc 
analysis of the TREAT study reported that CKD 
patients with poor initial haematopoietic response to 
ESA therapy, therefore needing, higher ESA doses, 
presented increased risk for adverse cardiovascular 
events and death, thus suggesting that the adverse 
outcome might be mainly due to the higher ESA 
doses used to achieve the target Hb values.19  
The present work aimed to study the effects of 
recombinant human erythropoietin (rHuEPO) 
treatment  at doses usually used to correct anaemia 
(100 and 200 IU/kg body weight [BW] per week) in 
rHuEPO-sensitive CKD patients and at higher 
rHuEPO doses (400 and 600 IU/kg BW per week), 
used in hyporesponsive CKD patients. In particular, 
this experimental study intended to access, using the 
remnant kidney rat model of chronic renal failure 
(CRF) induced by 5/6 nephrectomy, the crosstalk 
between CKD-associated anaemia and renal 
damage; in addition, to evaluate the effects of a 
short-term rHuEPO treatment  on  kidney disease 
progression, focusing on renal damage, hypoxia, 
inflammation and fibrosis. 
 
RESULTS 
Haematological and biochemical data 
Haematological data at baseline (0w), after one 
(1w) and three weeks (3w) after starting rHuEPO 
treatment (end of protocol) are presented in Table 1. 
The CRF group presented a significant reduction 
in red blood cell (RBC) count, Hb concentration and 
haematocrit (Ht) values, one week after 
nephrectomy, when compared to the Sham group. 
These alterations remained until the end of protocol 
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Table 1    Haematological data throughout the study (at baseline, after 1 and 3 weeks of treatment) 
Results are presented as mean ± SEM. a P<0.05 vs Sham group; b P<0.05 vs CRF group; c P<0.05 vs CRF100 group; d P<0.05 vs 
CRF200 group; e P<0.05 vs CRF400 group (Mann-Whitney test). 0w, start of protocol; 1w, 1 week after the start of rHuEPO 
treatment; 3w, 3 weeks after the start of rHuEPO treatment (end of protocol); CRF, chronic renal failure; EPO,  erythropoietin; Hb,  
haemoglobin; Ht,  haematocrit; PLT,  platelets; RBC,  red blood cells; RET,  reticulocytes;  RPI,  reticulocyte production index. 
 
(Table 1). No other significant changes were 
observed in the CRF group regarding 
haematological parameters. 
rHuEPO treatment induced a significant increase 
in RBC count, Hb concentration and Ht values in all 
CRF groups under rHuEPO therapy, as compared to 
the CRF group. The highest augmentation was found 
in the CRF400 and CRF600 groups, in which Hb 
concentration reached, at the end of protocol, 
15.45 ± 0.37 and 20.08 ± 0.37 g/dL, respectively, 
compared  to 12.06 ± 0.18 g/dL in the CRF animals. 
A low platelet count was found in the CRF400 and 
CRF600 groups at the end of the protocol. After one 
week of treatment, reticulocyte count and 
reticulocyte production index (RPI) were increased 
in the CRF200, CRF400 and CRF600 groups, 
returning to values similar to those of the Sham 
animals at the end of the protocol, excepting for the 
CRF600 rats whose values remained significantly 
increased. The CRF100 group presented a 
significant increase in reticulocyte count and RPI 
only after 3 weeks of treatment. 
While, increased serum EPO levels were found 
in the CRF group, when compared to the Sham 
group, unchanged values were encountered in all the 
CRF groups under rHuEPO treatment (Table 1).
 Sham 
(n = 8) 
CRF 
(n = 7) 
CRF100 
(n = 6) 
CRF200 
(n = 7) 
CRF400 
(n = 10) 
CRF600 
(n = 7) 
RBC (x 1012/L) 
0w 7.41±0.07 7.43±0.09 7.03±0.12 7.53±0.11 7.60±0.09 7.03±0.07 
1w 7.11±0.08 6.11±0.12a 7.02±0.21b 6.80±0.14b 7.62±0.06abd 8.08±0.11abcd 
3w 7.77±0.13 6.41±0.11a 7.92±0.40b 7.48±0.17b 8.39±0.21bd 10.53±0.20abcde 
Hb (g/dL) 
0w 13.85±0.13 13.63±0.18 13.55±0.13 13.54±0.17 13.68±0.13 13.66±0.18 
1w 13.94±0.11 12.26±0.22a 13.58±0.37b 13.86±0.20b 14.55±0.14b 16.33±0.29abcde 
3w 14.07±0.15 12.06±0.18a 14.65±0.52b 13.89±0.32b 15.45±0.37abd 20.08±0.37abcde 
Ht (%) 
0w 41.12±0.54 41.34±0.59 38.40±0.31 40.90±0.55 41.25±0.45 39.23±0.41 
1w 38.02±0.20 32.13±0.63a 38.73±1.19b 36.21±0.92b 41.88±0.49abcd 50.11±0.93abcde 
3w 41.77±0.80 33.56±0.57a 43.37±2.09b 38.03±0.87b 46.54±1.43bd 66.16±1.16abcde 
PLT (x 109/µL) 
0w 687.25±25.87 681.43±14.27 786.17±44.49 727.57±29.97 719.60±16.77 758.43±20.73 
1w 722.62±27.95 867.71±19.32 910.83±77.56 911.00±60.80 790.904±48.17 825.57±36.99 
3w 743.62±28.36 888.71±51.18 762.50±62.12 815.43±43.39 632.10±31.82bd 400.86±47.98abcde 
RET (%) 
0w 1.95±0.17 2.47±0.29 1.15±0.13 2.34±0.23 1.99±0.13 1.53±0.27 
1w 1.73±0.31 2.18±0.23 3.05±0.27 5.27±0.35abc 9.23±0.53abcd 6.41±0.53abce 
3w 1.61±0.19 2.53±0.28 3.30±0.25a 2.14±0.21 1.46±0.17bc 2.38±0.45 
RET (x109/L) 
0w 144.39±12.38 183.41±20.89 80.37±8.20 177.06±18.25 151.09±10.19 108.08±19.72 
1w 122.47±22.47 134.11±15.26 215.92±23.86 358.17±25.05ab 701.81±39.67abcd 520.08±45.99abcde 
3w 124.77±14.56 161.67±17.87 258.28±13.61a 158.84±14.67 119.90±12.17c 252.18±48.78ae 
RPI 
0w 1.94±0.16 2.47±0.28 1.07±0.10 2.34±0.23 1.99±0.14 1.48±0.26 
1w 1.72±0.31 1.34±0.23 3.02±0.44 4.86±0.51ab 10.13±0.55abcd 8.50±0.80abcd 
3w 1.60±0.19 1.37±0.15 3.42±0.17ab 1.93±0.17 1.57±0.16c 3.81±0.74abde 
EPO (mIU/mL) 
0w 2.48±0.09 3.04±0.22 2.03±0.06 3.23±0.25 2.77±0.31 2.43±0.90 
1w 3.52±0.39 5.68±0.41a 3.48±0.27b 5.44±0.46ac 4.32±0.32bc 3.65±0.62b 
3w 4.38±0.53 9.71±1.28a 4.31±0.49b 4.55±0.26b 4.34±0.45b 4.80±0.63b 
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Table 2    Serum biochemical data throughout the study (at baseline, after 1 and 3 weeks of treatment) and 
urinary biochemical data at the end of protocol 
Results are presented as mean ± SEM. a P<0.05 vs Sham group; b P<0.05 vs CRF group; c P<0.05 vs CRF100 group; d P<0.05 vs 
CRF200 group (Mann-Whitney test). 0w, start of protocol; 1w,  1 week after the start of rHuEPO treatment; 3w,  3 weeks after the start 
of rHuEPO treatment (end of protocol); AE,  Albumin excretion; BUN C,  blood urea nitrogen clearance; CC, Creatinine Clearance; 
CRF,  Chronic renal failure; GFR, Glomerular filtration rate 
 
Regarding serum biochemical data (Table 2), one 
week after rHuEPO treatment, serum blood urea 
nitrogen (BUN) and creatinine concentrations 
significantly increased in all CRF groups (with or 
without rHuEPO treatment), versus the Sham group, 
without  differences between groups; the values 
remained significantly increased until the end of  the 
protocol. At that moment, serum C-reactive protein 
(CRP) concentration was also significantly increased 
in the CRF group, when compared to the Sham, 
CRF400 and CRF600 groups. Concerning the 
biochemical urinary markers (Table 2), all CRF 
groups (with and without treatment), compared to 
the Sham, presented significantly decreased urinary  
BUN and creatinine levels, and clearances, as well 
as reduced glomerular filtration rates (GFR), without 
differences between groups. Albumin excretion was 
significantly increased in CRF, CRF400 and 
CRF600 groups, when compared to Sham, CRF100 
and CRF200 groups. CRF100 and CRF200 groups 
presented also significantly increased albumin 
excretion values, versus the Sham group.  
 
Blood pressure and body and tissues weights 
At the end of the protocol, a significantly 
reduced BW and a significant increased relative 
kidney weight (KW/BW) were observed in all CRF 
groups (with and without rHuEPO treatment), when 
compared to the Sham group (Table 3). In addition, 
the relative spleen weight (SW/BW) was 
significantly higher in the CRF600 group, as 
compared to Sham and to the other CRF groups, 
except to the CRF100 group. 
Heart rate (HR), systolic blood pressure (SBP), 
diastolic blood pressure (DBP) and mean blood 
pressure (MBP) values were significantly increased 
in the CRF group, versus the Sham and the CRF 
groups under rHuEPO treatment (Table 3). 
 All the rHuEPO-treated CRF groups presented a 
significant reduction in HR, SBP, DBP and MBP
 Sham CRF CRF100 CRF200 CRF400 CRF600 
Serum biochemical data 
BUN (mg/dL)       
0w 22.54±0.83 22.71±0.87 25.58±0.83 24.07±0.77 24.16±0.73 24.77±0.48 
1w 23.07±0.64 56.33±2.40a 63.50±2.36a 56.78±2.41a 60.49±3.20a 62.88±2.39a 
3w 22.64±0.91 54.10±3.63a 53.27±7.77a 56.63±1.97a 60.01±3.05a 58.08±1.69a 
Creatinine (mg/dL)       
0w 0.37±0.01 0.35±0.01 0.42±0.02 0.39±0.01 0.37±0.01 0.36±0.02 
1w 0.33±0.01 0.99±0.08a 1.18±0.06a 1.34±0.16a 1.23±0.10a 1.17±0.08a 
3w 0.45±0.04 1.00±0.07a 1.26±0.08a 1.27±0.23a 1.11±0.09a 1.23±0.12a 
CRP (U/L)       
0w 538.49±39.25 552.72±37.64 447.52±20.33 555.59±30.32 556.80±46.46 583.59±52.07 
1w 687.91±40.71 592.39±52.52 859.51±35.17ab 705.95±49.94 637.29±30.70c 691.28±50.34c 
3w 575.03±33.24 820.61±48.02a 767.56±27.10a 771.54±64.15a 605.91±42.61b 551.63±34.25bcd 
Urinary biochemical data 
BUN (mg/dL) 6573.00±658.14 2236.67±156.76a 2464.83±157.73a 2020.75±329.91a 2166.00±157.67a 2098.00±161.05a 
Creatinine (mg/dL) 116.99±13.72 37.32±2.40a 45.40±6.97a 31.15±4.89a 34.11±2.24a 38.44±3.18a 
AE (mg/L) 3.25±0.25 31.40±7.81a 9.33±2.15ab 7.25±1.89ab 19.43±2.33acd 28.33±5.88acd 
CC (mL/h/rat) 87.66±5.59 40.33±2.95a 38.23±4.72a 31.45±6.19a 37.21±5.66a 34.11±3.02a 
BUN C (mL/h/rat) 97.08±4.48 43.90±3.87a 54.32±6.74a 39.70±7.22a 43.96±6.81a 36.88±3.56a 
GFR (mL/h/rat) 91.83±3.93 42.06±3.37a 48.38±5.10a 35.26±6.56a 40.38±6.14a 35.46±3.26a 
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Table 3    Body weight, tissues weight and arterial blood pressure, at the end of protocol 
Results are presented as mean ± SEM. a P<0.05 vs Sham group; b P<0.05 vs CRF group; c P<0.05 vs CRF100 group; d P<0.05 vs 
CRF200 group; e P<0.05 vs CRF400 group; f P<0.05 vs CRF600 group (Mann-Whitney test). BW,  body weight; DBP,  diastolic 
blood pressure; HR,  heart rate; K,  kidney; MBP - mean blood pressure; SBP,  systolic blood pressure; SW,  spleen weight; W, 
weight. 
 
Table 4    Total score of advanced and mild kidneys lesions of rat groups under study 
 
Sha
m 
CRF CRF100 CRF200 CRF400 CRF600 
Advanced glomerular lesions 
Thickening of GBM 0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Mesangial expansion 0 0.00 ± 0.00 1.00 ± 0.00ab 0.00 ± 0.00c 0.40 ± 0.22c 0.00 ± 0.00c 
Nodular sclerosis 0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.20 ± 0.13 0.43 ± 0.43 
Global 
Glomerulosclerosis 
0 3.00 ± 0.00a 0.00 ± 0.00b 0.43 ± 0.43b 0.30 ± 0.30b 0.00 ± 0.00b 
Mild glomerular lesions 
Glomerular atrophy 0 3.00 ± 0.00a 1.33 ± 0.21ab 1.57 ± 0.37ab 0.50 ± 0.22abcd 0.28 ± 0.18bcd 
Hypercellularity 0 0.00 ± 0.00 1.00 ± 0.00ab 0.43 ± 0.20ac 0.60 ± 0.16ab 1.00 ± 0.00abd 
Dilatation of BS 0 0.00 ± 0.00 1.17 ± 0.40ab 0.43 ± 0.20a 0.20 ± 0.13 0.28 ± 0.18c 
Advanced tubulointerstitial lesions 
Hyaline cylinders 0 2.86 ± 0.14a 1.00 ± 0.36ab 1.71 ± 0.28ab 0.90 ± 0.23ab 0.14 ± 0.14bcde 
Granular cylinders 0 2.86 ± 0.14a 0.67 ± 0.21ab 0.71 ± 0.18ab 0.50 ± 0.17ab 0.14 ± 0.14bd 
Tubular calcification 0 3.00 ± 0.00a 0.00 ± 0.00b 0.00 ± 0.00b 0.00 ± 0.00b 0.00 ± 0.00b 
Necrosis 0 2.14 ± 0.14a 0.00 ± 0.00b 0.00 ± 0.00b 0.00 ± 0.00b 0.00 ± 0.00b 
IFTA 0 3.00 ± 0.00a 0.50 ± 0.22ab 0.28 ± 0.28b 0.00 ± 0.00bc 0.00 ± 0.00bc 
Mild tubulointerstitial lesions 
Tubular dilatation 0 1.86 ± 0.34a 1.67 ± 0.21a 1.71 ± 0.36a 1.30 ± 0.26a 1.28 ± 0.36a 
Inters. inflammat. infilt. 0 2.00 ± 0.00a 1.00 ± 0.00ab 1.28 ± 0.36a 1.30 ± 0.15ab 0.14 ± 0.14bcde 
Hidropic tubular degen. 0 ---- 3.00 ± 0.00a 1.14 ± 0.39ac 1.60 ± 0.22ac 1.00 ± 0.00ace 
Vacuolar tubulardegen. 0 ---- 1.00 ± 0.00a 0.00 ± 0.00c 0.00 ± 0.00c 0.00 ± 0.00c 
Vascular lesions 
Arteriolosclerosis 0 2.00 ± 0.00a 0.83 ± 0.17ab 0.28 ± 0.28b 0.20 ± 0.20bc 0.00 ± 0.00bc 
Arteriosclerosis 0 1.00 ± 0.00a 1.00 ± 0.00a 0.57 ± 0.30a 0.60 ± 0.16a 1.00 ± 1.00a 
Results are presented as mean ± SEM. a P<0.05 vs Sham group; b P<0.05 vs CRF group; c P<0.05 vs CRF100 group; d P<0.05 vs 
CRF200 group; e P<0.05 vs CRF400 group (Mann-Whitney test). BS, Bowman’s Space; Degen.,  Degeneration; GBM, glomerular 
basement membrane; IFTA, interstitial fibrosis and tubular atrophy; Inters. Inflammat. Infilt.,  Interstitial inflammatory infiltrate. 
 
 
 
Sham CRF CRF100 CRF200 CRF400 CRF600 
BW(kg) 0.420±0.007 0.389±0.007a 0.379±0.004a 0.369±0.010a 0.369±0.007a 0.367±0.006a 
Organ/BW(g/kg) 
KW/BW 2.767±0.071 3.827±0.185a 3.799±0.401a 3.441±0.167a 3.508±0.128a 3.509±0.163a 
SW/BW 1.869±0.130 2.334±0.112 2.555±0.181a 2.073±0.162 2.368±0.108 3.138±0.214 abde 
Arterial blood pressure 
HR (Beat/min) 334.43±3.18 411.88±3.39a 397.68±2.70ab 372.41±7.35abc 380.56±5.34ab 368.52±3.99abc 
SBP (mmHg) 106.25±0.70 190.75±1.64a 127.24±0.70ab 141.75±1.55abc 137.45±1.32abc 150.44±1.24abcde 
DBP (mmHg) 90.18±1.47 150.38±1.58a 109.29±1.15ab 109.25±1.16ab 102.40±3.76ab 117.00±1.64abcde 
MBP (mmHg) 91.62±2.31 152.63±1.43a 114.20±1.80ab 122.00±1.99abc 114.20±1.88ab 133.80±1.11abcde 
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when compared to the untreated CRF group; 
however, a trend towards increased SBP, DBP and 
MBP and decreased HR was found, accompanying 
rHuEPO dose increment. 
 
Histopathological findings 
At the end of protocol, no abnormal features were 
found in the kidneys of the Sham animals (Table 4). 
Regarding the CRF group, several glomerular and 
tubulointerstitial lesions were found: all the rats 
(n = 7) presented global glomerulosclerosis (Fig. 
1a2; Table 4) and glomerular atrophy (Fig. 1b2; 
Table 4), with a significantly increased total score 
for both advanced (Fig. 1a1) and mild (Fig. 1b1) 
glomerular lesions, when compared to all the other 
groups. Tubular calcification and necrosis were 
present in the CRF animals’ kidneys (Table 4), but 
absent in the rHuEPO-treated CRF groups. In 
addition, the CRF group presented hyaline (Fig.1c2) 
and granular cylinders (Table 4), as well as, 
interstitial fibrosis and tubular atrophy (IFTA) (Fig. 
1c3, Table 4), that were reduced or even absent in 
the rHuEPO-treated CRF groups. Interstitial 
inflammatory infiltrate (Fig. 1d2) and tubular 
dilations (Fig. 1d3) were also observed in the CRF 
group (Table 4). When necrosis is present, hidropic 
or vacuolar tubular degeneration is no longer 
observed and, therefore, these lesions were not 
quantified in the CRF group. The total score for both 
advanced (Fig. 1c1) and mild (Fig. 1d1) 
tubulointerstitial lesions were significantly higher in 
the CRF group, compared to all the other groups. 
Pyogranulomas were found in all CRF rats, a feature 
that was not found in the CRF animals under 
rHuEPO treatment. A higher score for 
arteriolosclerosis (Fig. 1e2) was observed in the 
CRF group. Arteriosclerosis score (Fig. 1e3) was 
similar or decreased in the rHuEPO-treated CRF 
groups, as compared to the untreated CRF group.  
The CRF100 group presented the highest total 
score for advanced glomerular lesions (Fig. 1a1), 
compared to all the other CFR groups under 
rHuEPO therapy. In addition, all the rats of the 
CRF100 group (6/6) presented mesangial expansion, 
hypercellularity (Fig. 1a3), dilatation of the 
Bowman’s Space (Fig. 1b3) and glomerular atrophy 
(Table 4). Advanced tubulointerstitial lesions, 
including hyaline (4/6) and granular cylinders (4/6), 
and some degree of IFTA (3/6), were found in the 
CRF100 rats (Table 4). Regarding the mild 
tubulointerstitial lesions, vacuolar tubular 
degeneration (6/6) was found only in the CRF100 
group; hidropic tubular degeneration (6/6), tubular 
dilation (6/6) and interstitial inflammatory infiltrate 
(6/6) were also observed in this group (Table 4). The 
CRF100 group presented also arteriolosclerosis (5/6) 
and arteriosclerosis (6/6) (Table 4). 
Regarding the other CRF groups under rHuEPO 
treatment (CRF200, CRF400 and CRF600), lower 
total scores for advanced (Fig. 1a1) and mild (Fig. 
1b1) glomerular lesions were found, as compared to 
the untreated CRF group. Glomerular atrophy was 
particularly high in CRF200 group (6/7), as well as, 
hypercellularity in the CRF200 (3/7), CRF400 (6/10) 
and CRF600 (7/7) groups (Table 4). Hidropic 
tubular degeneration (7/7, 10/10, 7/7, respectively) 
and tubular dilation (6/7, 9/10, 6/7, respectively) 
were present in the CRF200, CRF400 and CRF600 
groups, along with interstitial inflammatory infiltrate 
in the CRF200 (5/7) and CRF400 (10/10) groups 
(Table 4). Arteriosclerosis was also found in the 
CRF200 (3/7), CRF400 (6/10) and CRF600 (7/7) 
groups (Table 4).  
Adjacent to the outer surface of the scar in the 
5/6 remnant kidney of the rHuEPO-treated CRF rats, 
dysfunctional renal tissue was found, presenting 
global glomerulosclerosis, tubular dilation and, in 
some rats, hyaline and granular cylinders, tubular 
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Fig. 1 Glomerular, tubulointerstitial and vascular lesions. Total score and representative lesions observed in 
kidneys of rat groups under study, at the final time (PAS staining): A1, total score for advanced glomerular 
lesions; A2,  glomerulosclerosis; A3,  mesangial expansion and glomerular hypercellularity; B1, total score 
of mild glomerular lesions; B2, glomerular atrophy; B3, dilatation of the Bowman’s Space; C1, total score 
for advanced tubulointerstitial lesions; C2,  hyaline cylinder; C3, interstitial fibrosis and tubular atrophy 
(IFTA);  D1, total score for mild tubulointerstitial lesions; D2,  interstitial inflammatory infiltrate; D3,  
tubular dilatations; E1, total score for vascular lesions; E2, arteriolosclerosis;  E3, arteriosclerosis. Results are 
presented as mean ± standard error of the mean (SEM):  a P < 0.05, aa P < 0.01, aaa P < 0.001 vs Sham 
group; bb P < 0.01, bbb P < 0.001 vs CRF group; c P < 0.05, cc P < 0.01, ccc P < 0.001 vs CRF100 group; d 
P < 0.05, dd P < 0.01 vs CRF200 group; e P < 0.05, dd P < 0.01 vs CRF400 group (Mann-Whitney Test). 
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necrosis and IFTA (Fig. 2A1). These areas were 
negative in the immunostaining for EPO protein 
(Fig. 2A2) and strongly positive for nuclear factor 
kappa B (NF-κB) (Fig. 2A3) and transforming 
growth factor beta 1 (TGFβ1) (Fig. 2A4). 
The mild tubulointerstitial lesions observed in all 
CRF rats (without and with treatment) were 
significantly and negatively correlated with GFR 
(r = –0.283, P = 0.003) and positively with serum 
creatinine (r = 0.293, P = 0.001); no correlations 
were found between glomerular lesions and renal 
function data.  
 
Renal and liver protein expression of HIF-2α, 
EPO and EPOR 
A significant reduction in renal tissue expression 
of hypoxia inducible factor 2 alpha (HIF-2α) and 
EPO was observed in CRF and CRF100 groups, 
when compared to the Sham group (Fig. 3a1 – 3a3), 
and no protein expression of both HIF-2α and EPO 
was  found in the other CRF groups (CRF200, 
CRF400 and CRF600; Fig. 3a1 and 3a4).  
Significantly increased liver HIF-2α and EPOR 
protein expression was found in the CRF and 
CRF600 groups, when compared to the Sham group 
(Fig. 3c,d). Increased EPO protein expression levels 
were only found in the liver of CRF rats, as 
compared to the Sham animals (Fig. 3e). 
 
Renal expression of inflammatory and fibrosis 
markers 
Regarding the renal cortex and medulla 
expression of NF-κB, the CRF group presented a 
higher nuclear expression of NF-κB, when compared 
to the Sham group (Fig. 4a1–4a3 and 4b1–4b3). The 
rHuEPO-treated CRF groups presented a trend 
towards a dose-dependent reduction in the NF-κB 
protein levels (Fig. 4a1 and 4a4; 4b1 and 4b4). 
TGFβ1 expression assessed in the renal cortex 
(Fig. 4c1–4c4) and medulla (Fig. 4d1), as well as in Fi
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areas of renal fibrosis (Fig. 4e1–4e3), was 
particularly increased in the CRF group, when 
compared to the Sham group (Fig. 4c1; 4d1; 4e1; 
Table 4). Regarding the rHuEPO-treated  
CRF groups, a significant reduction of TGFβ1 
scores was found in the renal cortex and in the 
fibrosis areas of the CRF200, CRF400 and CRF600 
groups, when compared to the CRF group, achieving 
values similar to those found in the Sham group 
(Fig. 4c1 and 4e1). The CRF100 group presented a 
TGFβ1 score, in the fibrosis areas, similar to that 
found for the CRF group (Fig. 4e1). In the renal 
medulla, all the rHuEPO-treated CRF groups 
presented significantly reduced TGFβ1 scores, when 
compared to the CRF group, without differences 
between groups (Fig. 4d1). 
Kidney mRNA levels of interleukin (IL)-6 were 
significantly increased in the CRF group, when 
compared to the Sham group. The CRF groups under 
rHuEPO treatment presented a significant down-
regulation of IL-6 mRNA levels, compared to Sham 
and CRF groups (Fig. 4f). 
In addition, while IL-1β overexpression was 
found in the CRF and CRF100 groups, when 
compared to the Sham, the CRF200, CRF400 and 
CRF600 groups presented a significantly lower IL-
1β expression (Fig. 4g). 
 
DISCUSSION 
After 3 weeks of nephrectomy, the CRF rats 
developed a moderate degree of renal insufficiency, 
along with glomerulosclerosis and tubulointerstitial 
lesions. The substantial surgical removal of 
nephrons induced a compensatory hypertrophy of 
the remnant kidney, as viewed by the increased 
KW/BW ratio of these rats. In addition, the CRF rats 
developed a moderate anaemia; even though serum 
EPO levels were increased when compared to those 
of the Sham and rHuEPO-treated CRF groups. 
Indeed, it has been reported that in both CKD 
patients and animal models of CKD, the serum EPO 
levels are within the normal range or even 
increased.20–24 It is suggested that the serum EPO 
levels in CRF rats are, probably, insufficient to 
overcome renal anaemia.22, 25, 26 The remnant kidney 
of the CRF animals maintained some renal capacity 
to induce EPO synthesis, as showed by renal HIF-2α 
and EPO protein expression; even though, their 
expression levels were clearly reduced, when 
compared to the Sham kidneys, as the activation of 
HIF-2α appears to reduce with the progression of 
CKD.27 Serum CRP levels, as well as kidney 
inflammatory markers (IL-6, IL-1β and NF-κB), 
were increased in CRF group and might contribute 
to reduce renal EPO production.28–30 Although, the 
kidney is the major site of EPO production in adults, 
in conditions of renal injury and hypoxia, the liver 
may increase EPO synthesis.31, 32 As occurs in the 
kidney tissue,33, 34 HIF-2α mediates EPO production 
in the liver.35, 36 In our study, the CRF group 
presented an increased liver HIF-2α expression, 
when compared to the Sham group, accompanied by 
overexpression of EPO and EPOR, thus suggesting 
an increased contribution of the liver tissue to the 
serum EPO levels, as reported by others.37, 38  
Inflammation, another common feature of CKD 
patients39, 40 can induce functional iron deficiency 
due to its stimulatory effect on hepcidin synthesis,41 
which is the major regulator of iron homeostasis. In 
the current study, no alterations, eventually evoked 
by inflammation, were observed in iron metabolism 
that could influence erythropoiesis (data not shown). 
TGFβ1a well known  pro-fibrotic factor,42 was 
found to be overexpressed in the kidney of CRF rats, 
suggesting a major contribution to the fibrosis and 
glomerulosclerosis observed and to the increased 
expression of pro-inflammatory cytokines (Il-6 and 
IL-1β), thus aggravating renal injury.  
The CRF groups under rHuEPO treatment 
presented correction of anaemia, thus showing a 
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Fig. 3 Immunostaining for hypoxia inducible factor 2 alfa (HIF-2α) and erythropoietin (EPO) in kidney. HIF-
2α and EPO were not expressed in the glomerulus or renal medulla tubules (negative reaction). A1, quick 
score for HIF-2α;  A2, HIF-2α immunostaining Sham group: moderate positive nuclear and cytoplasmic 
immunoreactivity in convulated tubules (CT); A3, HIF-2α immunostaining CRF and CRF100 groups: light 
positive nuclear and cytoplasmic immunoreactivity in CT;A4, HIF-2α immunostaining CRF200, CRF400 
and CRF600 groups: negative reaction; B1,
 
quick score for EPO; B2,
 
EPO immunostaining Sham group: 
moderate positive cytoplasmic immunoreactivity in CT; B3, EPO immunostaining CRF and CRF100 groups: 
light positive cytoplasmatic immunoreactivity in CT; B4, EPO immunostaining CRF200, CRF400 and 
CRF600 groups: negative reaction. Evaluation of liver proteins by Western blotting and representative image 
of Western blot for the different groups. C, HIF-2α; D, EPO receptor (EPOR); E, EPO. Results are presented 
as mean ± standard error of the mean (SEM): a P < 0.05, aa P < 0.01 vs Sham group; b P < 0.05 vs CRF 
group; c P < 0.05 vs CRF100 group; d P < 0.05 vs CRF200 group; e P < 0.05 vs CRF400 group (Mann-
Whitney test). 
 
clear response to the increasing rHuEPO stimuli 
(Table 1). The CRF groups treated with highest 
rHuEPO doses (CRF400 and CRF600) presented a 
reduction in platelet count at the end of protocol, 
which was more pronounced in the CRF600 group. 
This reduction in platelet count can result from 
competition between precursor cells of the erythroid 
and megakaryocytic cell lines that share a common 
precursor.43 The increased SW/BW ratio suggests 
that the platelet reduction might also result from 
sequestration of platelets in the spleen. Indeed, this 
group (CRF600) presented the highest Ht, and, 
therefore, increased blood viscosity, which favours 
splenic stasis and cell sequestration. Another 
possible explanation is that this high rHuEPO 
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stimuli triggers extramedullary erythropoiesis (data 
not shown).  
The Hb and Ht values observed in CRF400 and 
CRF600 groups are above those recommended for 
CKD patients;44 however, the impact of high Hb 
levels and Ht are still debatable, as naturally 
occurring Hb levels >12 g/dL are not associated with 
increased  mortality in HD patients, suggesting that 
high Hb are not always harmful in CKD patients.45 
Until recently, higher ESA doses were used to 
overcome the hyporesponse to rHuEPO therapy; this 
clinical  practice was recently changed,44 as it was 
associated with a poor outcome of CKD patients.15, 
46
 In fact, there is a lack of studies assessing the 
effects of increasing rHuEPO doses on renal disease 
progression. All the rHuEPO-treated CRF groups 
presented an improvement of glomerular and 
advanced tubulointerstitial renal lesions, as well as 
in inflammation and fibrosis, these effects were, 
more pronounced for the highest doses (CRF400 and 
CRF600). However, all the treated groups presented 
mild tubulointerstitial lesions that could explain the 
absence of renal function improvement. Indeed, mild 
tubular lesions correlated significantly and 
negatively with GFR and positively with serum 
creatinine, in agreement with other studies.47 Kidney 
histopathological analysis of rHuEPO-treated rats 
revealed the presence of a dysfunctional tissue, 
adjacent to the scar areas which can contribute to 
hamper GFR improvement.  
Hypertension is a common cause of CKD and a 
recognized side effect of rHuEPO therapy. In the 
current study, all CRF groups developed a 
hypertensive state that was lower in those under 
rHuEPO therapy; however, rHuEPO treatment 
induced a blood pressure rise in a dose-dependent 
manner. The reduction of blood pressure in the 
context of CKD may present benefits, as it reduces 
albumin excretion, thus limiting the progression of 
CKD and the risk of cardiovascular disease.48 As 
observed by others,9, 49 we found that high blood 
pressure is associated with increased albumin 
urinary excretion, but without alterations in other 
markers of renal function (Table 2).  The CRF600 
group presented the highest increase in blood 
pressure, as compared with the other rHuEPO-
treated CRF groups, probably due to the increased 
blood viscosity. This increase in blood pressure is 
accompanied by worsening of arteriosclerosis, 
which results from increased Ht and hyperviscosity, 
thus leading to increased vascular resistance, a 
stimulus for vascular smooth muscle cell 
proliferation. In opposition with some studies,9, 49 no 
worsening of glomerular or tubulointerstitial lesions 
was observed. This different outcome may result 
from the earlier use of a short-term (3 weeks) 
rHuEPO treatment, in opposition to Garcia et al.9 
that evaluated a 6 week treatment without earlier 
initiation of rHuEPO therapy. The reduced time for 
the development of a hypertensive state in our study, 
considering the initiation of rHuEPO treatment one 
week after nephrectomy, contrasts with the study of 
Lebel et al.,49 in which rHuEPO therapy started 3 
weeks after nephrectomy.  
ESA therapy in the clinical practice is usually 
initiated in a more severe degree of anaemia; 
however, depending on patients’ characteristics and 
on the evaluation of risk-benefit, the use of this 
therapy in a moderate degree of anaemia might be 
viewed as a valid option if the beneficial effects here 
reported on renal function, fibrosis and inflammation 
could be further confirmed in the clinical setting. 
In conclusion, the model of CKD induced by 
nephrectomy used in this study showed that the liver 
may replace the kidney to produce EPO, in 
conditions of renal anaemia/hypoxia; kidney fibrosis 
and inflammation seem to be linked with the 
reduced EPO synthesis and anaemia/hypoxia. Our 
data also suggest that the crosstalk between
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Fig. 4 Immunostaining of NF-κB and TGFβ1 in renal cortex and medulla. For NF-κB only nuclear staining 
were considered for analysis. A1, quick score for NF-κB in renal cortex; A2, NF-κB immunostaining Sham 
group: moderate positive nuclear immunoreactivity in convulated tubules (CT); A3, NF-κB immunostaining 
CRF and CRF100 groups: intense positive nuclear immunoreactivity in glomerulus and CT; A4, NF-κB 
immunostaining CRF200, CRF400 and CRF600 groups: moderate positive nuclear immunoreactivity in CT; 
B1, quick score for NF-κB  in renal medulla; B2, NF-κB immunostaining Sham group: moderate positive 
nuclear immunoreactivity in renal medulla tubules; B3, NF-κB immunostaining CRF and CRF100 groups: 
intense positive nuclear immunoreactivity in renal medulla tubules; B4, NF-κB immunostaining CRF200, 
CRF400 and CRF600 groups: moderate positive nuclear immunoreactivity interstitial cells; C1, quick score 
for TGFβ1 in renal cortex; C2, TGFβ1 immunostaining Sham group: light positive cytoplasmic 
immunoreactivity in CT; C3, TGFβ1 immunostaining CRF and CRF100 groups: intense positive cytoplasmic 
immunoreactivity in CT and interstitial cells; C4, TGFβ1 immunostaining CRF200, CRF400 and CRF600 
groups: moderate positive cytoplasmic immunoreactivity in CT; D1, quick score for TGFβ1 in renal  
medulla; E1, quick score for TGFβ1 in renal fibrosis areas; E2, TGFβ1 immunostaining CRF and CRF100 
groups: intense positive cytoplasmic immunoreactivity in glomerulus, CT and interstitial cells; E3, TGFβ1 
immunostaining CRF200, CRF400 and CRF600 groups: moderate positive cytoplasmic immunoreactivity in 
CT and interstitial cells. F, Kidney relative mRNA expression of interleukin 6 (IL6), with β-actin as the 
reference gene. G, Kidney protein analysis of IL-1β by Western blot at the end of the protocol and 
representative image of Western blot for the different groups. Results are presented as mean ± standard error 
of the mean (SEM). a P < 0.05, aa P < 0.01 vs Sham group; b P < 0.05, bb P < 0.01 vs CRF group; c 
P < 0.05 vs CRF100 group; d P < 0.05 vs CRF200 group (Mann-Whitney test). 
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hypertension, anaemia, inflammation and rHuEPO 
dose is crucial to define the renal risk-benefits of this 
therapy in CKD. Actually, rHuEPO treatment 
corrected anaemia and improved urinary albumin 
excretion, particularly at lower doses; in addition, a 
short-term treatment with higher doses, used to 
overcome an episode of reduced hyporesponse to 
rHuEPO therapy, can present benefits by reducing 
inflammation, without worsening of renal lesions; 
however, the pro-hypertensive effect during a long-
term treatment should be considered, and carefully 
managed in order to avoid the negative cardiorenal 
impact. 
 
ANIMALS AND METHODS 
Animals and experimental protocol 
Male Wistar rats (Charles River Laboratories, 
Chatillon-sur-Chalaronne, France), 12 weeks old, 
were maintained in ventilated cages, in an air 
conditioned room, subjected to 12 hour dark/light 
cycles and given free access to rat laboratory chow 
(SAFE-A03, Augy, France)  and tap water. The rats 
were randomly divided in six groups: a Sham-
operated group, subjected to surgical process but 
without kidney mass reduction, and five groups with 
chronic renal failure induced by a two-stage (5/6) 
nephrectomy, with surgical excision of both poles of 
the left kidney (2/3 nephrectomy) by left flank 
incision and, one week later, complete removal of 
the right kidney through an identical procedure. 
After another week, while one of the CRF groups 
remained under vehicle treatment (saline solution; 
CRF group), the other four groups started 
subcutaneous (sc) rHuEPO (100, 200, 400 and 
600IU/kg BW per week; CRF100, CRF200, 
CRF400 and CRF600, respectively; NeoRecormon, 
Roche Pharmaceuticals, Basel, Switzerland) 
treatment, three times per week, for a further 3 
weeks. Animal experiments were conducted 
according to the European Community Council 
directives on animal care and to the national 
authorities. 
The animal HR, SBP, DBP and MBP measures 
were obtained by the tail-cuff method, using a 
sphygmomanometer (LE5001 Pressure meter, 
Panlab Havard Apparatus, Barcelona, Spain). 
 
Sample collection 
Blood samples were collected at baseline, one 
week after the start of treatment and at the end of the 
protocol (3 weeks of treatment), with rats under 
anaesthesia (intraperitoneal) with a 2 mg/kg BW of a 
2:1 (v:v) 50 mg/mL ketamine (Ketalar, Parke-Davis, 
Lab. Pfeizer Lda, Seixal, Portugal) solution in 2.5% 
chlorpromazine (Largactil, Rhône-Poulenc Rorer, 
Lab. Vitória, Amadora, Portugal). Blood samples 
were collected by venipuncuture, from the jugular 
vein, into Vacuette (Greiner Bio-One, 
Frickenhausen, Germany) tubes without 
anticoagulant (to obtain serum) or with K3EDTA for 
haematological and biochemical studies. Aliquots of 
serum and plasma were immediately stored at –80ºC 
until assayed. 
For collection of 24-hour urine the rats were 
enclosed, at the end of the protocol, in metabolic 
cages during 24 hours with free access to laboratory 
chow and tap water. Afterwards, urine volume and 
water consumption were recorded. Aliquots of urine 
were stored at –80ºC.  
At the end of the protocol, after blood collection, 
rats were killed by cervical dislocation; the kidney 
and the liver were immediately removed and placed 
in ice-cold Krebs-Henseleit buffer, cleaned and 
weighed. In order to isolate total RNA, small 
portions of kidney and liver from each rat, were 
immersed in RNAlater solution (Sigma-Aldrich, St. 
Louis, MO, USA) upon collection and stored at 4°C 
for 24 hours; afterwards, samples were frozen at –
20ºC. For Western blot analysis organs were 
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immediately frozen with liquid nitrogen and stored 
at –80ºC. 
 
Biochemical and haematological assays 
The RBC count, Hb concentration, Ht and 
platelets were assessed in whole blood K3EDTA 
using an automated blood cell counter (HORIBA 
ABX, Amadora, Portugal). Reticulocyte count was 
determined by microscopic counting on blood 
smears after vital staining with new methylene blue 
(reticulocyte stain; Sigma-Aldrich). 
The RPI was calculated as previously described 
by Hillman and Finch50 [(reticulocyte %/maturation 
index)*(Ht/normal Ht)], where normal Ht was the 
mean value presented by the Sham group, and the 
maturation index (maturation time of circulating 
blood reticulocytes that increase with premature 
release of reticulocytes from the bone marrow) was 
1 for Sham and 1.5 for anaemic groups. 
Serum EPO and CRP levels were evaluated by 
rat specific ELISA kits, according to the 
manufacturer’s instructions (MyBioSource, San 
Diego, CA, USA and eBioscience, San Diego, CA, 
USA, respectively). 
Serum BUN and creatinine were analyzed 
through automatic methods and equipment (Hitachi 
717 Chemistry Analyzer, Roche Diagnostics, Basel, 
Switzerland).  
The urinary levels of BUN and creatinine were 
analyzed using automatic methods (Cobas Integra 
400Plus, Roche Diagnostics). Creatinine clearance, 
BUN clearance and GFR were calculated according 
to Pestel et al.51 
 
Gene expression analysis 
Kidney RNA isolation and integrity control were 
performed as previously described by the authors.24 
One microgram of total RNA was reverse 
transcribed using iScript cDNA Synthesis Kit (Bio-
Rad Laboratories, Hercules, CA, USA), according to 
the manufacturer’s instructions.  One nanogram of 
cDNA was used for gene expression analysis with 
qPCR using a Mini-Opticon instrument (Bio-Rad 
Laboratories), the KAPA SYBR FAST qPCR kit 
(Kapa Biosystems, Inc., Wilmington, MA, USA) 
and specific primer pairs for IL-6 gene ( il6 
Forward: ATG TTG TTG ACA GCC ACT GC ; 
Reverse: TTT TCT GAC AGT GCA TCA TCG). 
qPCR reactions were performed using the following 
conditions: enzyme activation at 95ºC for 3 minutes; 
denaturation at 95ºC for 3 seconds; annealing at 
58ºC for 30 seconds. Gene expression was 
normalized to actin beta (Actb), and relative 
quantification was calculated using the 2-∆∆CT 
method.  
 
Western blot analysis 
The liver and kidney proteins were extracted 
using RIPA buffer (NaCl 150mmol/L, Tris-HCl 
50mmol/L pH8, Triton X-100 1%, ethylene glycol 
tetraacetic acid 5mmol/L, deoxycholic acid 0.5%, 
sodium lauryl sulfate 0.1%) and ultra-sonication. 
After centrifugation, protein concentration in 
supernatant was assayed using the bicinchoninic 
acid (BCA) method (Thermo Scientific, Pierce, IL, 
USA). Aliquots of the extract containing 50–100 µg 
of proteins were separated by reducing sodium 
dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) (10%) and transferred onto 
nitrocellulose membranes. The nitrocellulose 
membranes were blocked by using 7% non-fat milk 
in a solution of Tris-buffered salt with Tween-20. 
The membranes were incubated, overnight at 4ºC, 
with rabbit polyclonal antibody anti-EPAS-1 (HIF-
2α) 1:200, anti-EPO 1:20, anti-EPOR 1:200 (sc-
28706, sc-7956 and sc-697, respectively, from Santa 
Cruz Biotechnoloy, TX, USA) and goat polyclonal 
antibody anti-IL1β  1:1000 (AF-501-NA, R&D 
Systems, MN, USA); afterwards, membranes were 
incubated with anti-goat or anti-rabbit secondary 
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antibody-conjugated with horseradish peroxide 
1:1000 (ab97120, Abcam,  Cambridge, UK, and sc-
2004 Santa Cruz Biotechnology, Dallas, TX, USA, 
respectively). Immunoreactive proteins were 
detected by using the enhanced chemiluminescence 
method (ECL; WesternBright, Advansta, CA, USA). 
The immunoblot analysis was performed by 
densitometry (Bio1D++ version 99, Vilber 
Lourmat). To ensure even loading of the samples, 
membranes were probed with rabbit anti-β-tubulin 
antibody 1:500 (sc-9104, SantaCruz Biotechnology). 
The protein concentration found in each sample was 
normalized for the protein concentration observed in 
the Sham group. 
 
Histopathological analysis 
Samples were fixed in neutral formalin 10%, 
embedded in paraffin wax, and 3-µm thick sections 
were stained with Periodic acid Shiff (PAS). All 
samples were examined by light microscopy, using a 
Microscope Zeiss Axioplan 2 (Carl Zeiss 
Microscopy, LLC, NY, USA), and images were 
captured using a digital microscope camera (Leica 
DFC450; Leica Microsystems, Wetzlar, Germany). 
Lesions were evaluated in a double-blinded fashion 
by the pathologist, who evaluated and quantified 
lesions, according to methods previously described 
by our group.24  
 
Immunohistochemistry analysis 
Tissue sections were incubated in xylene and 
rehydrated via graded ethanol series to water. To 
retrieve antigen exposure, the samples were treated 
with 0.01mol/L citrate buffer solution at 95°C, for 
45 minutes. The samples were processed for indirect 
immune detection, using mouse or rabbit specific 
horseradish peroxidase (HRP)/ diaminobenzidine 
(DAB) detection immunohistochemistry (IHC) kit 
(ab80436, Abcam), according to the manufacturer’s 
protocol. Negative controls were included in all 
series, by omission of the primary antibodies. 
Polyclonal rabbit antibodies anti-EPAS-1 (HIF-2α) 
1:500 (sc-28706), anti-EPO 1:200 (sc-7956), anti-
NFκB p65 1:100 (sc-109) and anti-TGFβ1 (sc-146) 
1:100 diluted in TBS-Tween 0.05% were used as 
primary antibodies; tissue sections were incubated 
with the primary antibodies, overnight at 4°C in a 
humidified chamber; excess unbound primary 
antibody was removed by washing with TBS-Tween 
0.05% buffer. Tissue sections were counterstained 
with hematoxylin, dehydrated, and mounted in a 
non-aqueous media (DPX Mountant for Microscopy, 
VWR BDH, Prolabo, PA, USA) and examined with 
a microscope Nikon Eclipse Ci; images were 
captured using a digital microscope camera (Nikon 
DS-Ri2). Immunopositivity was scored in 
accordance to staining intensity (I) and percentage of 
positive cells or area (P), as previously described.24 
 
Statistical analysis 
Results are presented as mean ± standard error of 
the mean (SEM). For comparison between groups 
Mann-Whitney U test was performed. The strength 
of the association between the variables was 
estimated by Spearman correlation coefficient. 
Statistical significance was accepted at P < 0.05. 
Statistical analysis was performed using the IBM 
Statistical Package for Social Sciences (SPSS) for 
Windows, version 22.0 (IBM, Armonk, NY, USA). 
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ABSTRACT 
Hepcidin is the major central regulator of iron metabolism, controlling iron absorption and mobilization. 
Considering its interaction with several factors that are altered in chronic kidney disease (CKD), particularly 
in hyporesponsive CKD patients under therapy with high recombinant human erythropoietin (rHuEPO) 
doses, we aimed to study the impact of increasing rHuEPO doses on the regulation of iron-hepcidin 
metabolism. We performed blood, cellular and tissue studies, using the remnant kidney rat model of CKD 
induced by 5/6 nephrectomy, under rHuEPO (100, 200, 400 and 600IU/Kg body weight [BW]/week) 
treatment during 3 weeks. We found that the rHuEPO stimulus triggers a first wave to achieve correction of 
anemia, by inhibiting hepcidin synthesis, favouring erythropoiesis and iron absorption; this continuous 
stimulus enhanced iron absorption leading to iron overload, as showed by the hepatic iron deposits found in 
rats treated with higher rHuEPO dose that seems to trigger the up-regulation of hepcidin synthesis through 
the activation of the BMP6/SMAD pathway. Our data suggests that liver iron overload is an important 
stimulus for hepcidin synthesis, stronger than the inhibitory effect of high rHuEPO doses; moreover, our 
findings raise the hypothesis that when high inflammation (triggering hepcidin expression) is associated with 
increased iron stores in hemodialysis patients, hepcidin expression is also up-regulated via BMP6, enhancing 
hepcidin synthesis, leading, therefore, to worsening of anemia and, eventually, to a hyporesponse/resistance 
to rHuEPO therapy.         
 
 
Keywords: BMP6; chronic renal failure; erythropoietin; hepcidin; iron overload. 
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1. Introduction   
Iron has essential roles in several physiological 
processes. The majority of iron in the organism 
comes from the diet and from the internal iron 
turnover. The dietary iron is absorbed in the reduced 
form in the duodenum (Fig.1) and then effluxed 
through the iron exporter protein ferroportin (FPN), 
also present in the membrane of macrophages and 
hepatocytes, according to body iron requirements 
[1]. Iron circulates in plasma bound to transferrin 
(Tf), and the Tf receptors (TfR) mediate the cellular 
uptake of Tf-bound iron (Tf-Fe). There are two TfR 
types, the TfR1, which is expressed ubiquitously and 
has high affinity for Tf, and the TfR2 mainly present 
in hepatocytes [2]. 
Hepcidin, the central player of iron metabolism, 
is a peptide synthesized in the liver that regulates 
iron absorption and mobilization from macrophages 
and hepatocytes, by binding to FPN, the only known 
iron exporter, promoting its internalization and 
degradation [3].  
Hepcidin synthesis is highly regulated by several 
factors, including circulating iron and inflammation, 
which are stimulatory conditions; and hypoxia, 
erythropoiesis and erythropoietin, which act as 
inhibitors of hepcidin production (Fig. 1) [4-6]. Iron 
overload can be sensed by Tf saturation (TSAT), 
which is considered a sensor for circulating iron or 
by iron stores in the liver, and both can  induce bone 
morphogenetic protein 6 (BMP6) expression and 
activate the BMP-SMAD signaling pathway [7]. 
Some studies suggested that the induction of 
hepcidin by TfR2/HFE could also involve the 
MAPK/ERK signaling pathway [8]. In inflammatory 
conditions, the synthesis of interleukin (IL)-6 is 
stimulated, which induces hepcidin expression 
through the activation of STAT3 pathway [9]. Iron 
metabolism and erythropoiesis are closely linked, as 
erythropoiesis efficiency depends on iron 
availability. Indeed, accelerated erythropoiesis is 
able to inhibit hepcidin synthesis, in order to 
stimulate iron absorption and mobilization. Under 
hypoxic conditions, erythropoiesis is stimulated by 
increased erythropoietin (EPO) production, which is 
regulated by the hypoxia inducible factor (HIF) 
system. EPO itself and the HIF system are able to 
repress hepcidin synthesis [10, 11]; however, recent 
studies reported that, in vivo, these factors indirectly 
regulate hepcidin synthesis [12-14]. Thus, despite 
the advances in the last years, the exact mechanisms 
underlying the regulation of hepcidin synthesis are 
not yet well understood.  
Anemia, a major complication in chronic kidney 
disease (CKD) patients can be treated with  iron 
supplementation and erythropoiesis stimulating 
agents (ESA) [15], but 5-10% of them develop 
resistance to ESA therapy [16], a condition where 
higher doses are needed to achieve the target 
hemoglobin (Hb) values [17, 18]. 
Hepcidin is increased in hemodialysis (HD) 
patients [18, 19] and it has been reported to be 
mainly due to inflammatory conditions [20] and to 
the reduction of urinary excretion of this peptide 
[21]. Given the close interaction of hepcidin 
synthesis with several factors that are altered in 
CKD patients, particularly altered in hyporesponsive 
CKD patients, we figured as important to study the 
impact of increasing ESA doses on the regulation of 
iron-hepcidin metabolism. To accomplish this goal, 
we performed blood, cellular and tissue studies that 
cannot be performed in CKD patients, by using the 
remnant kidney rat model of CKD-associated 
anemia to understand the relationship between iron-
hepcidin metabolism and erythropoiesis induced by 
increasing recombinant human EPO (rHuEPO) 
doses. 
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2. Methods   
2.1. Animals and experimental protocol 
Male Wistar rats (Charles River Lab., Inc., 
Chatillon-sur-Chalaronne, France), 12 weeks old, 
were maintained in ventilated cages, in an air 
conditioned room, subjected to 12 h dark/light 
cycles and given free access to rat laboratory chow 
(SAFE-A03, Augy, France)  and tap water. The rats 
were randomly divided in six groups (6-7 animals 
each group): Sham operated group and five groups 
with chronic renal failure (CRF) induced by a two-
stage (5/6) nephrectomy, as previously described 
[22]. One week after nephrectomy, four CRF groups 
started subcutaneous rHuEPO (NeoRecormon, 
Roche, Basel, Switzerland) treatment (100, 200, 400 
and 600IU/Kg body weight [BW]/week, 
respectively, CRF100, CRF200, CRF400 and 
CRF600) for 3 weeks, while the other CRF group 
remained under vehicle treatment. All animals 
received human care and animal experiments were 
conducted according to the European Communities 
Council Directives on Animal Care. The 
experiments were approved by the Portuguese 
Foundation for Science and Technology and the 
Local Ethics Committee (ORBEA: Organ 
Responsible for Animal Welfare) of the Faculty of 
Medicine from the University of Coimbra. 
 
2.2. Sample collection 
Blood samples were collected at baseline, one 
week after starting rHuEPO treatment and at the end 
of the protocol, with rats under anesthesia as 
previously described [22].  Aliquots of serum and 
plasma were immediately stored at -80ºC until 
assayed. 
At the end of the protocol, after blood collection, 
the rats were sacrificed by cervical dislocation; liver 
and duodenum were immediately removed and 
placed in ice-cold Krebs-Henseleit buffer, cleaned 
and weighted. In order to isolate total RNA, small 
portions of liver and duodenum, from each rat, were 
immersed in RNAlater® solution (Sigma-Aldrich 
Co. LLC. St. Louis, Missouri, USA) upon collection 
and stored at -20ºC. For western blot analysis small 
portions of the organs were immediately frozen with 
liquid nitrogen and stored at -80ºC. 
 
2.3. Biochemical and hematological assays 
Red blood cells count, hematocrit (Ht) and Hb 
concentration were assessed in whole blood 
K3EDTA, using an automated blood cell counter 
(HORIBA ABX, Amadora, Portugal). Reticulocyte 
count was measured by microscopic counting on 
blood smears after vital staining with New 
methylene blue (reticulocyte stain; Sigma-Aldrich 
Co. LLC. St. Louis, Missouri, USA). 
Serum alanine transaminase (ALT) and aspartate 
aminotransferase (AST) were analyzed through 
automatic methods and equipment (Hitachi 717 
Chemistry Analyzer, Roche Diagnostics, Basel, 
Switzerland).  
Serum C-reactive protein (CRP) levels were 
evaluated by a rat specific ELISA kit, according to 
manufacture instructions (eBioscience, San Diego, 
CA, USA). 
Serum iron and ferritin were analyzed through 
automatic methods and equipment (ROCHE Integra 
400, Roche Diagnostics, Basel, Switzerland). Serum 
Tf levels were evaluated by rat specific ELISA kit 
(Transferrin Rat ELISA Kit, abcam, Cambridge, 
UK). Tf saturation (TSAT) was calculated using the 
formula (Iron µg/dL*100)/(Tf mg/dL*2). 
 
2.4. Perls' Prussian blue staining 
Liver samples were fixed in neutral formalin 
10%, embedded in paraffin wax, and 3µm thick 
sections were stained with Perls' Prussian blue stain. 
Briefly, tissue sections were deparaffinised, hydrated 
and immersed in a freshly prepared potassium 
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ferrocyanide solution (10g/L in 0.1M hydrochloric 
acid) at room temperature. Counterstaining was 
made with safranin.  All samples were examined by 
light microscopy (Microscope Nikon Eclipse Ci) and 
images were captured using a digital microscope 
camera (Nikon DS-Ri2). 
 
2.5. Gene expression analysis by qPCR 
Liver and duodenum RNA isolation and integrity 
control were performed as previously described [22]. 
One µg of total RNA was reversely transcribed, 
using iScript™ cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, California, USA), according 
to manufacturer instructions.  One ng of cDNA was 
used for gene expression analysis with qPCR, using 
a Mini-Opticon instrument (Bio-Rad Laboratories), 
the KAPA SYBR® FAST qPCR kit (Kapa 
Biosystems, Inc., Wilmington, MA, USA) and 
specific primer pairs (Table 1). qPCR reactions were 
performed using the following conditions: enzyme 
activation at 95ºC for 3min; denaturation at 95ºC for 
3sec; annealing for 30sec (for each pair of primers, 
the temperature is referred in Table 1). Gene 
expression was normalized to actin beta (actb) and 
glyceraldehyde 3-phosphate dehydrogenase (gapdh), 
and relative quantification was calculated using the 
2-∆∆CT method.  
 
2.6. Protein analysis by Western Blot 
The liver and duodenum proteins were extracted 
as previously described [22]. Aliquots of the extract, 
containing 100 µg of proteins, were separated by 
reducing SDS-PAGE (10 %) and transferred onto 
nitrocellulose membranes. The blots were blocked 
by using 7% non-fat milk in a solution of Tris-
buffered salt with Tween-20, and then incubated 
overnight, at 4ºC, with rabbit anti-SLC40A1 (FPN) 
antibody 1:100 (ab58695), rabbit anti-SMAD1/5/9 
1:500 (ab66737), rabbit anti-SMAD4 1:1000 
(ab40759, abcam,  Cambridge, UK), rabbit anti- 
Table 1 – List of primer sequences and annealing 
temperatures 
F: Forward; R: Reverse; actb - beta – actin; bmp6 - bone 
morphogenetic protein 6; epas1 - endothelial PAS domain-containing 
protein 1; epo – erythropoietin; gapdh - glyceraldehyde 3-phosphate 
dehydrogenase; hamp – hepcidin; hfe2 - hemojuvelin; hif1a – 
hypoxia inducible factor 1 alpha; slc11a2 - divalent metal transporter 
1; tfrc – transferrin receptor 1; tfr2 – transferrin receptor 2; tmprss6 – 
matriptase-2. 
 
phospho-SMAD1/5/9 (#13820, Cell Signaling 
Technology, MA, USA), goat anti-hepcidin 1:100 
(sc-240553), mouse anti-ERK1 1:200 (sc-376852) 
and rabbit anti-phospho-ERK1/2 (Thr 202/Tyr 204) 
1:100 (sc-16982, Santa Cruz Biotechnoloy, Inc, TX, 
USA); afterwards, they were incubated with anti-
goat (ab97120) or with anti-rabbit (sc-2004) 
secondary antibody-conjugated with horseradish 
peroxide 1:1000 (abcam,  Cambridge, UK; Santa 
Gene Primer sequences (5’ → 3’) Annealing 
Temperature 
tfrc 
F: GGGAGCCATTGTCATACACC 
58ºC 
R: GTCGCAAAGCAGAGTCTTCC 
tfr2 
F: AGCTGGGACGGAGGTGACTT 
58ºC 
R: TCCAGGCTCACGTACACAACAG 
hfe2 
F: TTCCAATCCTGCCTCTTTGAT 
58ºC 
R: GGAAAAGGTGCAAGTTCTCCAA 
hamp 
F: GGCAGAAAGCAAGACTGATGAC 
58ºC 
R: ACAGGAATAAATAATGGGGCG 
bmp6 
F: GGTGGAGTACGACAAGGAGTT 
56ºC 
R: GTCACAACCCACAGATTGCTA 
tmprss6 
F: AGAAGGTGGATGTGCAACTGATC 
59ºC 
R: CTTGCCCTTGCGATAACCA 
hif1a 
F: CTCACCATCAGTTACTTAC 
58ºC 
R: GTCACCATCATCTGTTAG 
epas1 
F: TGACTTCACTCATCCTTGCGACCA 
59ºC 
R: ATTCATAGGCAGAGCGGCCAAGTA 
epo 
F: TCTGACTGACCGCGTTACTC 
59ºC 
R: GCCCAGAGGAATCAGTAGCA 
slc11a2 
F: ATAGCAGACGCCCCCATG 
58ºC 
R:AGGCCCGAAGTAACATCCAA  
actb 
F: TACAGCTTCACCACCACAGC 
57ºC 
R: AAGGAAGGCTGGAAGAGAGC 
gapdh 
F: TGCCACTCAGAAGACTGGG 
59ºC 
R: ACGGATACATTGGGGGTAGG 
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Cruz Biotechnoloy, Inc, TX, USA). Immunoreactive 
proteins were detected by using the enhanced 
chemiluminescence method (ECL; WesternBright, 
Advansta, CA, USA). The analysis of the 
immunoblots was performed by densitometry 
(Bio1D++ version 99, Vilber Lourmat). To ensure 
even loading of the samples, all immunoblots were 
probed with rabbit anti-β-tubulin antibody 1:500 (sc-
9104, SantaCruz Biotechnology, TX, USA). The 
protein concentration in each sample was 
normalized for Sham group. 
 
2.7. Statistical analysis 
Results are presented as mean ± standard error of 
the mean (SEM). For comparison between groups, 
Mann-Whitney U test was performed. Statistical 
significance was accepted at p<0.05. Statistical 
analysis was performed using the IBM Statistical 
Package for Social Sciences (SPSS), for Windows, 
version 22.0 (IBM, Armonk, NY, USA). 
 
3. Results  
The CRF group developed anemia, as showed by 
the reduction in RBC count, Hb concentration and 
Ht, when compared to Sham group (Table 2). After 
one week of rHuEPO treatment, anemia was 
corrected, in a rHuEPO dose-dependent manner, as 
showed by the increasing values of RBC count, Hb 
concentration and Ht. Reticulocyte count increased 
after one week of rHuEPO treatment, as compared to 
Sham and CRF groups; this rise in reticulocytes was 
dose-dependent for CRF100, CRF200 and CRF400 
groups, showing the CRF600 group a decrease to a 
value that was still significantly higher. At the end 
of the protocol, RBC count, Hb concentration and Ht 
were even more increased than after one week of 
treatment; however, we found a normal reticulocyte 
count, excluding CRF100 and CRF600 groups 
(Table 2). 
 
Significantly high serum CRP levels (Table 2) were 
found in CRF, CRF100 and CRF200 groups, 
compared to Sham, CRF400 and CRF600 groups, at 
the end of the protocol. CRF400 and CRF600 groups 
presented CRP levels similar to the Sham group. No 
significant alterations were found in ALT and AST, 
for all CRF groups, as compared to Sham group 
(Table2).  
At the end of protocol, we found that serum iron 
concentration was significantly reduced in the 
CRF600 group, when compared with Sham, CRF 
and CRF200 groups (Fig. 2A). Ferritin levels were 
significantly increased in CRF400 and CRF600 
groups, as compared to CRF and CRF200 groups 
(Fig. 2B). Serum Tf levels (Fig. 2C) were 
significantly reduced and TSAT (Fig. 2D) increased 
in CRF200, CRF400 and CRF600 groups versus 
Sham, CRF and CRF100 groups. Liver histological 
sections stained with Perls' Prussian blue showed 
iron deposition as hemosiderin in the CRF600 group 
(Fig. 3). 
Liver TfR1 mRNA levels were up-regulated in 
CRF, CRF200, CRF400 and CRF600 groups, 
compared to Sham group, whereas mRNA levels 
were down-regulated in the CRF100 group (Fig. 
4A). The same pattern was found for TfR2 mRNA 
levels (Fig. 4B). Liver hemojuvelin (HJV) mRNA 
levels did not differ between groups (Fig. 4C). In 
accordance with lower hepcidin mRNA levels for all 
CRF groups, except in CRF600 group (Fig. 4D), 
hepcidin synthesis was lower, reaching significantly 
lower values in CRF200 and CRF400 groups 
(Fig.5A); the CRF600 group presented a 
significantly higher expression and synthesis of 
hepcidin (Fig. 4D and Fig. 5A, respectively). BMP6 
mRNA levels were down-regulated in all CRF 
groups, excepting CRF600 group that presented a 
significant up-regulation (Fig. 4E). Matriptase-2 
mRNA levels were increased in CRF, CRF200 and  
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Fig. 1 – Schematic diagram of the molecular pathways and mediators that regulate hepcidin expression in 
liver.  The dietary iron (Fe) is absorbed in the reduced form (Fe II) in the duodenum and transported within 
the enterocyte through the divalent metal iron transporter 1 (DMT1), and then effluxes, through the iron 
exporter protein ferroportin (FPN). Hepcidin, the central player of iron metabolism, regulates iron absorption 
and mobilization from enterocytes, macrophages and hepatocytes, by binding to FPN, an iron exporter, 
promoting its internalization and degradation. In normal blood iron concentrations, haemochromatosis 
protein (HFE) and transferrin-bound iron (Tf-Fe) compete for binding to  transferrin receptor 1 (TfR1); 
however, in conditions of increased Tf saturation (TSAT), Tf-Fe displaces HFE that binds to the TfR2 
forming a complex with hemojuvelin (HJV) that acts as a co-receptor of bone morphogenetic protein 6 
(BMP6), a ligand to BMP receptor, which activates the phosphorylation of SMAD1, SMAD5 and SMAD9, 
that will form a complex with SMAD4. This complex is translocated into the nucleus, activating (+) the 
transcription of the hepcidin gene. HJV can be regulated by matriptase-2, which promotes the cleavage of 
HJV, forming a soluble form that blunts the action of BMP6. Iron stores in the liver that can directly induce 
BMP6 expression and activate the BMP-SMAD signaling pathway. Induction of hepcidin by TfR2/HFE 
could also involve the MAPK/ERK signaling pathway. Interleukin (IL)-6 induces hepcidin expression 
through the activation of STAT3 pathway. Erythropoiesis, erythropoietin, low iron and hypoxia act as 
inhibitors (-) of hepcidin production. 
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Table 2 – Hematological and biochemical data at the start of the protocol, 1 and 3 weeks (end of protocol) 
according to group and rHuEPO treatment 
Results are presented as Mean ± SEM. a p<0.05 vs Sham group; b p<0.05 vs CRF group; c p<0.05 vs CRF+rHuEPO 100IU; d p<0.05 vs 
CRF+rHuEPO 200IU; e p<0.05 vs CRF+rHuEPO 400IU (Mann-Whitney test). 0w –start of protocol; 1w – 1 week after starting 
rHuEPO treatment; 3w – 3 weeks after starting rHuEPO treatment (end of protocol); ALT – alanine transaminase; AST - aspartate 
aminotransferase; CRP – C-reactive protein; Hb – hemoglobin; Ht – hematocrit; CRF – chronic renal failure; RBC – red blood cells; Ret 
– Reticulocytes.   
 
 
CRF400 groups, in contrast with reduced expression 
in CRF100 and CRF600 groups (Fig. 4F). 
Concerning HIF system, we found an up-regulation 
of HIF-1α (Fig. 4G) and HIF-2α (Fig. 4H) in CRF 
and CRF600 groups, and an increased expression of 
EPO mRNA levels in the same groups (Fig. 4I); a 
down-regulation was observed for HIF-1α in 
CRF100, CRF200 and CRF400 groups (Fig. 4G), 
and the same was observed for EPO expression (Fig. 
4I). 
In the duodenum, a down-regulation of divalent 
metal iron transporter 1 (DMT1) mRNA levels (Fig. 
4J) was found in all CRF groups, when compared 
with Sham group, except in CRF600 group, 
presenting an overexpression of DMT1 mRNA 
levels. The protein levels of FPN in the duodenum 
increased in a rHuEPO dose-dependent manner, 
except in the CRF600 group that presented a 
reduction, also found in the CRF group (Fig. 5B).  
No differences were found in protein liver 
pERK1/2:ERK1/2 ratio between groups (Fig. 5C); 
however, an increase in protein liver pSMAD1/5/9: 
SMAD1/5/9 ratio (Fig. 5D) and a reduction in total 
protein SMAD4 (Fig. 5E) were found in the CRF100 
and CRF600 groups, while CRF200 and CRF400 
groups showed a significant increase. 
 
Parameters Sham CRF CRF100 CRF200 CRF400 CRF600 
RBC (x 1012/L) 
0w 7.41±0.07 7.43±0.09 7.03±0.12 7.53±0.11 7.60±0.09 7.03±0.07 
1w 7.11±0.08 6.11±0.12a 7.02±0.21b 6.80±0.14b 7.62±0.06abd 8.08±0.11abcd 
3w 7.77±0.13 6.41±0.11a 7.92±0.40b 7.48±0.17b 8.39±0.21bd 10.53±0.20abcde 
Hb (g/dL)       
0w 13.85±0.13 13.63±0.18 13.55±0.13 13.54±0.17 13.68±0.13 13.66±0.18 
1w 13.94±0.11 12.26±0.22a 13.58±0.37b 13.86±0.20b 14.55±0.14b 16.33±0.29abcde 
3w 14.07±0.15 12.06±0.18a 14.65±0.52b 13.89±0.32b 15.45±0.37abd 20.08±0.37abcde 
Ht (%)       
0w 41.12±0.54 41.34±0.59 38.40±0.31 40.90±0.55 41.25±0.45 39.23±0.41 
1w 38.02±0.20 32.13±0.63a 38.73±1.19b 36.21±0.92b 41.88±0.49abcd 50.11±0.93abcde 
3w 41.77±0.80 33.56±0.57a 43.37±2.09b 38.03±0.87 46.54±1.43bd 66.16±1.16abcde 
Ret (x 109/L) 
0w 144.39±12.38 183.41±20.89 80.37±8.20 177.06±18.25 151.09±10.19 108.08±19.72 
1w 122.47±22.47 134.11±15.26 215.92±23.86 358.17±25.05ab 701.81±39.67abcd 520.08±45.99abcde 
3w 124.77±14.56 161.67±17.87 258.28±13.61a 158.84±14.67 119.90±12.17c 252.18±48.78ae 
CRP (µg/mL) 
0w 538.49±39.25 552.72±37.64 447.52±20.33 555.59±30.32 556.80±46.46 583.59±52.07 
1w 687.91±40.71 592.39±52.52 859.51±35.17ab 705.95±49.94 637.29±30.70c 691.28±50.34c 
3w 575.03±33.24 820.61±48.02a 767.56±27.10a 771.54±64.15a 605.91±42.61b 551.63±34.25bcd 
ALT (U/L)       
0w 25.25±1.75 25.14±1.89 16.00±0.58 26.14±3.79 26.10±1.46 18.57±2.43 
1w 34.50±1.78 33.14±1.91 33.67±1.99 27.00±4.99 31.00±1.17 36.00±2.73 
3w 39.75±2.68 33.57±1.43 33.40±1.17 31.28±3.08 32.80±3.55 35.86±2.26 
AST (U/L)       
0w 72.87±2.66 73.57±4.20 78.00±2.78 69.14±7.37 65.90±3.18 72.28±3.16 
1w 84.00±3.09 88.43±6.13 79.17±1.85 71.00±9.41 72.10±4.26 78.14±3.13 
3w 73.43±4.79 80.14±8.42 92.00±7.54 75.00±7.85 87.80±7.77 86.50±4.60 
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Fig. 2 – Iron data at the end of the protocol by group. Results are expressed as mean±SEM. a) p<0.05 vs 
Sham group, b) p<0.05 vs CRF group, c) p<0.05 vs CRF100 group, d) p<0.05 vs CRF200 group (Mann – 
Whitney test). CRF – chronic renal failure; TSAT – transferrin saturation. 
 
4. Discussion 
Under anemic conditions, the reduction of 
oxygen delivery to tissues leads to hypoxia, a 
recognized inhibitor of hepcidin transcription [4]. In 
our study, the CRF group developed anemia due to 
the reduced EPO renal production. No significant 
changes were observed, neither in serum iron, Tf 
and ferritin, nor in the gene expression of HJV and 
BMP6; in line with this, no significant changes were 
observed in SMAD1/5/9 phosphorylation and a 
significant increase was found for total SMAD4; 
however, a down-regulation in hepcidin gene 
expression was observed in the CRF group that 
seems to result from the up-regulation of HIF and 
(hepatic) EPO gene expressions, triggered to induce 
erythropoiesis. These findings are in accordance 
with recent reports by Mastrogiannaki et al. [23] and 
Ravasi, et al. [14]. Matriptase-2, known as negative 
modulator of hepcidin synthesis [24], was up-
regulated under the hypoxic conditions in CRF rats, 
and may also contribute to reduce hepcidin mRNA 
levels. The reduction in hepcidin protein synthesis in 
the CRF group, though without statistical 
significance, was associated to a significant decrease 
in duodenal protein FPN and in the expression of 
DMT1 gene, in accordance with the normal values 
of serum iron, Tf and ferritin. The significant up-
regulation in TfR1 and TfR2 is, thus, probably 
related to hypoxia [25]. 
The treatment with the lowest dose of rHuEPO 
(CRF100) triggered the increase in RBC production, 
as showed by the significantly higher values in all 
hematologic parameters under study, leading to 
normoxia. The erythropoietic rise did not 
significantly change serum iron, Tf and ferritin 
concentrations, explaining the significant down-
regulation in Tfr1 and Tfr2 mRNA levels. Indeed, 
hepcidin protein synthesis and most of the factors 
regulating hepcidin reached to values similar to 
those presented by the Sham group, suggesting a 
main role for rHuEPO in the slight inhibition of 
hepcidin (Fig. 1). 
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Fig. 3 – Liver sections of Sham (A) and CRF600 (B) groups demonstrating staining for hemosiderin (Perls 
Stain x100).  
 
In the CRF200 group the production of 
reticulocytes was significantly increased in the first 
week of treatment with rHuEPO, and normal 
afterwards, with hematologic values similar to those 
observed in the Sham group; however, some 
changes were already observed in iron metabolism, 
namely, a significant reduction in hepcidin 
synthesis, leading to a significant increase in 
duodenal protein FPN, increasing iron absorption 
and, thus, increasing TSAT and inducing TfR1 and 
TfR2 mRNA levels. The higher levels of rHuEPO, 
the significant increase in matriptase-2 and the 
significant reduction in BMP6 gene expressions, 
associated with no increase in phosphorylated 
SMAD proteins, may explain the observed reduction 
in liver hepcidin protein. 
In the CRF400 group, the increased rHuEPO 
dose triggered a stronger erythropoietic stimulus in 
the first week of treatment, leading to a significant 
increase in reticulocyte production. In spite of the 
continuous high exogenous erythropoietic stimulus 
by rHuEPO, after 3 weeks of treatment only slightly 
higher RBC values were observed. The reduction in 
liver hepcidin was still observed with this dose, as 
well as the changes in the others factors modulating 
its synthesis; the disturbances in iron metabolism, 
enhancing iron absorption and favouring the 
increase in iron stores were also observed. 
 
With the highest rHuEPO dose (CRF600), an 
increase in reticulocyte number was observed after 1 
week of treatment; however, the control on their 
production was weaker, as after 3 weeks of 
treatment the reticulocyte count and the RBC 
concentration was significantly higher than that 
observed in the Sham group. In spite of the up-
regulation of HIF system, the high rHuEPO dose and 
the increasing erythropoiesis, known to inhibit 
hepcidin synthesis [26-28], we found a significant 
increase in liver hepcidin protein that seems to be 
triggered via BMP6;strengthening this hypothesis, 
we found a significant increase in SMAD1/5/9 
phosphorylation and a slight reduction in total 
SMAD 4. This increase in hepcidin synthesis 
explains the reduction in duodenal protein FPN, 
triggering the reduction in iron absorption, as 
showed by the significant decrease in serum iron, the 
increase in ferritin and the increased hepatic iron 
stores, though no changes in liver function markers 
were found. 
Iron liver can directly induce BMP6 expression 
and activate the BMP-SMAD signaling pathway [7], 
which is in agreement with our results (Fig 1). 
Moreover, the increased gene expression of TfR2 
was not linked to an increase in HJV gene 
expression, and any changes in the ERK1/2 pathway 
were found supporting the hypothesis of a direct
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 action of iron liver (and not of TSAT) in the 
regulation of hepcidin synthesis. Diaz et al. reported 
similar findings, using a model of accelerated 
erythropoiesis [29]. Increased levels of BMP2 have 
been also reported [30], though BMP6 seems to be 
the most important BMP in hepcidin regulation [31]. 
Our data suggest that the rHuEPO stimuli trigger 
a first wave to achieve correction of the 
anemia/hypoxia, by inhibiting hepcidin synthesis, 
favouring erythropoiesis through an increase in iron 
absorption. In spite of the continuous exogenous 
increasing rHuEPO stimulus, the bone marrow 
stroma is able to control erythropoiesis; however, 
the iron stores will continuously increase, due to the 
increased iron absorption. When the ability of the 
bone marrow stroma fails to control abnormally high 
erythropoietic stimulus (CRF600), erythrocytosis 
develops and the increased hepatic iron stores are 
able to trigger hepcidin synthesis via BMP6. Thus, 
hepatic iron-induced hepcidin synthesis prevails 
over the other factors regulating hepcidin synthesis 
(Fig. 1).    
In our model, the increase in hepcidin due to an 
inflammatory condition should be excluded, as the 
CRF600 group presented CRP levels similar to 
Sham group. As reported by others, in a moderate 
degree of renal insufficiency hepcidin has been 
correlated with iron stores, but not with 
inflammatory markers [32]. In addition, the increase 
in hepcidin is not due to reduced excretion, as no 
difference in glomerular filtration rate between all 
CRF groups was found (data not shown).  
Recent studies raised concerns about the 
increased proportion of patients with serum ferritin 
values ≥800 ng/mL [33], and tissue iron 
accumulation (liver and spleen) in CKD patients 
[34] that may lead to further and more severe iron 
disturbances. Iron stores are usually evaluated by 
measuring ferritin blood levels; however, ferritin and 
liver iron are not always correlated, as some patients 
with ferritin levels below 500 ng/mL may present 
liver iron accumulation [35]. In a study by our 
group, using a rat model of nephrectomy, we found 
iron deposition in renal tubules, along with extensive 
tubulointerstitial lesions that could be responsible 
for CKD progression [22]. 
Our work raises the hypothesis that when high 
inflammation (triggering hepcidin synthesis) is 
associated with increased iron stores in HD patients, 
hepcidin synthesis is enhanced through BMP6, 
leading, therefore, to worsening of anemia and, 
eventually, to a hyporesponsiveness to ESA therapy. 
In summary, our data suggest that liver iron 
overload is an important stimulus for hepcidin 
synthesis, stronger than the inhibitory effect of high 
rHuEPO doses (Fig.1), and that liver iron overload 
should be further studied as a potential factor for the 
development of a hyporesponse to rHuEPO therapy. 
Moreover, the search for new, and more sensitive, 
biomarkers of tissue iron overload is warranted. 
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ABSTRACT 
Anemia of chronic kidney disease (CKD) can be corrected by treatment with recombinant human erythropoi-
etin (rHuEPO); however, some patients become hyporesponsive. The molecular mechanisms underlying this 
resistance remain to be elucidated. Our aim was to study hyporesponsiveness to rHuEPO therapy using the 
remnant kidney rat model of anemia associated with CKD induced by 5/6 nephrectomy. 
At starting, male Wistar rats were divided in 3 groups, for a 3-week protocol: Sham, CRF (vehicle) and 
rHuEPO (200IU/kg body weight [BW]/week) treated groups; at the end of protocol, the rHuEPO treated rats 
were subdivided in responders (CRF200) and non-responders (CRF200NR), according to their hematologic 
response; blood, cellular and tissue studies were performed. The CRF200 group achieved correction of ane-
mia, while the CRF200NR group developed anemia, after an initial response (1st week) to rHuEPO therapy. 
CRF and CRF200NR groups presented the highest serum CRP levels; CRF200NR showed also high levels of 
renal inflammatory markers, such as interleukin (IL)-6, IL-1β, nuclear factor kappa B, connective tissue 
growth factor (CTGF) and transforming growth factor beta 1 (TGF-β1); no changes were found in iron me-
tabolism. Our data suggest that the development of anemia/rHuEPO hyporesponsiveness is associated with a 
higher systemic and renal inflammatory condition, favoring hypoxia and triggering an increase in renal ex-
pression of HIF-1α, TGF-β1 and CTGF that will further aggravate renal fibrosis, which will further enhance 
the inflammatory response, creating a cycle that promotes disease progression. New therapeutic strategies to 
reduce inflammation in CKD patients could improve the response to rHuEPO therapy and reduce 
hyporesponsiveness. 
Keywords: anemia; CTGF; erythropoietin; hyporesponsiveness; inflammation; TGF-β1 
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1. Introduction 
Anemia is a common complication in chronic 
kidney disease (CKD) patients that develops early in 
the course of the disease, increasing its frequency 
and severity with the progression of CKD [1]. Wors-
ening of anemia has been associated with increasing 
morbidity and mortality, mainly, in patients under 
dialysis therapy [2-4]. Several factors contribute to 
CKD anemia, including inflammation, reduced red 
blood cell (RBC) life span, iron deficiency, uremic 
toxins, as well as, erythropoietin (EPO) deficiency, 
which is the major cause [5]. In the adult life, the 
kidney is the major organ producing EPO and the 
liver a secondary one [6]. The production of EPO is 
regulated by hypoxia, through the hypoxia induci-
ble-factor (HIF) system, including the oxygen-
dependent regulated subunits (HIF-1α, HIF-2α and 
HIF-3α) and the constitutive subunits (HIF-1β and 
HIF-2β) [7]. Under normoxia, HIF-2α is hydroxylat-
ed by an oxygen dependent prolyl-hydroxilase and, 
afterwards, the von Hippel–Lindau tumor suppressor 
protein targets the HIF-α subunit for rapid ubiquiti-
nation and proteasomal degradation. However, under 
hypoxic conditions the HIF-α subunits that are not 
hydroxylated, accumulate and translocate to the 
nucleus forming a complex with HIF-β activating 
the transcription of EPO gene and of other HIF tar-
get genes [7]. HIF-1α and HIF-2α are similar, but 
their target genes are different, HIF-1α regulates 
glycolytic genes and pro-fibrotic genes, whereas 
HIF-2α is the main responsible for EPO production 
[7]. An acute activation of the HIF system by tissue 
hypoxia leads to a protective response; however, a 
continuous activation, as occurs in CKD, can con-
tribute to the progression of the disease, through the 
enhancement of renal fibrosis [8], which is the 
common final feature in CKD disease, irrespective 
of the initial cause [9].  
According to the clinical practice guidelines, 
anemia of CKD patients can be corrected by the use 
of erythropoiesis-stimulating agents (ESA), such as 
recombinant human erythropoietin (rHuEPO) [10]. 
EPO and ESA stimulate erythropoiesis through the 
activation of a homodimer EPO receptor (EPOR); 
several pleiotropic effects, such as renoprotection, 
are also attributed to ESA treatment, due to their 
interaction with an heterodimer EPOR [11]. The 
majority of CKD patients respond to ESA therapy; 
however, about 5–10% of CKD patients are 
hyporesponsive [12], which has been associated with 
increased risk of cardiovascular events and mortality 
[13-15]. According to the Kidney Disease Improving 
Global Outcomes (KDIGO) guidelines [10], CKD 
patients can present initial or acquired ESA 
hyporesponsiveness. In a primary hyporesponse to 
ESA treatment, the patient presents no increase in 
hemoglobin (Hb) concentration after one month of 
treatment with adequate weight-based ESA dose; an 
acquired ESA resistance develops when, after treat-
ment with a stable ESA dose achieving target Hb 
concentration, the patient requires two increases in 
ESA dose (up to 50% beyond the stable dose) to 
achieve Hb concentration. Several factors can con-
tribute to this condition, such as iron deficiency 
(absolute or functional), inflammation and uremic 
toxins, among others [16,17]. Inflammation is a 
common feature in CKD patients, mainly in those on 
dialysis therapy [15,17] and has been associated 
with increased levels of hepcidin [18]; this liver 
peptide regulates iron metabolism by degrading 
ferroportin (an iron exporter), present in the mem-
brane surface of enterocytes, hepatocytes and mac-
rophages; thus, hepcidin controls iron absorption and 
mobilization from iron stores [19,20]. Increased 
hepcidin levels lead to a functional iron deficiency, 
due to a reduced iron absorption and mobilization 
and to an increase in ferritin levels [21]. The molec-
ular mechanisms linking these factors that may un-
derlie the development of a hyporesponse to ESA 
remain to be elucidated. This is, probably, due to the 
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lack of well-designed in vivo studies that cannot be 
performed in humans, due to ethical reasons. In that 
way, we used the 5/6 nephrectomy-induced remnant 
kidney rat model of CKD-associated anemia under 
rHuEPO therapy, to study the underlying causes of 
hyporesponsiveness to ESA therapy, focusing on 
iron metabolism, renal damage, hypoxia, inflamma-
tion and fibrosis. 
 
2. Animals and methods   
2.1. Animals and experimental protocol 
Male Wistar rats (Charles River Lab., Inc., 
Chatillon-sur-Chalaronne, France), 12 weeks old, 
were maintained in ventilated cages, in an air condi-
tioned room, subjected to 12h dark/light cycles and 
given free access to rat laboratory chow (SAFE-
A03, Augy, France)  and tap water. The rats were 
randomly initially divided in three groups: a sham 
operated group (n=8), subjected to surgical process 
but without kidney mass reduction, and two chronic 
renal failure (CRF) groups induced by a two-stage 
(5/6) nephrectomy, with surgical excision of both 
poles of the left kidney (2/3 nephrectomy) by left 
flank incision and, one week later, complete removal 
of the right kidney through identical procedure. 
After another week, while one of the CRF groups 
remained under vehicle treatment (saline solution – 
CRF group, n=7), the other group started subcutane-
ous (sc) rHuEPO (200 IU/Kg body weight 
[BW]/week of NeoRecormon®, Roche Pharmaceu-
ticals, Basel, Switzerland) treatment, 3 times per 
week, for further 3 weeks. At the end of protocol 
and according to the hematological response, the 
rHuEPO-treated group was further subdivided in 
responder (CRF200, n=7) or non-responder 
(CRF200NR, n=5). To define non-response to 
rHuEPO we used, as the cut-off value, the highest 
value of Hb concentration observed in the CRF 
group. Thus, the rats presenting an Hb concentration 
lower than the cut-off value, were classified as non-
responders. All animals received human care and 
animal experiments were conducted according to the 
European Communities Council Directives on Ani-
mal Care. The experiments were approved by the 
Portuguese Foundation for Science and Technology 
and the Local Ethics Committee (ORBEA: Organ 
Responsible for Animal Welfare) of the Faculty of 
Medicine from the University of Coimbra. 
 
2.2. Sample collection 
Blood samples were collected at baseline, one 
week after starting treatment and at the end of the 
protocol (3 weeks of treatment) with rats under anes-
thesia (intraperitoneal) with a 2 mg/kg BW of a 2:1 
(v:v) 50 mg/mL ketamine (Ketalar®, Parke-Davis, 
Lab. Pfeizer Lda, Seixal, Portugal) solution in 2.5% 
chlorpromazine (Largactil®, Rhône-Poulenc Rorer, 
Lab. Vitória, Amadora, Portugal). Blood samples 
were collected by venipuncuture, from the jugular 
vein, into Vacuette® (Greiner Bio-One GmbH, 
Germany) tubes without anticoagulant (to obtain 
serum) or with K3EDTA for hematological and 
biochemical studies. Aliquots of serum and plasma 
were immediately stored at -80ºC until assayed. 
At the end of protocol, after blood collection, and 
under anesthesia, rats were sacrificed by cervical 
dislocation, and the kidney, the liver and the duode-
num were immediately removed and placed in ice-
cold Krebs-Henseleit buffer, cleaned and weighted. 
A bone marrow aspirate from the femur was also 
performed. In order to isolate total RNA, small por-
tions of kidney, liver and duodenum from each rat, 
were immersed in RNAlater® solution (Sigma-
Aldrich Co. LLC. St. Louis, Missouri, USA) upon 
collection and stored at 4°C for 24h; afterwards, 
samples were frozen at -20ºC. For western blot anal-
ysis organs were immediately frozen with liquid 
nitrogen and stored at -80ºC. 
 
2.3. Biochemical and hematological assays 
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RBC count, Hb, hematocrit (Ht), mean cell vol-
ume (MCV), mean cell hemoglobin (MCH), mean 
cell hemoglobin concentration (MCHC) and platelet 
count (PLT) were assessed in whole blood K3EDTA, 
using an automated blood cell counter (HORIBA 
ABX, Amadora, Portugal). Reticulocyte count was 
determined by microscopic counting on blood 
smears after vital staining with New methylene blue 
(reticulocyte stain; Sigma-Aldrich Co. LLC. St. 
Louis, Missouri, USA). 
Reticulocyte production index (RPI) was calcu-
lated as previously described by Hillman and Finch 
[22] [(reticulocyte %/maturation index)* (Ht/normal 
Ht)], where normal Ht was the mean value presented 
by the Sham group, and the maturation index (matu-
ration time of circulating blood reticulocytes that 
increases with increasing production and/or with 
premature release of reticulocytes from the bone 
marrow) was 1 for Sham and 1.5 for anemic groups. 
Serum EPO and C-reactive protein (CRP) levels 
were evaluated by rat specific ELISA kits, according 
to manufacture instructions (MyBioSource, San 
Diego, CA, USA and eBioscince, San Diego, CA, 
USA, respectively). 
Serum blood urea nitrogen (BUN), creatinine 
and uric acid were analyzed through automatic 
methods and equipments (Hitachi 717 Chemistry 
Analyzer, Roche Diagnostics, Basel, Switzerland). 
Serum iron and ferritin were analyzed through 
automatic methods and equipments (Roche Integra 
400, Roche Diagnostics, Basel, Switzerland). Serum 
transferrin (Tf) levels were evaluated by rat specific 
ELISA kit (Transferrin Rat ELISA Kit, abcam, 
Cambridge, UK). Tf saturation (TSAT) was calcu-
lated using the formula (Iron µg/dL*100)/(Tf 
mg/dL*2). 
 
2.4. Gene expression analysis 
Kidney, liver and duodenum RNA isolation and 
integrity control were performed as previously de-
scribed [23]. One µg of total RNA was reverse tran-
scribed using iScript™ cDNA Synthesis Kit (Bio-
Rad Laboratories, Hercules, California, USA) ac-
cording to manufacturer instructions.  One ng of 
cDNA was used for gene expression analysis with 
qPCR using a Mini-Opticon instrument (Bio-Rad 
Laboratories), the KAPA SYBR® FAST qPCR kit 
(Kapa Biosystems, Inc., Wilmington, MA, USA) 
and specific primer pairs (Table 1).  
 
Table 1 - List of primer sequences and annealing 
temperatures 
 
Gene Primer sequences (5’ → 3’) Annealing temperature 
actb 
F: TACAGCTTCACCACCACA GC 
57ºC 
R: AAGGAAGGCTGG AAGAGA GC 
bmp6 
F: GGTGGAGTACGACAAGGA GTT 
56ºC 
R: GTCACAACCCACAGATTGCTA 
ctgf 
F: CGTAGACGGTAAAGCAATGG 
60ºC 
R: AGTCAAAGAAGCAGCAAACAC 
epas1 
F: TGACTTCACTCATCCTTGCGACCA 
59ºC 
R: ATTCATAGGCAGAGCGGCCAAGTA 
gapdh 
F:  TGCCACTCAGAAGACTGTGG 
59ºC 
R: ACGGATACATTGGGGGTAGG 
hamp 
F: GGCAGAAAGCAAGACTGATGAC 
58ºC 
R: ACAGGAATAAATAATGGGGCG 
hfe2 
F: TTCCAATCCTGCCTCTTTGAT 
58ºC 
R: GGAAAAGGTGCAAGTTCTCCAA 
il6 
F: ATGTTGTTGACAGCCACTGC  
58ºC 
R: TTTTCTGACAGTGCATCATCG  
slc11a2 
F: ATAGCAGACGCCCCCATG 
58ºC 
R: AGGCCCGAAGTAACATCCAA 
tfrc 
F:  GGGAGCCATTGTCATACACC 
58ºC 
R: GTCGCAAAGCAGAGTCTTCC 
tfr2 
F: AGCTGGGACGGAGGTGACTT 
58ºC 
R: TCCAGGCTCACGTACACAACAG 
tmprss6 
F: AGAAGGTGGATGTGCAACTGATC 
59ºC 
R: CTTGCCCTTGCGATAACCA 
F: Forward; R: Reverse; actb - Beta-actin; bmp6 - bone morpho-
genetic protein 6; ctgf - connective tissue growth factor; epas1- 
endothelial PAS domain protein 1; gapdh - glyceraldehyde 3-
phosphate dehydrogenase; hamp – hepcidin; hfe2 - hemojuvelin; 
il6 – interleukin 6; slc11a2 - divalent metal transporter 1; tfrc – 
transferrin receptor 1; tfr2 – transferrin receptor 2; tmprss6 – 
matriptase-2. 
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qPCR reactions were performed using the fol-
lowing conditions: enzyme activation at 95ºC for 
3min; denaturation at 95ºC for 3sec; annealing for 
30sec (for each pair primer temperature refer to 
Table 1).  
Gene expression was normalized to actb (beta 
actin) and gapdh (glyceraldehyde 3-phosphate dehy-
drogenase) genes, and relative quantification was 
calculated using the 2-∆∆CT method. In the liver, the 
expression of the following genes was analyzed: 
bmp6 (bone morphogenetic protein 6), epas1 (endo-
thelial PAS domain-containing protein 1, HIF2α), 
hamp (hepcidin), hfe2 (hemojuvelin), tfrc (TF recep-
tor (TfR) 1), tfr2 (TfR2) and tmprss6 (matriptase-2). 
In the kidney the expression of ctgf (connective 
tissue growth factor) and il6 (interleukin (IL)-6) 
genes was analyzed. In the duodenum, the expres-
sion of the slc11a2 (divalent metal transporter 1) 
gene was evaluated.  
 
2.5. Western blot analysis 
Liver and kidney proteins were extracted using 
RIPA buffer (NaCl 150mM, Tris-HCl 50mM pH8, 
Triton X-100 1%, ethylene glycol tetraacetic acid 
5mM, deoxycholic acid 0.5%, sodium lauryl sulfate 
0.1%) and ultra-sonication. After centrifugation, the 
protein concentration of the supernatant was assayed 
using the bicinchoninic acid (BCA) method (Thermo 
Scientific Pierce, IL, USA). Aliquots of the extract 
containing 50-100 µg of proteins were separated by 
reducing SDS-PAGE (10%) and transferred onto 
nitrocellulose membranes. The nitrocellulose mem-
branes were blocked by using 7% non-fat milk in a 
solution of Tris-buffered salt with Tween-20. The 
membranes were incubated, overnight at 4ºC, with 
rabbit polyclonal antibody anti-EPO 1:200 (sc-
7956), anti-EPOR 1:200 (sc-697, Santa Cruz Bio-
technoloy, Inc, TX, USA) and with goat polyclonal 
antibody anti-IL1β  1:1000 (AF-501-NA, R&D 
Systems, MN, USA); afterwards, they were incubat-
ed with anti-goat (ab97120) or anti-rabbit (sc-2004) 
secondary antibody-conjugated with horseradish 
peroxide 1:1000 (abcam,  Cambridge, UK and Santa 
Cruz Biotechnoloy, Inc, TX, USA), respectively. 
Immunoreactive proteins were detected by using the 
enhanced chemiluminescence method (ECL; West-
ernBright, Advansta, CA, USA). The immunoblots 
analysis was performed by densitometry (Bio1D++ 
version 99, Vilber Lourmat). To ensure even loading 
of the samples, membranes were probed with rabbit 
anti-β-tubulin antibody 1:500 (sc-9104, SantaCruz 
Biotechnology, TX, USA). The protein concentra-
tion found for each sample was normalized for the 
protein concentration observed in the Sham group. 
 
2.6. Histopathological analysis 
Kidney samples were fixed in neutral formalin 
10%, embedded in paraffin wax, and 3µm thick 
sections were stained with Periodic acid of Shiff 
(PAS). All samples were examined by light micros-
copy using a Microscope Zeiss Axioplan 2 and im-
ages were captured using a digital microscope cam-
era (Leica DFC450). Lesions were evaluated in a 
double-blinded fashion by the pathologist, who 
evaluated and quantified lesions as previously de-
scribed [23].  
 
2.7. Immunohistochemistry 
Tissue (kidney and liver) sections were incubated 
in xylene, rehydrated via graded ethanol series to 
water. To retrieve antigen exposure, the samples 
were treated with 0.01M citrate buffer solution at 
95°C to during 45min. The samples were processed 
for indirect immune detection using a mouse/rabbit 
specific horseradish peroxidase (HRP)/ diaminoben-
zidine (DAB) detection immunohistochemistry 
(IHC) kit (ab80436, Abcam Inc, Cambridge, UK), 
according to the manufactor’s protocol. Negative 
controls were included in each experiment, by omis-
sion of the primary antibodies. Polyclonal rabbit 
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antibody anti-HIF-1α 1:200 (sc-53546), anti-EPAS-
1 (HIF-2α) 1:500 (sc-28706), anti-EPO 1:200 (sc-
7956), anti-nuclear factor kappa B (NF-κB) p65 
1:100 (sc-109) and anti-transforming growth factor 
beta 1 (TGF-β1) 1:100 (sc-146) diluted in TBS-
Tween 0.05% served as primary antibodies and were 
incubated overnight at 4°C in a humidified chamber. 
Excessive, unbound primary antibody was removed 
by washing with TBS-Tween 0.05% buffer. Sections 
were counterstained with hematoxylin, dehydrated, 
and mounted in a non-aqueous media (DPX 
Mountant for Microscopy, VWR BDH Prolabo, PA, 
USA) and examined with a microscope Nikon 
Eclipse. Images were captured using a digital micro-
scope camera (Nikon DS-Ri2). Immunopositivity 
was scored in accordance to brown staining intensity 
(I) and percentage of positive cells or area (P), as 
previously described [23]. 2.8. Statistical analysis 
Results are presented as mean ± standard error mean 
(SEM). For comparison between groups Mann-
Whitney U test was performed. Statistical signifi-
cance was accepted at p<0.05. Statistical analysis 
was performed using the IBM Statistical Package for 
Social Sciences (SPSS) for Windows, version 22.0 
(IBM, Armonk, NY, USA). 
 
3. Results 
3.1. Hematological and serum biochemical data 
After one week of nephrectomy the CRF group 
presented a reduction in RBC count, Hb concentra-
tion and Ht, when compared to Sham group, reflect-
ing the development of anemia that remained until 
the end of protocol (Table 2). MCHC showed an 
increase at both follow-up times, compared to Sham 
rats. No significant alterations were found in the 
other hematological parameters (Table 2).  
The introduction of rHuEPO treatment corrected 
anemia after one week in the CRF200 group, as 
showed by the increase in RBC count, Hb concentra-
tion and Ht, which were further increased at the end 
of protocol, to values that were similar to those pre-
sented by Sham group. The CRF200NR group 
showed a slight correction of the anemic state after 
one week of treatment; however, at the end of the 
experimental protocol, RBC count, Hb concentration 
and Ht showed a reduction to values that were simi-
lar to those found in the CRF group. Reticulocytes 
and RPI values in the CRF group remained stable 
and similar to those observed for the Sham group 
along the study. In the CRF200 and CRF200NR 
groups, after one week of rHuEPO treatment reticu-
locytes and RPI values increased significantly, but at 
the end of protocol, their values were similar to 
those of Sham and CRF groups, except the RPI 
value in the CRF200NR group, which was signifi-
cantly lower versus Sham and CRF200 groups (Ta-
ble 2). Both rHuEPO-treated groups presented re-
duced MCV values and increased MCHC levels at 
the end of protocol; the CRF group presented also a 
trend towards an increase in MCV and significantly 
higher values of MCHC.  
Regarding serum EPO levels, we found that the 
CRF group presented significantly increased values 
along the study (more than 2 fold the Sham value, at 
the end of protocol); the CRF200NR also showed 
increased serum EPO levels after 1 week of treat-
ment that reached statistical significance at 3 weeks 
of treatment; the CRF200 presented a significant 
increase at the 1st week and decreased afterwards 
(Table 2). 
The microscopic analysis of bone marrow aspi-
rates examination of rats showed that in CRF200NR 
the proportion of red-cell precursors was significant-
ly lower than in Sham and in the other CRF groups. 
The erythroid:myeloid (E:M) ratio was 1:2 for the 
Sham group and CRF group, while for the 
CRF200NR group the ratio was 1:7 the CRF200 
presented a E:M ratio of 2:1. 
Serum urea and creatinine concentrations were 
significantly higher in all CRF groups, at 1 and 3  
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Table 2 – Hematological data throughout the study (at baseline, o weeks, and after 1 and 3 weeks of treat-
ment) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results are presented as mean ± SEM. a p<0.05 vs Sham group; b p<0.05 vs CRF group; c p<0.05 vs CRF200 group; d p<0.05 vs 
CRF200NR group (Mann-Whitney test). 0w –start of protocol; 1w – 1 week after the start of rHuEPO treatment; 3w – 3 weeks after the 
start of rHuEPO treatment (end of protocol); CRF – chronic renal failure; EPO – erythropoietin; Hb – hemoglobin; Ht – hematocrit; 
MCH – mean cell hemoglobin; MCHC – mean cell hemoglobin concentration; MCV – mean cell volume; RBC – red blood cells; Ret – 
reticulocytes; RPI – reticulocyte production index. 
 
weeks of protocol, when compared to the Sham 
group (Table 3). No difference in serum urea was 
found between CRF groups; however, serum creati-
nine was significantly increased in the CRF200NR, 
when compared to the CRF and the CRF200 groups. 
No significant changes were found in uric acid val-
ues. At the end of protocol, all the CRF groups pre-
sented increased serum CRP levels, compared to the 
Sham group; the CRF and CRF200NR groups 
showed the highest PCR values (Table 3). 
 
3.2. Body and tissue weights 
All CRF groups showed significantly reduced 
BW at the end of the study, when compared to Sham 
 
Sham 
(n=8) 
CRF 
(n=7) 
CRF200R 
(n=7) 
CRF200NR 
(n=5) 
Hematological data 
RBC (x 109/L) 
0w 7.41±0.07 7.43±0.09 7.53±0.11 7.66±0.13 
1w 7.11±0.08 6.11±0.12a 6.80±0.14b 6.68±0.07ab 
3w 7.77±0.13 6.41±0.11a 7.48±0.17b 6.22±0.43ac 
Hb (g/dL) 
0w 13.85±0.13 13.63±0.18 13.54±0.17 13.62±0.19 
1w 13.94±0.11 12.26±0.22a 13.86±0.20b 13.58±0.29b 
3w 14.07±0.15 12.06±0.18a 13.89±0.32b 11.60±0.75ac 
Ht (%) 
0w 41.12±0.54 41.34±0.59 40.90±0.55 41.32±0.66 
1w 38.02±0.20 32.13±0.63a 36.21±0.92b 35.54±0.82ab 
3w 41.77±0.80 33.56±0.57a 38.03±0.87b 30.90±2.38ac 
Ret (%) 
0w 1.95±0.17 2.47±0.29 2.34±0.23 3.02±0.60 
1w 1.73±0.31 2.18±0.23 5.27±0.35ab 5.28±0.71ab 
3w 1.61±0.19 2.53±0.28a 2.14±0.21 1.84±0.33 
Ret (x109/L) 
0w 144.39±12.38 183.41±20.89 177.06±18.25 233.48±49.15 
1w 122.47±22.47 134.11±15.26 358.17±25.05ab 352.66±46.76b 
3w 124.77±14.56 161.67±17.87 158.84±14.67 112.82±17.66 
RPI 
0w 1.94±0.16 2.47±0.28 2.34±0.23 3.04±0.61 
1w 1.72±0.31 1.34±0.23 4.86±0.51ab 4.50±0.46ab 
3w 1.60±0.19 1.37±0.15 1.93±0.17 0.90±0.14ac 
MCV (fL) 
0w 55.75±0.53 55.57±0.30 54.29±0.36 54.00±0.71 
1w 53.62±0.59 52.57±0.65 53.28±0.47 53.20±0.97 
3w 53.50±0.42 52.28±0.28 51.00±0.31ab 50.00±0.95ab 
MCH (pg) 
0w 18.69±0.19 18.34±0.24 18.03±0.26 17.74±0.31 
1w 19.66±0.34 20.11±0.38 20.44±0.27 20.38±0.40 
3w 18.16±0.32 18.80±0.23 18.58±0.33 18.74±0.25 
MCHC (g/dL) 
0w 33.65±0.16 32.97±0.41 33.13±0.25 32.92±0.43 
1w 36.62±0.26 38.20±0.36a 38.37±0.46a 38.30±0.31a 
3w 33.80±0.71 35.94±0.30a 36.47±0.54a 37.68±0.53ab 
Serum EPO (mIU/mL) 
0w 2.48±0.09 3.04±0.22 3.23±0.25 3.35±0.72 
1w 3.52±0.39 5.68±0.41a 5.44±0.46a 4.71±0.48 
3w 4.38±0.53 9.71±1.28ac 4.55±0.26 6.35±0.51ac 
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group (CRF: 0.389±0.007 Kg, CRF200: 
0.369±0.010 Kg, CRF200NR: 0.343±0.019 Kg ver-
sus Sham: 0.420±0.07 Kg, p<0.05). Moreover, all 
CRF groups presented an increased kidney weight 
(KW)/BW ratio, when compared to Sham group 
(CRF: 3.827±0.185 g/Kg, CRF200: 3.441±0.167 
g/Kg, CRF200NR: 4.751±0.996 g/Kg versus Sham: 
2.767±0.071 g/Kg, p<0.05).  
 
3.3. Iron metabolism  
No significant alterations were found in serum 
iron and ferritin levels between groups (Fig. 1A1 
and 1A2). Tf concentration (Fig. 1A3) was signifi-
cantly reduced and TSAT (Fig. 1A4) was signifi-
cantly increased in both CRF groups under rHuEPO 
treatment, when compared to Sham and CRF groups. 
Liver TfR1 (Fig. 1B1) was significantly up-
regulated in the CRF and CRF200 groups, when 
compared to Sham group; the CRF200NR group 
presented a down-regulation in TfR1, as compared 
to CRF and CRF200 groups. Liver TfR2 (Fig. 1B2) 
mRNA levels were increased in the CRF and in both 
CRF200 groups, reaching statistical significance 
only for CRF200 group. A significant down-
regulation of HJV (Fig. 1B3) was observed in the 
CRF200NR, when compared to the other groups. A 
significant down-regulation of BMP6 (Fig. 1B4) 
(Fig. 1B5) was observed for all the CRF groups; a 
significant up-regulation of matriptase-2 was found 
in CRF200 rats and a significant down-regulation of 
hecpidin (Hamp) mRNA levels was observed in the 
CRF and CFR200NR animals (Fig. 1B6). Liver HIF-
2α mRNA levels (Fig. 1B7) were up-regulated in the 
CRF and CRF200NR group. Regarding duodenal 
DMT1 mRNA levels (Fig. 1B8), a significant down-
regulation was observed for the CRF and CRF200 
groups, whereas in the CRF200NR a trend for in-
creased mRNA levels was found that was signifi-
cantly higher versus the CRF200 group. 
 
 
Table 3 – Serum biochemical data throughout the study (at baseline, o weeks, and after 1 and 3 weeks of 
treatment) 
 
 
 
 
 
 
 
 
 
 
 
 
Results are presented as mean ± SEM. a p<0.05 vs Sham group; b p<0.05 vs CRF group; c p<0.05 vs CRF200 group; d p<0.05 vs 
CRF200NR group (Mann-Whitney test). 0w –start of protocol; 1w – 1 week after the start of rHuEPO treatment; 3w – 3 weeks after the 
start of rHuEPO treatment (end of protocol); CRF – chronic renal failure; CRP – C-reactive protein. 
 
 
 
Sham 
(n=8) 
CRF 
(n=7) 
CRF200 
(n=7) 
CRF200NR 
(n=5) 
Urea (mg/dL)     
0w 22.54±0.83 22.71±0.87 24.07±0.77 22.16±1.00 
1w 23.07±0.64 56.33±2.40a 56.78±2.41a 53.23±7.52a 
3w 22.64±0.91 54.10±3.63a 56.63±1.97a 54.67±5.76a 
Creatinine (mg/dL) 
0w 0.37±0.01 0.35±0.01 0.39±0.01 0.38±0.02 
1w 0.33±0.01 0.99±0.08a 1.34±0.16a 1.94±0.40ab 
3w 0.45±0.04 1.00±0.07a 1.27±0.23a 2.21±0.62abc 
Uric acid (mg/dL) 
0w 0.82±0.06 0.84±0.08 0.86±0.08 0.72±0.06 
1w 0.79±0.07 0.91±0.09 0.87±0.04 0.76±0.07 
3w 0.78±0.10 1.08±0.12 1.28±0.23 0.83±0.06 
CRP (µg/mL) 
0w 538.5±39.3 552.7±37.6 555.6±30.3 542.1±27.7 
1w 687.9±40.7 592.4±52.5 706.0±49.9 703.5±28.5 
3w 575.0±33.2 820.6±48.0a 771.5±64.2a 803.0±39.8a 
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3.4. Histopathological findings  
The histopathological analysis of the kidney 
showed that the CRF group presented the highest 
total score for glomerular (Fig. 2A1 and 2A2), tubu-
lointerstitial (Fig. 2A3 and 2A4) and vascular le-
sions (Fig. 2A5). All animals in this group presented 
glomerulosclerosis and tubular atrophy, accompa-
nied by the presence of hyaline and granular cylin-
ders, tubular dilations, calcification and necrosis, as 
well as, interstitial fibrosis and tubular atrophy 
(IFTA) and interstitial inflammatory infiltrate (Table 
4). The presence of tubular necrosis hampers the 
observation of hydropic and vacuolar tubular degen-
eration, as these lesions precede tubular necrosis. 
Arteriolosclerosis and arteriosclerosis were also 
found in all rats from CRF group (Table 4). Both 
CRF groups under rHuEPO treatment presented an 
improvement in all the lesions, when compared to 
the CRF group, as showed by the reduced total 
scores (Fig. 2A1 – 2A5); however, a significantly 
higher score for mild glomerular lesions was ob-
served in the CRF200NR group, when compared to 
the CRF200 group (Fig. 2A2) that results from the 
increased score for glomerular atrophy and dilation 
of Bowman´s space (Table 4). The histological data 
was similar for the two rHuEPO-treated groups, 
excepting for the tubulointerstitial lesions that pre-
sented a higher score for hyaline cylinders and IFTA 
in the CRF200NR group (Table 4). Tubular dilations 
and interstitial inflammatory infiltrate were observed 
in both groups with a similar total score (Table 4). 
Arteriolosclerosis showed also a trend towards high-
er scores in CRF200NR group. 
 
Table 4 – Scoring of glomerular, tubulointerstitial and vascular kidneys lesions by group at the end of proto-
col 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results are presented as Mean ± SEM. a p<0.05 vs Sham group; b p<0.05 vs CRF group; c p<0.05 vs CRF200 group (Mann-Whitney 
test). BS - Bowman’s Space; GBM - glomerular basement membrane; IFTA - interstitial fibrosis and tubular atrophy. 
 
 
 
Sham 
(n=8) 
CRF 
(n=7) 
CRF200 
(n=7) 
CRF200NR 
(n=5) 
Advanced glomerular lesions 
Thickening of GBM 0 0.00±0.00 0.00±0.00 0.00±0.00 
Mesangial expansion 0 0.00±0.00 0.00±0.00 0.40±0.40 
Nodular sclerosis 0 0.00±0.00 0.00±0.00 0.00±0.00 
Global Glomerulosclerosis 0 3.00±0.00a 0.43±0.43b 0.60±0.60b 
Mild glomerular lesions 
Glomerular atrophy 0 3.00±0.00a 1.57±0.37ab 2.00±0.45ab 
Hypercellularity 0 0.00±0.00 0.43±0.20ab 0.00±0.00c 
Dilatation of BS 0 0.00±0.00 0.43±0.20a 1.00±0.00abc 
Advanced tubulointerstitial lesions 
Hyaline Cylinders 0 2.86±0.14a 1.71±0.28ab 2.40±0.24ab 
Granular Cylinders 0 2.86±0.14a 0.71±0.18ab 0.40±0.24ab 
Tubular Calcification 0 3.00±0.00a 0.00±0.00b 0.20±0.20b 
Necrosis 0 2.14±0.14a 0.00±0.00b 0.40±0.40b 
IFTA 0 3.00±0.00a 0.28±0.28b 1.20±0.49ab 
Mild tubulointerstitial lesions 
Tubular Dilatation 0 1.86±0.34a 1.71±0.36a 1.80±0.49a 
Interstitial Inflammatory Infil-
trate 
0 2.00±0.00a 1.28±0.36a 1.60±0.40a 
Hidropic Tubular Degeneration 0 ---- 1.14±0.39a 0.80±0.58 
Vacuolar TubularDegeneration 0 ---- 0.00±0.00 0.60±0.40 
Vascular lesions 
Arteriolosclerosis 0 2.00±0.00a 0.28±0.28b 0.40±0.24b 
Arteriosclerosis 0 1.00±0.00a 0.57±0.30a 0.60±0.24a 
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3.5. Renal and liver protein expression 
The CRF200NR group presented an increased 
renal expression of HIF-1α (Fig. 2B1 – 2B5). A 
significant reduction in tissue renal expression of 
HIF-2α was observed in the CRF and CRF200NR 
groups, when compared to Sham group, while no 
protein expression was found in the CRF200 group 
(Fig. 2C1 – 2C5). Regarding renal tissue expression 
of EPO, we found that the CRF group presented a 
significant reduction in EPO expression, when com-
pared to Sham group, whereas no protein expression 
was found in the CRF200 and CRF200NR groups 
(Fig. 2D1 – 2D5).  
Significantly increased protein levels of EPO and 
EPOR were found in the liver of CRF and 
CRF200NR groups, when compared to Sham (Fig. 
3A1and 3A2).  
 
3.6. Expression of kidney inflammatory and fibrosis 
markers 
A significantly higher nuclear expression of NF-
κB in renal cortex (Fig. 4A1 – 4A5) and medulla 
(Fig. 4B1 – 4B5) was found in the CRF and 
CRF200NR groups, when compared to Sham and 
CRF200 groups, and similar changes were found for 
the renal tissue expression of TGF-β1 (Fig. 4C1 – 
4C5). Renal IL-6 mRNA expression was significant-
ly up-regulated in the CRF and CRF200NR rats, 
whereas a significant down-regulation was observed 
in CRF200 animals (Fig. 4D1). CTGF mRNA levels 
were significantly up-regulated in all CRF groups, 
presenting the CRF200NR the highest value (Fig. 
4D2). Overexpression of IL-1β was found in the 
CRF and CRF200NR groups, when compared to 
Sham and CRF200 groups; the CRF200 group pre-
sented a significantly reduced kidney IL-1β levels 
(Fig. 4E). 
 
4. Discussion 
The correction of CKD-associated anemia can be 
achieved by the use of ESA [10]. Most of the pa-
tients respond to this therapy, however, 5-10% of 
CKD patients become hyporesponsive, presenting 
worsening of anemia and a poorer outcome [12]. 
ESA hyporesponse is well documented by several 
observational and clinical studies in humans; how-
ever, the cellular and molecular mechanisms under-
lying remain to be clarified.  
In this study, using the 5/6 nephrectomy-induced 
remnant kidney rat model of CKD-associated ane-
mia under rHuEPO therapy, we found that a group 
of rats (CRF200NR), after an initial adequate re-
sponse to rHuEPO (with increased RBC count, Hb 
concentration, Ht and reticulocytes) developed 
hyporesponsiveness to rHuEPO in the two following 
weeks of treatment, as showed by the significantly 
reduced values of RBC count, Hb concentration and 
Ht, at the end of protocol (Table 2). This group pre-
sented a hyporegenerative anemia at the 3rd week, 
with a poor erythropoietic response, as reflected by 
the RPI and E:M ratio that were significantly re-
duced (Table 2). The CRF group also presented 
anemia, showing a reduction in reticulocytes and in 
RPI to values that were, however, similar to those 
found for Sham and CRF200 groups, indicating, 
therefore, some response to anemia. As an attempt to 
compensate anemia, both CRF and CRF200NR 
groups presented increased serum EPO levels, due, 
in part, to increased liver EPO production (Fig. 3A1) 
[24,25] that appears to be inadequate to overcome 
anemia [23,26,27]. Considering that the CRF200NR 
group was under treatment with the same rHuEPO 
dose, and the endogenous (hepatic) EPO was in-
creased, it would be expected to find an increase in 
RPI and E:M ratio, but none of this was found, sug-
gesting a blockade to EPO stimuli. Antibodies anti-
rHuEPO could also be a cause for ESA hyporespon-
siveness [16]; however, in a previous study conduct-
ed by our group, we found that until 3 weeks of 
rHuEPO treatment no antibodies anti-rHuEPO were
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Fig. 2 – Glomerular, tubulointerstitial and vascular lesions and immunostaining of hypoxia inducible factor 1 
alfa (HIF-1α), HIF-2α and erythropoietin (EPO) in kidney. Total score and representative lesions observed in 
kidneys of rat groups under study, at the final time (PAS staining): A1 – total score for advanced glomerular 
lesions; A2 - total score for mild glomerular lesions; A3 - total score for advanced tubulointerstitial lesions; 
A4 - total score for mild tubulointerstitial lesions; A5 -  total score for vascular lesions; A6 – glomeruloscle-
rosis; A7 -  glomerular atrophy; A8 – tubular necrosis and interstitial fibrosis and tubular atrophy (IFTA); A9 
– tubular dilations, hyaline cylinders and - interstitial inflammatory infiltrate; A10 – arteriolosclerosis. The 
expression of HIF-1α, HIF-2α and EPO were not present in the glomerulus or renal medulla tubules (negative 
reaction). B1 - quick score for HIF-1α; B2 – HIF-1α immunostaining Sham group: light positive cytoplasmic 
immunoreactivity in convoluted tubules (CT); B3 - HIF-1α immunostaining CRF group: moderate positive 
cytoplasmic immunoreactivity in CT; B4 - HIF-1α immunostaining CRF200 group: light positive cytoplas-
mic immunoreactivity in CT; B5 – HIF-1α immunostaining CRF200NR group: moderate positive cytoplas-
mic immunoreactivity in CT; C1 - quick score for HIF-2α; C2 – HIF-2α immunostaining Sham group: mod-
erate positive nuclear and cytoplasmic immunoreactivity in CT; C3 - HIF-2α immunostaining CRF group: 
light positive nuclear and cytoplasmic immunoreactivity in CT; C4 - HIF-2α immunostaining CRF200 group: 
negative reaction; C5 – CRF200NR group: light positive nuclear and cytoplasmic immunoreactivity in CT; 
D1 - quick score for EPO; D2 – EPO immunostaining Sham group: moderate positive cytoplasmic immuno-
reactivity in CT; D3 - EPO immunostaining CRF group: light positive cytoplasmic immunoreactivity; D4 
and D5 - EPO immunostaining CRF200 and CRF200NR groups: negative reaction. Results are presented as 
mean ± SEM. a p<0.05, aa p<0.01, aaa p<0.001 vs Sham group, b p<0.05, bb p<0.01, bbb p<0.001 vs CRF 
group, c p<0.05 vs CRF200 group (Mann-Whitney test).  
 
 
Fig. 3 – Evaluation of liver proteins by western blotting and representative image of western blot for the 
different groups.  A1 – EPO; A2 - EPO receptor (EPOR). Results are presented as mean ± SEM.  a p<0.05, aa p<0.01 
vs Sham group, b p<0.05 vs CRF group (Mann-Whitney Test). 
 
detected in rats serum [28]. In the case of CRF group 
the reduced renal tissue is unable to increase EPO 
levels required to correct anemia. 
Inflammation has been associated with ESA 
hyporesponsiveness [29,30]. Inflammation can lead 
to ESA hyporesponsiveness, due to the inhibitory 
effects of inflammatory cytokines on erythropoiesis, 
on EPO production, and by reducing disturbances in 
iron metabolism. Several cytokines (such as tumor 
necrosis factor alpha [TNF-α], IL-1β and interferon 
gamma [IFN-γ]) induce erythropoiesis suppression, 
through a direct action on erythroid progenitors [32]. 
We found that serum CRP levels were increased in 
all CRF groups, presenting CRF and CRF200NR the 
highest CRP values (Table 3), consistent with the 
presence of higher inflammatory condition. It was
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Fig. 4 – Immunostaining of nuclear factor kappa B (NF-κB) and transforming growth factor beta 1 (TGF-β1) 
in kidney. For NF-κB only nuclear staining were considered for analysis A1 - quick score for NF-κB in renal 
cortex; A2 - NF-κB immunostaining Sham group: moderate positive nuclear immunoreactivity in convulated 
tubules (CT); A3 - NF-κB immunostaining CRF group: intense positive nuclear immunoreactivity in glomer-
ulus and CT; A4 - NF-κB immunostaining CRF200 group: moderate positive nuclear immunoreactivity in 
CT; A5 - NF-κB immunostaining CRF200NR group: : intense positive nuclear immunoreactivity in glomeru-
lus and CT; B1 – quick score for NF-κB  in renal medulla. B2 - NF-κB immunostaining Sham group: moder-
ate positive nuclear immunoreactivity in renal medulla tubules; B3
 
- NF-κB immunostaining CRF group: 
intense positive nuclear immunoreactivity in renal medulla tubules; B4 - NF-κB immunostaining CRF200 
group: moderate positive nuclear immunoreactivity in renal medulla tubules; B5 - NF-κB immunostaining 
CRF200NR group: intense positive nuclear immunoreactivity in renal medulla tubules; C1 - quick score for 
TGF-β1 in renal cortex; C2 – TGF-β1 immunostaining Sham group: light positive cytoplasmic immunoreac-
tivity in CT; C3 – TGF-β1 immunostaining CRF group: intense positive cytoplasmic immunoreactivity in 
CT, glomerulus and interstitial cells; C4 – TGF-β1 immunostaining CRF200 group: moderate positive cyto-
plasmic immunoreactivity in CT; C5 – TGF-β1 immunostaining CRF200NR group: intense positive cyto-
plasmic immunoreactivity in CT, glomerulus and interstitial cells. Kidney relative mRNA expression of in-
flammatory and fibrosis related genes, with Β-actin as the reference gene. D1 - interleukin 6 (IL6): D2 - 
connective tissue growth factor (CTGF); E – Kidney western blot analysis of IL-1β and representative image 
of western blot for the different groups. Results are presented as mean ± SEM: a p<0.05, aa p<0.01 vs Sham 
group; c p<0.05 vs CRF200 group (Mann-Whitney test).  
 
recently reported that a minor   increase of CRP 
values in CKD patients increases the risk for devel-
opment of ESA hyporesponsiveness [31]. In addi-
tion, CRF and CRF200NR groups also showed high 
levels of renal inflammatory markers, such as IL-6 
and IL-1β (Fig. 4D1 and 4E, respectively). The pro-
inflammatory cytokines, IL-1β and TNF-α, ex-
pressed in a NF-κB dependent manner, are known to 
induce EPO suppression [33,34]. This is in line with 
our data as in CRF and CRF200NR groups we found 
an increased renal expression of NF-κB, IL-1β and 
IL-6 (Fig. 4); moreover, we observed a reduced 
renal EPO expression in the CRF group and no renal 
EPO expression in the CRF200NR (Fig. 2). Under 
inflammatory conditions, the activation of inflam-
matory cells lead to the production of oxygen me-
tabolites that are able to reduce RBC life span, by 
inducing metabolic changes and RBC membrane 
injuries [35]. The reduced glomerular filtration rate 
(GFR) in CKD leads to accumulation of high levels 
of uremic toxins that induce metabolic and morpho-
logical RBC changes and are pro-inflammatory 
inducers; thus, uremic toxins may contribute to en-
hance the oxidative stress, RBC removal, inhibition 
of erythropoiesis, favoring ESA hyporesponsiveness 
[36]. We found significantly increased serum creati-
nine levels in the CRF200NR group when compared 
to the CRF and CRF200 groups (Table 1), reflecting 
a reduced GFR and, thus, increased levels of uremic 
toxins that might contribute to rHuEPO hyporespon-
siveness. 
Inflammation and uremic toxins may also induce 
a reduction in renal EPO production [5]. Uremic 
toxins, by enhancing oxidative stress, aggravate 
local hypoxia in renal tubular cells, promote disturb-
ances in the oxygen (O2) sensing system and in EPO 
production [37].  
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Erythropoiesis and iron metabolism are closely 
linked, as increased erythropoiesis leads to an in-
crease in iron absorption and mobilization, in order 
to meet bone marrow requirements. It has been re-
ported that CKD patients under dialysis and ESA 
therapies present inflammation and high hepcidin 
levels, leading to a functional iron deficiency that is 
enhanced in the non-responders to rHuEPO [38]. In 
our study, in spite of the evidences of an inflamma-
tory condition in CRF group, no significant changes 
were found in iron metabolism, hepcidin expression 
was down-regulated, and the expression of the fac-
tors responsible for hepcidin up-regulation was simi-
lar versus Sham group, except TfR1 that was up-
regulated (Fig. 1). In fact, we found a down-
regulation of hepcidin expression in CRF and 
CRF200NR groups. Hepcidin expression is regulat-
ed by the balance between several factors, including 
inflammation, liver iron, TSAT (stimulators of hep-
cidin synthesis), hypoxia and erythropoiesis (inhibi-
tors of hepcidin synthesis) [19]. In CRF rats, hypox-
ia and anemia appears to have a stronger influence 
on hepcidin expression than inflammation. The 
down-regulation of hepcidin in CRF200NR rats 
seems to be due to other inhibitory factors, namely 
to the down-regulation of TfR1, HJV and BMP6. 
Moreover, rHuEPO has an inhibitory effect on hep-
cidin expression [38,39]. 
Inflammation and anemia are linked to progres-
sion of renal disease and are both enhanced in non-
responders to ESA therapy [15,17]. In the kidney, 
hypoxia leads to activation of the HIF system, stimu-
lating several target genes [7]. HIF-2α is the main 
regulator of renal and liver EPO production [40], 
whereas HIF-1α appears as the main regulator of 
glycolytic enzymes and of other factors involved in 
renal fibrosis, such as connective tissue growth fac-
tor (CTGF) [41]. Renal fibrosis is the final feature of 
CKD progression, characterized by tubular atrophy, 
increased deposition of extracellular matrix (ECM) 
and alterations in renal blood vessels [9]. The initial 
(acute) activation of HIF-1α is a protective mecha-
nism triggered to achieve correction of ane-
mia/hypoxia; however, a continuous activation pro-
motes several renal lesions, leading to renal fibrosis 
and tissue injury. CTGF is a marker of renal fibrosis, 
as it increases the production of ECM, fibroblasts 
cell growth and TGF-β1 activity [42,43]. CTGF and 
TGF-β1 have similar effects, leading to renal fibro-
sis. TGF-β1 also promotes glomerulosclerosis and 
presents immunomodulatory effects [44]. Indeed, 
TGF-β1 released by injured renal cells acts as an 
anti-inflammatory agent, through the recruitment of 
monocytes; however, its continuous expression leads 
to a pathological accumulation of ECM and release 
of excessive inflammatory cytokines, such as IL-1β 
and IL-6, through a NF-κB-dependent manner, thus 
promoting fibrosis [44]. These enhanced continuous 
response mechanisms create a vicious cycle where 
inflammation promotes hypoxia and vice-versa; 
moreover, both conditions contribute to increase the 
expression of NF-κB, which appears to directly 
regulate HIF-1α expression [45]. The development 
of anemia (Fig. 5) in the rHuEPO hyporesponsive 
group (CRF200NR), associated with uremia and a 
systemic and renal inflammatory state, by favoring 
renal hypoxia, trigger an increase in renal expression 
of HIF-1α, TGF-β1 and CTGF, that will further 
aggravate renal fibrosis (showed by the increased 
score of IFTA). The renal fibrosis, by inducing an 
inflammatory response, creates a vicious cycle that 
promotes CKD progression (Fig. 5). The CRF and 
the CRF200NR groups presented similar inflamma-
tory and fibrosis features. The more advanced renal 
lesions of CRF rats may explain the reduced expres-
sion of the HIF system, due to the reduced renal 
capacity to induce HIF activation [46]. 
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It is known that rHuEPO stimulates erythropoie-
sis and has also pleiotropic properties, namely anti-
inflammatory and renoprotective effects, among 
others [11]. Indeed, we found that both CRF groups 
under rHuEPO treatment presented an improvement 
in all types of renal lesions, when compared to the 
CRF group (Fig. 2 and Table 4). The CRF200NR 
group presented a better renal lesion profile than the 
CRF group, but worse than the CRF200 animals, 
presenting higher scores for glomerular atrophy, 
dilatation of Bowman’s Space, hyaline cylinders and 
IFTA (Table 4); a trend towards a higher KW/BW 
ratio, indicating a higher level of kidney hypertrophy 
was also observed (Table 3). In addition, no im-
provements were found in NF-κB, TGF-β1, IL-6 and 
IL-1β renal expression, nor in serum CRP levels in 
the CRF200NR group, when compared to the CRF 
group. A significant increase in kidney CTGF ex-
pression was also found in the CRF200NR group, 
along with increased HIF-1α levels, when compared 
to the CRF group. Thus, the existence of ane-
mia/hypoxia, due to the reduced response to 
rHuEPO, and inflammation seem to blunt the plei-
otropic effects of rHuEPO.  
In conclusion, our study suggests that inflamma-
tion is an important determinant in hyporesponsive-
ness to rHuEPO (when no major changes in iron 
metabolism are observed) blunting the response to 
endogenous (hepatic) EPO and to rHuEPO. This 
hyporesponse causes the reappearance of anemia 
that contributes to worsening of renal fibrosis and to 
the progression of CKD, thus explaining the poorer 
outcome of non-responders CKD patients. Our data 
suggest that a therapeutic approach able to reduce 
inflammation in CKD patients could improve the 
response to ESA therapy and reduce premature mor-
tality associated with that condition. 
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ABSTRACT 
Our aim was to study the effect of a broad range of recombinant human erythropoietin (rHuEPO) doses on 
hematological and biochemical parameters, blood pressure (BP) and renal function and damage in the rat, 
focusing on endothelial nitric oxide synthase (eNOS) and hypoxia-inducible factors (HIFs). 
Male Wistar rats were divided in 5 groups receiving different doses of rHuEPO (100, 200, 400 and 600 IU/kg 
body weight (BW)/week) and saline solution (control), during 3 weeks. Blood and 24h urine were collected 
to perform hematological and biochemical analysis. BP was measured by the tail-cuff method. The kidney 
tissue was collected to mRNA and protein expression assays and to characterize renal lesions. 
A dose-dependent increase in red blood cells count, hematocrit and hemoglobin levels was found with 
rHuEPO therapy, in rHuEPO200, rHuEPO400 and rHuEPO600 groups. Increased reticulocyte count was 
found in the rHuEPO400 and rHuEPO600 groups. BP raised in all groups receiving rHuEPO. The 
rHuEPO200 and rHuEPO600 groups presented increased kidney protein levels of HIF2α and a reduction in 
kidney protein levels of eNOS, along with the highest grade of vascular and tubular renal lesions.  
Our study showed that rHuEPO-induced hypertension is present before significant hematological changes 
and, therefore, might involve indirect (hematological) and direct (renal) effects which varies according to the 
dose used. The presence of renal hypoxia reduces eNOS activity. Excessive erythrocytosis increases blood 
hyperviscosity which can be modulated by an increase in reticulocytes, reducing renal hypoxia. Hypertension 
leads to early renal damage without alterations in traditional markers of renal function, thus masking the 
serious adverse effects and risks. 
Keywords: direct renal vascular effects; endothelial nitric oxide synthase; hypertension; hypoxia; recombi-
nant human erythropoietin therapy; reticulocytes.  
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1. Introduction 
The main clinical indication of recombinant hu-
man erythropoietin (rHuEPO) is the correction of 
anemia in chronic kidney disease (CKD) and cancer 
patients [1], but the discovery of non-hematopoietic 
actions of rHuEPO [2, 3] increased the number of 
patients that could putatively benefit from this thera-
py [4-6]; however, to achieve those effects higher 
doses are usually needed, which increase the risk 
and incidence of adverse events [7]. Several studies 
reported that CKD patients treated with higher 
rHuEPO doses present a higher mortality rate and 
increased cardiovascular events [8, 9]. In addition, 
clinical trials using rHuEPO for the treatment of 
acute ischemic stroke showed increased mortality 
rates in patients under high rHuEPO doses [7, 10]. 
Hypertension is a common side-effect associated 
with rHuEPO therapy [11, 12], as previously report-
ed in predialysis and hemodialysis patients [11, 13, 
14]. The same effect was also demonstrated in 
healthy subjects under rHuEPO therapy with pro-
longed low-dose treatments or with short-term ad-
ministration of high doses [15, 16]. This situation is 
particularly applicable in illicit rHuEPO use in 
sports, as doping, raising serious concerns about the 
potential adverse effects on athletes, as we and oth-
ers previously reported in animal models and in 
human studies [17, 18]. 
Several mechanisms have been proposed to ex-
plain the hypertension associated with rHuEPO 
therapy [13]. rHuEPO-stimulated erythropoiesis 
increases the hematocrit (Ht), thus causing an in-
crease in blood viscosity, with a consequent increase 
in vascular resistance and blood pressure (BP). The 
rHuEPO-evoked increase in hemoglobin (Hb) and 
Ht levels are the result of red blood cell (RBC) mass 
increase and plasma volume reduction [19]. Howev-
er, these effects seem to be unable to entirely explain 
the hypertension observed with this therapy; in fact, 
previous studies has showed that rHuEPO might 
directly act on both endothelial and vascular smooth 
muscle cells (VSMC), promoting a disequilibrium 
between vasodilators and vasoconstrictors [10]. 
The kidney plays a major role in BP control due 
to its capacity to excrete sufficient sodium and water 
to regulate the extracellular fluid and the blood vol-
ume [20]. Renal disease and hypertension are strictly 
linked in such a way that each could be the cause or 
the consequence of the other [21]. In fact, hyperten-
sion impairs renal microvasculature, compromising 
kidney function, promoting hypoxia and evolution of 
damage, which is exacerbated by the disequilibrium 
between vasodilators and vasoconstrictors [12]. 
Despite the evidence of rHuEPO-evoked BP raise, 
independently of hematological actions, the contri-
bution of renal vasculature impairment and kidney 
hypoxia/damage to the pro-hypertensive properties 
of rHuEPO remain to be elucidated. 
In this work we aimed to study the effect of in-
creasing doses of rHuEPO on hematological and 
biochemical parameters, and to clarify mechanisms 
associated with BP increase. 
 
2. Animals and methods 
 
2.1. Animals and experimental protocol 
Male Wistar rats (Charles River Lab. Inc., 
Chatillon-sur-Chalaronne, France), with 320-350 g 
of body weight (BW), were maintained in ventilated 
cages, in an air conditioned room, subjected to 12 h 
dark/light cycles and given free access to rat labora-
tory chow (SAFE-A03, Augy, France) and tap wa-
ter. Animal experiments were conducted according 
to the European Community Council directives on 
animal care and to the national authorities. The rats 
were randomly divided in five groups (7-8 rats each 
group) receiving a subcutaneous (sc) injection of 
saline solution (control group) or rHuEpo (NeoRe-
cormon®, Roche) 100, 200, 400 or 600 IU/kg 
BW/week (rHuEPO100, rHuEPO200, rHuEPO400 
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and rHuEPO600 groups, respectively), 3 times per 
week, during 3 weeks. 
Systolic, diastolic and mean blood pressure 
(SBP, DBP and MBP) measures were obtained by 
the tail-cuff method, using a sphygmomanometer 
(LE5001 Pressure meter, Panlab Havard Apparatus, 
Barcelona, Spain) in appropriate contention cages, 
according to previously described [22]. In brief, 
before the measurements, the rats were warmed for 
10-20 min at 25-30 ºC in order to allow the detection 
of tail artery pulsations and to achieve the pulse 
level ready. BP and HR values were obtained aver-
aging 8-10 measurements of two consecutive days. 
To minimize stress-induced fluctuations in BP, all 
the rats were adapted to appropriate cages and to 
measurements during at least 2 weeks before the 
beginning of measurements. The same person took 
the final values in the same peaceful environment 
between 2:00 and 6:00 pm. 
 
2.2. Sample collection 
Blood samples were collected, at the end of pro-
tocol, with rats under anesthesia (intraperitoneal) 
with a 2 mg/kg BW of a 2:1 (v:v) 50 mg/mL keta-
mine (Ketalar®, Parke-Davis, Lab. Pfeizer Lda, 
Seixal, Portugal) solution in 2.5% chlorpromazine 
(Largactil®, Rhône-Poulenc Rorer, Lab. Vitória, 
Amadora, Portugal). Blood samples were collected 
by venipuncuture, from the jugular vein, into 
Vacuette® tubes without anticoagulant (to obtain 
serum) or with K3EDTA (to obtain plasma) for he-
matological and biochemical studies.  Aliquots were 
immediately stored at -80ºC until assayed. 
For collection of 24h urine the rats were enclo-
sure, at the end of protocol, in metabolic cages dur-
ing 24h with free access to laboratory chow and tap 
water. Afterwards, urine volume and water con-
sumption were recorded. Aliquots of urine were 
made and stored at -80ºC.  
At the end of protocol, after blood collection and 
under anesthesia, the rats were sacrificed by cervical 
dislocation; kidneys were immediately removed and 
placed in ice-cold Krebs-Henseleit buffer, cleaned 
and weighted. In order to isolate total RNA, 0.2 g 
samples of kidney, from each rat, were immersed in 
RNAlater® solution (Sigma-Aldrich Co. LLC. St. 
Louis, Missouri, USA) upon collection and stored at 
4°C for 24h; afterwards, samples were frozen at -
20ºC. For western blot analysis organs were imme-
diately frozen with liquid nitrogen and stored at -
80ºC. 
 
2.3. Biochemical and hematological assays 
Serum creatinine, blood urea nitrogen (BUN) 
and uric acid were analyzed through automatic 
methods and equipment (Hitachi 717 Chemistry 
Analyzer, Roche Diagnostics, Basel, Switzerland). 
RBC count, Ht, Hb, mean cell volume (MCV) and 
mean cell hemoglobin concentration (MCHC) were 
assessed in whole blood K3EDTA using an automat-
ed counter (HORIBA ABX, Amadora, Portugal). 
Reticulocyte count was measured by microscopic 
counting on blood smears after vital staining with 
New methylene blue (reticulocyte stain; Sigma-
Aldrich Co. LLC. St. Louis, Missouri, USA). Brief-
ly, after blood collection into K3EDTA tubes and 10 
min of homogenization, 25 µL of blood were added 
to 25 µL of reticulocyte stain (New methylene blue). 
After 20 min of rest, 2 blood smears from each rat 
were made. 
Serum levels of vascular endothelial growth fac-
tor (VEGF) were evaluated by rat specific ELISA 
kit, according to manufacture instructions (Sigma-
Aldrich Co. LLC. St. Louis, Missouri, USA). 
The urinary levels of urea, creatinine, uric acid 
and albumin were analyzed using automatic methods 
(Cobas Integra 400Plus, Roche Diagnostics, Basel, 
Switzerland). Creatinine clearance and glomerular 
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filtration rate (GFR) were calculated according to 
Pestel et al.[23]. 
 
2.4. Gene expression analysis 
Kidney RNA isolation and integrity control were 
performed as previously described by us [24]. One 
microgram of total RNA was reversely transcribed 
using iScript™ cDNA Synthesis Kit (Bio-Rad La-
boratories, Hercules, California, USA) according to 
manufacturer instructions. One nanogram of cDNA 
was used for gene expression analysis with qPCR 
using a Mini-Opticon instrument (Bio-Rad Labora-
tories), the KAPA SYBR® FAST qPCR kit (Kapa 
Biosystems, Inc., Wilmington, MA, USA) and spe-
cific primer pairs (Table 1). qPCR reactions are 
performed using the following conditions: enzyme 
activation at 95ºC for 40s; denaturation at 95ºC for 
3s; annealing for 30s (for each pair primer tempera-
ture refer to Table 1). Gene expression was normal-
ized to beta actin (actb) and alpha tubulin (tuba), and 
relative quantification was calculated using the 2-
∆∆CT
 method. The following genes expression was 
analyzed in the kidney: arnt (aryl hydrocarbon re-
ceptor nuclear translocator; HIF-1β); arnt2 (aryl 
hydrocarbon receptor nuclear translocator 2; HIF-
2β); epas1 (endothelial PAS domain protein 1; HIF-
2α); epo (erythropoietin); hif1α (eypoxia-inducible 
factor 1, alpha subunit) and vegfα (vascular endothe-
lial growth factor alpha; VEGFα). 
 
2.5. Western Blot 
Kidney proteins were extracted using RIPA buff-
er (NaCl 150mM, Tris-HCl 50mM pH8, Triton X-
100 1%, ethylene glycol tetraacetic acid 5mM, de-
oxycholic acid 0.5%, Sodium lauryl sulfate 0.1%) 
and ultra-sonication. After centrifugation, protein 
concentration in supernatant was assayed using the 
bicinchoninic acid (BCA) method (Thermo Scienti- 
fic Pierce, IL, USA). Aliquots of the extract contain-
ing 100 µg of protein were separated by reducing 
Table 1 - List of primer sequences and annealing 
temperatures 
F: Forward; R: Reverse; actb – beta actin; arnt - aryl hydrocarbon 
receptor nuclear translocator; arnt2 - aryl hydrocarbon receptor 
nuclear translocator 2; epas1- endothelial PAS domain protein 1; epo- 
erythropoietin; hif1a- hypoxia-inducible factor 1, alpha subunit; tuba 
– alfa tubulin; vegfa - vascular endothelial growth factor alpha. 
 
SDS-PAGE (10 %) and transferred onto nitrocellu-
lose membranes. The membranes were blocked 
using 7% non-fat milk in a solution of Tris-buffered 
salt with Tween-20. The nitrocellulose membranes 
were incubated, overnight at 4ºC, with rabbit anti-
EPAS-1 (HIF2α) antibody 1:200 (sc- sc-28706), 
rabbit anti-IL-3/IL-5/GM-CSFRβ antibody (β com-
mon receptor) 1:100 (sc-678), mouse anti-ERK1 
1:200 (sc-37685), rabbit anti-phospho-ERK1/2 
1:100 (sc-16982), rabbit-anti AKT1/2/3 1:150 (sc-
8312, Santa Cruz Biotechnoloy, Inc, Texas, USA), 
rabbit anti-phospho AKT1/2/3 1:250 (ab81283), 
rabbit anti-STAT5 1:250 (ab32043), rabbit anti-
phospho-STAT5 1:250 (ab30648), mouse anti-
phospho eNOS  1:500 (612393) and mouse anti-
eNOS 1:500 (610297, BD Biosciences, New Jersey, 
USA); afterwards, they were incubated with anti-
mouse (A9044) or anti-rabbit (sc-2004) secondary 
Gene Primer sequences (5’ → 3’) Annealing tem-
perature  
actb 
F: TACAGCTTCACCACCACAGC 
57ºC 
R: AAGGAAGGCTGGAAGAGAGC 
arnt 
F: AGAATGGCTGTGGATGAG 
56ºC 
R: GGTTCCTGGCTAGAGTTC 
arnt2 
F: TGAAAGAAGGAGAAGCCCAATA 
58ºC 
R: CATCAGAGTTATGCCGAGACAG 
epas1 
F: TGACTTCACTCATCCTTGCGACCA 
59ºC 
R: ATTCATAGGCAGAGCGGCCAAGTA 
epo 
F: TCTGACTGACCGCGTTACTC 
59ºC 
R: GCCCAGAGGAATCAGTAGCA 
hif1a 
F: CTCACCATCAGTTACTTAC 
58ºC 
R: GTCACCATCATCTGTTAG 
tuba 
F: CAC CCG TCT TCA GGG CTT CTT GGT TT 
59ºC 
R: CAT TTC ACC ATC TGG TTG GCT GGC TC 
vegfa 
F: GAAGTTCATGGACGTCTACCAG 
58ºC 
R: CATCTGCTATGCTGCAGGAAGCT 
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antibody-conjugated with horseradish peroxide 
(Sigma-Aldrich Co. LLC. St. Louis, Missouri, USA; 
Santa Cruz Biotechnoloy, Inc, Texas, USA, respec-
tively). Immunoreactive proteins were detected by 
using the enhanced chemiluminescence method 
(ECL WesternBright, Advansta, California, USA). 
The analysis of the immunoblots was performed by 
densitometry (Bio1D++ version 99, Vilber Lour-
mat). To ensure even loading of the samples, all 
immunoblots were probed with rabbit anti-β-tubulin 
antibody 1:500 (sc-9104, SantaCruz Biotechnology, 
Texas, USA). The protein concentration in each 
sample was normalized for Control group. 
 
2.6. Histopathological analysis 
Samples were fixed in neutral formalin 10%, 
embedded in paraffin wax, and 3µm thick sections 
were stained with Periodic acid of Shiff (PAS). All 
samples were examined by light microscopy using a 
Microscope Zeiss Axioplan 2 and images were cap-
tured using a digital microscope camera (Leica 
DFC450). Lesions were evaluated on the total tissue 
on the slide in a double-blinded fashion by the 
pathologist, who evaluated and quantified lesions 
according to previously described by us [24]. Brief-
ly, glomerular damage was assessed by evaluating 
mesangial expansion, nodular sclerosis, glomerulo-
sclerosis, glomerular basement membrane, capsule 
of Bowman thickening, glomerular atrophy or hy-
pertrophy and hyalinosis of the vascular pole.  A 
semi-quantitative rating for each slide ranging from 
normal (or minimal) to severe (extensive damage) 
was assigned to each component. Severity was grad-
ed as absent/normal, mild, moderate, and severe. 
Scoring was defined according to the extension 
occupied by the lesion (5% area): normal <25%; 
mild 25-50%; moderate 50-75%; severe >75%. The 
final score of each sample was obtained by the aver-
age of score observed in individual glomeruli in the 
considered microscopic fields. Glomerular hypertro-
phy was analysed by measuring the area of ten glo-
meruli in cortical area and ten juxtamedullary glo-
meruli, selected by unbiased method, in each rat, 
using for analysis the ImageJ processing software 
(National Institutes of Health, Maryland, USA). 
Analysed tubulointerstitial lesions comprised inter-
stitial inflammatory infiltration, presence of hyaline 
and granular cylinders, hidropic and vacuolar degen-
eration, and the association of interstitial fibrosis and 
tubular atrophy (IFTA). Tubulointerstitial damage 
was evaluated and graded by the same semi-
quantitative method used in glomerular analysis, 
with the exception of IFTA, which was graded as 
normal, if absent, as mild, moderate, and severe, if 
present in <25%, between 25-50%, and over 50% of 
affected area, respectively. The evaluation of vascu-
lar lesions was concentrated on arteriolosclerosis 
and arteriosclerosis. Arteriolosclerosis was scored as 
0 if absent, as 1 if one arteriole with arteriolosclero-
sis was present, and as 2 if more than one arteriole 
with arteriolosclerosis was observed in the entire 
slide. Arteriosclerosis was scored as 0 if no intimal 
thickening was present, as 1 if intimal thickening 
was less than the thickness of media, and as 2 if 
intimal thickening was more than the thickness of 
the media and considering the worst artery on the 
slide. 
 
2.7. Statistical analysis 
Results are presented as mean ± standard error 
mean (SEM). For comparison between groups 
Mann-Whitney test was performed. The strength of 
the association between the variables vascular and 
tubular lesions, SBP, hematological (RBC, Hb, Ht 
and reticulocytes) and biochemical (serum BUN and 
creatinine, creatinine clearance and GFR) markers 
was estimated by Spearman’s correlation coefficient. 
Statistical significance was accepted at p<0.05. Sta-
tistical analysis was performed using the IBM Statis-
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tical Package for Social Sciences (SPSS) for Win-
dows, version 22.0 (IBM, New York, USA). 
 
3. Results 
We found a significant dose-dependent increase 
in RBC, Ht, Hb and MCV values and a reduction in 
MCHC for the rHuEPO200, rHuEPO400 and 
rHuEPO600 groups (Table 2). A significant increase 
in reticulocyte count was found for the rHuEPO400 
and rHuEPO600 groups. The group receiving the 
lower dose (rHuEPO100) did not show any signifi-
cant alteration in the hematological parameters, as 
compared to the control group (Table 2). 
The markers of renal function in serum and urine 
were not significantly altered, with the exception of 
BUN that was significantly decreased in the 
rHuEPO400 group and increased in the rHuEPO600 
group, both compared to the control (Table 2). The 
rHuEPO600 group presented significantly increased 
serum uric acid levels, versus rHuEPO100 and 
rHuEPO400 groups. Increased serum levels of 
VEGF were found in the rHuEPO200 and 
rHuEPO600 groups, when compared to all the other 
groups (Table 2). 
SBP, DBP and MBP values were significantly 
increased in all groups receiving rHuEPO, as com-
pared to the control (Table 2). The rHuEPO200 and 
rHuEPO600 groups presented significantly higher 
SBP values, when compared to the rHuEPO100 and 
rHuEPO400 groups. In the rHuEPO600 group, MBP 
was significantly higher versus the other rHuEPO-
treated groups (Table 2). 
Kidney gene expression (mRNA levels) of 
HIF1α and HIF1β was unchanged in all the groups 
treated with rHuEPO, versus the control (Fig. 1A), 
except for the rHuEPO400 group that showed a 
significant decrease versus all the other groups. 
Regarding HIF2α and HIF2β, mRNA overexpres-
sion was found in the rHuEPO200 and rHuEPO600 
groups, accompanied by an increase in the VEGF 
expression in the same groups, together with a sig-
nificantly lower EPO mRNA expression in all 
groups, when compared to the control group (Fig. 
1A and 1B). 
Significant kidney HIF2α protein overexpression 
was found in the rHuEPO200 and rHuEPO600 
groups, when compared to the control, rHuEPO100 
and rHuEPO400 groups, showing these last two 
groups a significant down-expression of HIF2α 
versus the control (Fig. 2A). The β common receptor 
protein expression in the kidney was increased in all 
rHuEPO-treated groups, when compared to the con-
trol (Fig. 2B), accompanying by augmented phos-
phorylated/total STAT5 ratio (Fig. 2D). In addition, 
phosphorylated/total eNOS ratio was significantly 
decreased in the rHuEPO200 and rHuEPO600 
groups when compared to the control, rHuEPO100 
and rHuEPO400 groups, and significantly increased 
in the rHuEPO100 and rHuEPO400 groups, versus 
the control (Fig. 2C). The protein phosphory-
lated/total AKT1/2/3 ratio was increased in all 
rHuEPO-treated groups, when compared to the con-
trol; however, the rHuEPO200 and rHuEPO600 
groups presented a significantly reduction versus the 
rHuEPO400 group (Fig. 2E). The phosphory-
lated/total ERK1/2:ERK1/2 ration (Fig. 2F) was 
significantly decreased in the rHuEPO100 and 
rHuEPO400 groups, whereas in the other two groups 
(rHuEPO200 and rHuEPO600) no significant 
changes were found when compared to the control. 
However, the rHuEPO400 group showed signifi-
cantly increased values when compared to the 
rHuEPO100 and rHuEPO400 ones.       
Glomerular hypertrophy (Fig. 4b) was the only 
glomerular lesion found in all groups receiving 
rHuEPO (rHuEPO100: 10050.4±388.7 µm2;
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Table 2 –Hematological, biochemical and blood pressure data at the end of study protocol 
Results are presented as mean ± SEM: a p<0.05 vs control group; b p<0.05 vs rHuEPO100 group; c p<0.05 vs rHuEPO200 group; d 
p<0.05 vs rHuEPO400 group (Mann-Whitney Test). BUN - Blood urea nitrogen; Hb – Hemoglobin; Ht – Hematocrit;  DBP - Diastolic 
blood pressure; EPO - Erythropoietin; GFR - Glomerular filtration rate; MBP - Mean blood pressure; RBC - Red blood cell; Ret – 
Reticulocytes; SBP - Systolic blood pressure; VEGF - Vascular endothelial growth factor. 
 
 
Parameters/ Groups Control rHuEPO100 rHuEPO200 rHuEPO400 rHuEPO600 
Hematological data 
RBC (x 1012/L) 7.99±0.17 8.20±0.13 9.41±0.12ab 9.85±0.23ab 10.53±0.39abc 
Hb (g/dL) 14.47±0.19 14.74±0.30 17.06±0.32ab 18.14±0.40ab 19.60±0.60abc 
Ht (%) 43.57±0.85 44.89±1.19 53.21±1.16ab 57.37±1.20abc 66.56±1.03abcd 
Ret (%) 2.33±0.18 2.63±0.31 1.90±0.27b 5.41±0.48abc 4.17±0.51abc 
Ret (x109/L) 205.68±16.16 215.01±26.67 179.34±26.07 535.60±52.38abc 469.55±31.74abc 
MCV (fL) 54.50±0.48 54.88±0.35 57.14±0.59a 58.29±0.71ab 59.86±1.03abc 
MCHC (g/dL) 33.27±0.35 32.90±0.33 32.10±0.21a 31.63±0.1abc 31.14±0.36ab 
Serum biochemical data 
BUN (mg/dL) 21.02±0.33 22.36±0.51 21.70±0.42 18.36±0.38abc 23.06±0.70ad 
Creatinine (mg/dL) 0.37±0.02 0.32±0.02 0.36±0.03 0.39±0.02 0.40±0.02 
Uric acid (mg/dL) 0.81±0.06 0.85±0.03 0.93±0.11 0.76±0.05 1.14±0.19bd 
VEGF (pg/mL) 321.97±29.54 340.35±33.51 826.64±39.17abd 306.50±19.61 697.57±68.02abd 
Urine biochemical data 
Urea (mg/dL) 5280.00±617.13 5950.00±575.39 6525.00±359.94 5457.00±340.07 5400.00±733.03 
Creatinine (mg/dL) 83.00±7.16 82.86±5.65 97.50±7.96 90.00±6.17 90.00±15.92 
Uric acid (mg/dL) 10.58±0.66 8.43±0.97 11.00±1.47 11.96±1.91 11.88±1.01 
AE (mg/L) 3.00±0.33 3.00±0.65 2.00±0.31 3.71±0.84 2.17±0.48 
CC(mL/h/rat) 108.75±5.24 113.32±5.38 105.13±8.49 107.16±8.67 108.06±16.00 
GFR (mL/h/rat) 108.76±5.27 111.11±6.21 109.34±6.87 117.68±8.83 110.88±16.21 
Blood pressure 
SBP (mmHg) 105.20±0.90 119.06±1.12a 129.15±0.85ab 118.70±1.9ac 145.64±1.23abcd 
DBP (mmHg) 88.38±1.74 104.05±0.92a 100.73±1.30ab 98.62±2.44a 110.43±1.55abcd 
MBP (mmHg) 89.50±2.31 107.50±0.95a 107.31±1.71a 103.53±2.05a 122.71±1.55abcd 
Fig. 1 – Relative mRNA 
expression of kidney genes. A) 
hypoxia-inducible factors (HIF) 
system genes; B) erythropoietin 
(EPO) and vascular endothelial 
growth factor alpha (VEGFα) 
genes. β - actin was used as the 
reference gene. Results are 
presented as mean ± SEM: a 
p<0.05, aa p<0.01, aaa p<0.001 
vs control group; b p<0.05 vs 
rHuEPO100 group; c p<0.05 vs 
rHuEPO200UI group; d p<0.05, 
dd p<0.01 vs rHuEPO400 group; 
e p<0.05 vs rHuEPO600 (Mann-
Whitney test). 
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rHuEPO200: 11727.9±363.8 µm2; rHuEPO400: 
10852.4±355.6 µm2; rHuEPO600: 10888.0±334.8 
µm2 versus control: 7950.9±398.7 µm2, p<0.05, 
Mean±SEM).  
Regarding the vascular profile, no lesions were 
found in the control group, as expected (Fig. 3a and 
3b); however, arteriolosclerosis (Fig. 3a and 4d) was 
found in all rHuEPO-treated groups, with a higher 
degree in the rHuEPO200, rHuEPO400 and 
rHuEPO600 groups. Arteriosclerosis (Fig. 3b and 
4f) was present in all groups, with statistically sig-
nificant changes encountered in the rHuEPO200 and 
rHuEPO600 groups. Hyperemia was encountered in 
all rHuEPO-treated rats (Fig. 3c and 4h). Additional-
ly, media proliferation in larger arteries (Fig. 4f) and 
arterioles was observed in all groups. Some degree 
of neovascularization occurred in all groups receiv-
ing rHuEPO (Fig. 4g and 4h). Tubular lesions were 
found in all groups under rHuEPO therapy, includ-
ing the presence of hyaline (Fig. 3d and 5a) and 
granular (Fig. 3e and 5b) cylinders, as well as hi-
dropic (Fig. 3f and 5c) and vacuolar (Fig. 3g and 5d) 
tubular degeneration. A mild degree of interstitial 
inflammatory infiltration (Fig. 3h and 5e) was ob-
served in the rHuEPO200 and rHuEPO600 groups, 
together with a mild degree of IFTA (Fig. 3i and 5f) 
in the rHuEPO600 group.  
We found that tubular lesions correlated positive-
ly and significantly with rHuEPO dose (r=0.422, 
p<0.001), Ht (r=0.412, p<0.001), Hb (r=0.386, 
p<0.001), SBP (r=0.337, p<0.001), RBC (r=0.368, 
p<0.001), serum creatinine (r=0.263, p=0.004) and 
reticulocytes count (r=0.234, p=0.013).  
In addition, vascular lesions correlated positively 
and significantly with rHuEPO dose (r=0.497, 
p<0.001), SBP (r=0.433, p<0.001), Ht (r=0.405, 
p=0.001), Hb (r=0.404, p=0.001) and RBC (r=0.382, 
p=0.002).  
 
 
4. Discussion 
Although several mechanisms has been proposed 
to explain the rHuEPO-evoked BP raise the issue 
remains highly debatable, deserving further elucida-
tion [13].  
In our study, increased SBP was found in all 
groups receiving rHuEPO therapy, even in the ab-
sence of significant hematological changes, as ob-
served in the rHuEPO100 group, thus suggesting the 
involvement of others factors. In fact, VSMC within 
the media layer of arteries can be a direct target to 
rHuEPO due to promotion of proliferation and con-
traction, thus leading to increased vascular resistance 
[25]. In our model, some degree of medial layer 
proliferation was observed in some arteries, which is 
consistent with a direct action of rHuEPO on these 
cells (Fig. 6).  
It is well established that rHuEPO therapy alters 
hemorheology [26], viewed by the Ht increase 
which causes blood hyperviscosity, thus increasing 
vascular resistance. Excessive erythrocytosis and/or 
polycythemia are conditions associated with an 
increase in viscosity and cellularity, which are re-
sponsible for a reduction in renal blood flow (RBF), 
renal oxygen delivery and, consequently, renal hy-
poxia [27]. The reduction in RBF is also responsible 
for increased vascular resistance, contributing to 
hypertension.  
The increased expression of HIF2α in the 
rHuEPO200 and rHuEPO600 groups is consistent 
with the presence of renal hypoxia, due to blood 
hyperviscosity, which modulates tissue perfusion 
[28]. It was also reported that kidneys of hypoxic 
rats present hyperemia [29], which was also encoun-
tered in our study. However, considering the Hb 
levels observed in the rHuEPO200 and rHuEPO600 
groups, the kidney tissue should be normoxic and, 
therefore, the HIF system would not be overex-
pressed. 
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Fig. 3 – Total score for vascular and tubulointerstitial lesions at the end of protocol. Results are presented as 
Mean ± SEM: a) p<0.05 vs control group; b) p<0.05 vs rHuEPO100 group; c) p<0.05 vs rHuEPO200 group; 
d) p<0.05 vs rHuEPO400 group (Mann-Whitney Test). 
 
As expected, some adaptive mechanisms to ex-
cessive erythrocytosis should be present in our mod-
el, in agreement with other studies. In fact, in a 
model overexpressing EPO, there was an adaption to 
excessive RBC mass by the regulation of blood 
viscosity, which is achieved by increasing the pro-
portion of young RBC that are more flexible and, 
therefore, allow a  reduced flow resistance [30]. 
Since Hb is the major intracellular protein of RBC, 
the MCHC reflects the protein content of the cell 
and, thus, the intracellular viscosity. An increase in 
the intracellular protein content leads to an increase 
in intracellular viscosity that will compromise RBC 
flexibility [31]. The presence of increased MCV and 
reticulocytes in the higher rHuEPO doses 
(rHuEPO400 and rHuEPO600), along with a reduc-
tion in MCHC, indicates the presence of a more 
young and flexible population of RBC, modulating 
the excessive erythrocytosis, which would favor and 
increase RBF, features that are not observed in the 
rHuEPO200 group. However, the organ capacity to 
respond to blood viscosity is only maintained if no 
injury was observed, which is not the case for the 
rHuEPO600 group, once the presence of interstitial 
inflammatory infiltrate, IFTA and granular cylinders 
is compatible with more pronounced degenerative 
processes, blunting the positive modulator effect of 
increased reticulocytes.  
 HIF system activation evoked an overexpression 
of kidney VEGFα mRNA and an increased serum 
VEGFα concentration, despite unchanged EPO 
mRNA expression in the renal tissue. The reduced
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Fig. 4 – Representative images of glomerular and vascular lesions at the end of protocol (PAS staining, orig-
inal magnification x400). a) normal glomerulus; b) glomerular hypertrophy; c) normal arteriole; d) arteriolo-
sclerosis (grade 2) ; e) normal arteria; f) arteriosclerosis (grade 1); g) neovascularization and arteriosclerosis 
(grade 1); h) hyperemia (grade 2) and neovascularization.  
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Fig. 5 – Representative images of tubulointerstitial lesions at the end of protocol (PAS staining, original 
magnification x400). a) hyaline cylinders (grade 1); b) granular cylinders (grade 1); c) hidropic degeneration 
(grade 1); d) vacuolar degeneration (grade 1); e) interstitial inflammatory infiltrate (grade 2); f) interstitial 
fibrosis and tubular atrophy (grade 1). 
 
EPO mRNA expression could be due to the exoge-
nous rHuEPO treatment, as elevated circulating 
levels of rHuEPO can supress endogenous EPO 
synthesis [15, 32, 33]. VEGF is responsible for an-
giogenesis in regions under hypoxia, increasing the 
blood supply [34], which is in agreement with the 
presence of neovascularization found in several 
animals treated with rHuEPO in our study.  
In the context of hypertensive states, VEGF app- 
ears to be beneficial as it mediates vasodilation 
through the increase in eNOS activity that will im-
prove NO availability.  VEGF induces phosphoryla-
tion on ser1177 to increase eNOS activity, through 
the AKT or ERK signalling pathways [35]. Alt-
hough the AKT pathway was increased in the 
rHuEPO200 and rHuEPO600 groups (Fig. 2E) 
(though not in the same extent as in the rHuEPO100 
and rHuEPO400 groups), eNOS phosphorylation 
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was reduced (Fig. 2C).  It is reported that hypoxia 
affects eNOS activity by promoting post-translation 
modifications or by decreasing eNOS mRNA tran-
scription and reducing eNOS mRNA half-life [36], 
thus explaining our data. It is also important to refer 
that high levels of RBC and Hb are responsible from 
scavenging the NO released by endothelial cells, 
thus limiting its bioavailability [37]. Excessive 
erythrocytosis also alters the vascular system, by 
increasing vascular permeability and/or susceptibly 
to injury, which contributes to endothelial dysfunc-
tion [38]. The presence of a dysfunctional endotheli-
um compromises vasodilation, justifying the BP 
raise due to increased peripheral vascular resistance 
(Fig. 6).  
In the rHuEPO100 and rHuEPO400 groups, the 
increased eNOS phosphorylation seems to be modu-
lated by the rHuEPO-evoked AKT signalling path-
way, as the VEGF levels were not increased. EPO 
acts through the EPO receptor (EPOR)-activated 
STAT5 pathway to promote erythropoiesis; howev-
er, EPO is also responsible for non-hematopoietic 
effects, which are believed to occur due to the di-
merization of EPOR and β Common Receptor (βCR) 
[39]. Recent findings suggest that this receptor may 
be responsible for the changes on eNOS activity 
mediated by EPO, which is in agreement with our 
study [40].  
Previous studies performed in people leaving at 
high altitude have demonstrated that when RBF is 
reduced there is a simultaneous decline in renal 
plasma flow and an increase of filtration fraction, 
with unchanged GFR [27, 41], which is in agree-
ment with our data. Considering that no change in 
GFR was observed in the higher dose group 
(rHuEPO600), the increased serum BUN levels may 
be due to non-renal causes, such as increased protein 
catabolism and/or hemoconcentration [42]. The 
kidney lesions observed in our model (glomerular 
hypertrophy and vascular and tubular damage) re-
sembles those observed in individuals with exces-
sive erythrocytosis and mild hypertension [27].  
One major limitation of our study is the absence 
of kidney oxygenation measurements; indeed, it was 
reported that HIF system could be activated by an 
independent-oxygen pathway, through the AKT 
signalling pathway [43]; however the absence of 
HIF activation in the rHuEPO100 and rHuEPO400 
groups, together with the other findings in the  
rHuEPO200 and rHuEPO600 groups, discard that 
hypothesis.   
In combination, our findings suggest a direct ef-
fect of rHuEPO on renal vasculature, with increased 
VSMC proliferation, accompanied by increased Ht 
and blood viscosity, reduced eNOS expression, 
altogether contributing to the development of renal 
hypoxia and hypertension, culminating with the 
presence of vascular and tubulointerstitial lesions 
only with 3 weeks of rHuEPO treatment (Fig.6).  
Despite the features of rHuEPO treatment ob-
served in our study, other reports showed contrary 
observations. In fact, in rats with CKD induced by 
nephrectomy or with diabetic nephropathy, low 
doses of rHuEPO were able to correct anemia and 
ameliorate endothelial dysfunction by increasing 
eNOS activity, without affecting blood pressure [44-
46]. The treatment with higher rHuEPO doses ap-
pears to present renoprotective and cardio-protective 
effects in animal models [47, 48] and in clinical 
studies [7, 49]. These controversial results should 
take into account the presence or absence of an un-
derlying pathological condition, such as CKD. The 
use of rHuEPO to correct anemia presents benefits 
by reducing hypoxia and inflammation, which may 
restore the restore eNOS activity. 
 
6. Conclusions 
Our study showed that rHuEPO-induced hyper-
tension might involve indirect (hematological) and 
direct (renal) effects which varies according to the 
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Fig. 6 – Schematic diagram of mechanisms involved in rHuEPO-induced hypertension. BP – blood pressure; 
eNOS – endothelial nitric oxide synthase; EPO – erythropoietin; Ht – hematocrit; HIF2a – hypoxia inducible 
factor 2 alpha; MCV – mean cell volume; MCHC – mean cell haemoglobin concentration; rHuEPO – recom-
binant human EPO; RBC – Red blood cells; RBF – renal blood flow; VEGF - vascular endothelial growth 
factor. 
 
dose used. Thus, rHuEPO therapy should be used 
rationally and under adequate surveillance, as hyper-
tension develops even with lower doses. Especial 
caution with higher doses should be taken, as 
rHuEPO-induced hypertension leads to early renal 
damage without alterations in traditional markers of 
renal function, thus masking the serious adverse 
effects and risks. 
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ABSTRACT 
Erythropoiesis and iron metabolism are closely linked as iron is an essential player in hemoglobin synthesis 
and hepcidin plays a central role in iron metabolism. The control of hepcidin depends on several factors; 
however, the crosstalk between them is poorly clarified for different physiological and pathological condi-
tions. Our aim was to study the impact of increasing recombinant human erythropoietin (rHuEPO) doses on 
erythropoiesis, iron metabolism and hepcidin, using a rat model. 
Male Wistar rats, 12 weeks old, were divided in 5 groups: control (vehicle) and rHuEPO-treated groups (100, 
200, 400 and 600 IU/kg body weight/week), 3 times per week, during 3 weeks. Hematological and iron data 
were evaluated, as well as, the expression of several genes involved in iron metabolism. Liver hepcidin pro-
tein was evaluated by Western Blot. 
The rHuEPO treatment induced an increase in erythrocyte count, hemoglobin concentration and hematocrit in 
a dose dependent manner; the highest dose induced extramedullary erythropoiesis in the spleen. Transferrin 
saturation (TSAT) increased in the rHuEPO200, rHuEPO400 and rHuEPO600 groups. Tf receptor 2 (TfR2), 
hemojuvelin (HJV) and bone morphogenetic protein 6 (BMP6) mRNA levels were up-regulated in 
rHuEPO200 group. Matriptase-2 was down-regulated in rHuEPO200 group, and up-regulated in the other 
rHuEPO-treated groups. Hepcidin synthesis was increased in rHuEPO200 group, and repressed in the 
rHuEPO400 and rHuEPO600 groups.  
Our study showed that when a high erythropoietic stimulus occurs, independent of tissue oxygenation, the 
hepcidin synthesis is mainly regulated by TSAT, through the TfR2/HJV/BMP6 pathway; however, when the 
erythropoiesis rate reaches a specific threshold, the extramedullary hematopoiesis is also triggered, and the 
control of hepcidin synthesis is switched to matriptase-2 that blunts the TfR2/HJV/BMP6 complex and, thus, 
inhibits hepcidin synthesis.  
Keywords: erythropoiesis, hepcidin, iron, matriptase-2, transferrin saturation. 
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1. Introduction 
Erythropoiesis and iron metabolism are deeply 
linked, as iron is needed for hemoglobin (Hb) syn-
thesis.  An erythropoietic stimuli increases iron 
demand into the bone marrow. Body iron is acquired 
through the diet and is mostly contained in Hb of 
circulating red blood cells (RBC) [1]. Heme-iron is 
absorbed through a receptor on the apical membrane 
of the duodenal enterocyte, releasing iron after di-
gestion. The non-heme iron is absorbed in the enter-
ocyte through the divalent metal iron transporter 1 
(DMT1) and released into the circulation by the iron 
exporter ferroportin (FPN), present on the basolat-
eral surface of the enterocytes, and also present in 
macrophages and hepatocytes [1]. Iron is transported 
by transferrin (Tf) to the locals where it is needed 
for heme synthesis or to be stored. Iron levels are 
physiologically controlled by the balance between 
iron influx and iron demands, being hepcidin the 
major regulator. Hepcidin is a liver peptide that 
binds to FPN, inducing its internalization and degra-
dation [2]; thus, hepcidin regulates iron absorption 
and mobilization to avoid iron deficiency or over-
load. Several factors can regulate hepcidin synthesis, 
such as iron stores, inflammation, erythropoiesis and 
hypoxia [3]. High concentrations of diferric Tf and 
inflammation stimulate hepcidin synthesis, whereas 
increased erythropoiesis and hypoxia inhibit hep-
cidin synthesis; however, the crosstalk between 
these factors is not well established.  
Erythropoiesis-stimulating agents (ESA) are 
mainly used to treat anemia in chronic kidney dis-
ease patients (CKD) and in patients receiving chem-
otherapy [4]. The discovery of non-hematopoietic 
actions for ESA [5] opened the possibility of their 
use in the treatment of other pathologies [6-8]; how-
ever, to achieve those effects, higher doses of ESA 
are usually needed [9]. A successful treatment with 
ESA increases erythropoiesis and iron demand into 
the bone marrow, leading to an increase in iron ab-
sorption and mobilization. The interaction between 
erythropoiesis, iron absorption and iron stores, 
namely which of them prevails in the regulation of 
hepcidin synthesis, is not fully elucidated. Although, 
some studies showed that stimulated erythropoiesis, 
even in the presence of iron overload, inhibits hep-
cidin synthesis [10,11], others reported a dominance 
of liver iron stores over erythropoiesis [12].  
In this study we aimed to study the effect of re-
combinant human erythropoietin (rHuEPO) therapy 
on erythropoiesis and on iron metabolism, and the 
effect of each factor on hepcidin regulation, using a 
rat model. 
 
2. Materials and methods 
2.1. Animals and experimental protocol 
Male Wistar rats (Charles River Lab. Inc., 
Chatillon-sur-Chalaronne, France), with 320-350 g 
of body weight (BW), were maintained in ventilated 
cages, in an air conditioned room, subjected to 12 h 
dark/light cycles and given free access to rat labora-
tory chow (SAFE-A03, Augy, France) and tap wa-
ter. All animals received human care and animal 
experiments were conducted according to the Euro-
pean Communities Council Directives on Animal 
Care. The experiments were approved by the Portu-
guese Foundation for Science and Technology and 
the Local Ethics Committee (ORBEA: Organ Re-
sponsible for Animal Welfare) of the Faculty of 
Medicine from the University of Coimbra. 
The rats were randomly divided in five groups 
(7-8 rats each group) receiving a subcutaneous (sc) 
injection of saline solution (control group) or of 
rHuEpo (NeoRecormon®, Roche, Basel, Switzer-
land) 100, 200, 400 or 600 IU/kg BW/week 
(rHuEPO100, rHuEPO200, rHuEPO400 and 
rHuEPO600 groups, respectively), 3 times per week, 
during 3 weeks. 
 
2.2. Sample collection 
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Blood samples were collected at baseline, and 1 
and 3 weeks (end of protocol) after starting rHuEPO 
treatment, with the rats under anesthesia (intraperi-
toneal) with 2 mg/kg BW of a 2:1 (v:v) 50 mg/mL 
ketamine (Ketalar®, Parke-Davis, Lab. Pfeizer Lda, 
Seixal, Portugal) solution in 2.5% chlorpromazine 
(Largactil®, Rhône-Poulenc Rorer, Lab. Vitória, 
Amadora, Portugal). Blood samples were collected 
by venipuncuture, from the jugular vein, into 
Vacuette® tubes without anticoagulant (to obtain 
serum) or with K3EDTA (to obtain plasma) for he-
matological and biochemical studies.  Plasma and 
serum aliquots were immediately stored at -80ºC 
until assayed. 
At the end of protocol, the rats under anesthesia 
were sacrificed by cervical dislocation; liver, spleen 
and duodenum were immediately removed and 
placed in ice-cold Krebs-Henseleit buffer, cleaned 
and weighted. In order to isolate total RNA, 0.2 g of 
liver, spleen and duodenum samples, from each rat, 
were immersed in RNAlater® solution (Sigma-
Aldrich Co. LLC. St. Louis, Missouri, USA) upon 
collection and stored at 4°C for 24h; afterwards, 
samples were frozen at -20ºC. For western blot anal-
ysis organs were immediately frozen with liquid 
nitrogen and stored at -80ºC. 
 
2.3. Hematological and iron metabolism studies 
RBC count, Hb, hematocrit (Ht), mean cell vol-
ume (MCV), mean cell hemoglobin (MCH), mean 
cell hemoglobin concentration (MCHC), red cell 
distribution width (RDW) and platelet count were 
assessed in whole blood K3EDTA, using an auto-
mated counter (HORIBA ABX, Amadora, Portugal). 
Reticulocytes were evaluated by microscopic count-
ing on blood smears, after vital staining with New 
methylene blue (reticulocyte stain; Sigma-Aldrich 
Co. LLC. St. Louis, Missouri, USA). 
Reticulocyte production index (RPI) was calcu-
lated as previously described by Hillman and Finch 
[13][(reticulocyte %/maturation index)*(Ht/normal 
Ht)], where normal Ht was the mean value presented 
by the control group, and the maturation index (mat-
uration time of circulating blood reticulocytes that 
increase with premature release of reticulocytes 
from the bone marrow) was 1 for all groups.  
Serum iron and ferritin were analyzed through 
automatic methods and equipment (ROCHE Integra 
400, Roche Diagnostics, Basel, Switzerland). Serum 
Tf levels were evaluated by rat specific ELISA kit 
(Transferrin Rat ELISA Kit, abcam, Cambridge, 
UK). Tf saturation (TSAT) was calculated using the 
formula (Iron µg/dL*100)/(Tf mg/dL*2). 
 
2.4. Spleen histological analysis 
Spleen samples were fixed in neutral formalin 
10%, embedded in paraffin wax, and 4µm thick 
sections were stained with hematoxylin and eosin for 
extramedullary erythropoiesis analysis. All samples 
were examined by light microscopy (Microscope 
Nikon Eclipse Ci) and images were captured using a 
digital microscope camera (Nikon DS-Ri2). 
 
2.5. Gene expression analysis 
Liver, spleen and duodenum RNA isolation and 
integrity control were performed as previously de-
scribed by us [14]. One microgram of total RNA 
was reversely transcribed using iScript™ cDNA 
Synthesis Kit (Bio-Rad Laboratories, Hercules, 
California, USA), according to manufacturer instruc-
tions. One nanogram of cDNA was used for gene 
expression analysis with qPCR, using a Mini-
Opticon instrument (Bio-Rad Laboratories), the 
KAPA SYBR® FAST qPCR kit (Kapa Biosystems, 
Inc., Wilmington, MA, USA) and specific primer 
pairs (Table 1). qPCR reactions are performed using 
the following conditions: enzyme activation at 95ºC 
for 40s; denaturation at 95ºC for 3s; annealing for 
30s (for each pair primer temperature, refer to Table 
1). Gene expression was normalized to actin beta 
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(Actb) and alpha tubulin (α-tubulin), and relative 
quantification was calculated using the 2-∆∆CT meth-
od. The expression of the following genes was ana-
lyzed in the liver: bmp6 – BMP6; hamp – hepcidin; 
hfe – HFE; hfe2 - HJV; tfrc – TfR1; tfr2 – TfR2; 
tmprss6 – matriptase-2; in the spleen we analyzed 
the gene expression of epor (EPO receptor), and in 
the duodenum the expression of slc11a2 gene 
(DMT1).  
 
Table 1 - List of primer sequences and annealing 
temperatures 
F: Forward; R: Reverse; actb - beta – actin; bmp6 - bone mor-
phogenetic protein 6; epor – erythropoietin receptor;  hamp – 
hepcidin; hfe – hemochromatosis protein; hfe2 - hemojuvelin; 
slc11a2 - divalent metal transporter 1; tfrc – transferrin receptor 
1; tfr2 – transferrin receptor 2; tmprss6 – matriptase-2; tuba – 
alpha-tubulin. 
 
2.6. Protein analysis by Western Blot 
Liver proteins were extracted using RIPA buffer 
(NaCl 150mM, Tris-HCl 50mM pH8, Triton X-100 
1%, ethylene glycol tetraacetic acid 5mM, deo-
xycholic acid 0.5%, Sodium lauryl sulfate 0.1%) and 
ultra-sonication. After centrifugation, protein con-
centration of the supernatant was assayed using the 
bicinchoninic acid (BCA) method (Thermo Scien-
tific Pierce, IL, USA). Aliquots of the extract, con-
taining 50 µg of protein, were separated by reducing 
SDS-PAGE (12 %) and transferred onto nitrocellu-
lose membranes. The blots were blocked by using 
7% non-fat milk in a solution of Tris-buffered salt 
with Tween-20. The nitrocellulose membranes were 
incubated, overnight at 4ºC, with goat anti-hepcidin 
1:100 (sc-240553, Santa Cruz Biotechnoloy, Inc, 
Texas, USA), rabbit anti-SMAD1/5/9 1:500 
(ab66737, abcam,  Cambridge, UK) and rabbit anti-
phospho SMAD1/5/9 1:500 (#13820, Cell Signaling 
Technology, Massachusetts, USA); afterwards, they 
were incubated with anti-goat (ab97120) or anti-
rabbit (sc-2004) secondary antibody-conjugated with 
horseradish peroxide (abcam,  Cambridge, UK and 
Santa Cruz Biotechnoloy, Inc, Texas, USA, respec-
tively). Immunoreactive proteins were detected by 
using the enhanced chemiluminescence method 
(ECL WesternBright, Advansta, California, USA). 
The analysis of the immunoblots was performed by 
densitometry (Bio1D++ version 99, Vilber Lour-
mat). To ensure even loading of the samples, all 
immunoblots were probed with rabbit anti-β-tubulin 
antibody 1:500 (sc-9104, SantaCruz Biotechnology, 
Texas, USA). The protein concentration in each 
sample was normalized for control group. 
 
2.7. Statistical analysis 
Statistical analysis was performed using the IBM 
Statistical Package for Social Sciences (SPSS) for 
Windows, version 22.0 (IBM, NY, USA). Results 
are presented as mean ± standard error mean (SEM). 
For comparison between groups Mann-Whitney test 
was performed. Statistical significance was accepted 
Gene Primer sequences (5’ → 3’) Annealing  temperature  
actb 
F:TACAGCTTCACCACCACAGC 
57ºC 
R:AAGGAAGGCTGGAAGAG GC 
bmp6 
F:GGTGGAGTACGACAAGGAGTT 
56ºC 
R:GTCACAACCCACAGATTGCTA 
epor 
F:CCGGGATGGGCTTCAACTAC 
59ºC 
R:TCCAGTGGCACAAAACTCGAC 
hamp 
F:GGCAGAAAGCAAGACTGATGAC 
58ºC 
R:ACAGGAATAAATAATGGGGCG 
hfe 
F:TGGGCAAGATCACCTTGAATT 
58ºC 
R:GGATCCTGTGCTCTTCCCACT 
hfe2 
F:TTCCAATCCTGCCTCTTTGAT 
58ºC 
R:GGAAAAGGTGCAAGTTCTCCAA 
slc11a2 
F:ATAGCAGACGCCCCCATG 
58ºC 
R:AGGCCCGAAGTAACATCCAA 
tfrc 
F:GGGAGCCATTGTCATACACC 
58ºC 
R:GTCGCAAAGCAGAGTCTTCC 
tfr2 
F:AGCTGGGACGGAGGTGACTT 
58ºC 
R:TCCAGGCTCACGTACACAACAG 
tmprss6 
F:AGAAGGTGGATGTGCAACTGATC 
59ºC 
R:CTTGCCCTTGCGATAACCA 
tuba 
F:CACCCGTCTTCAGGGCTTCTTGGTTT 
59ºC 
R:CATTTCACCATCTGGTTGGCTGGCTC 
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at p < 0.05.  
 
3. Results 
3.1. Hematological data 
The lowest rHuEPO dose group (rHuEPO100) 
showed an increase in Hb concentration and reticu-
locytes after 1 week of rHuEPO treatment, returning 
both parameters to values similar to those of the 
control group, at the end of protocol (Table 2). A 
significant increase in RDW was also found in the 
rHuEPO100 group. 
The rHuEPO200, rHuEPO400 and rHuEPO600 
groups showed a significant dose-dependent increase 
in RBC count, Hb concentration and Ht, more pro-
nounced at the end of protocol (Table 2). After 1 
week of rHuEPO treatment, we found a significant 
dose-dependent increase in reticulocytes and RPI, 
when compared to the control group; although the 
values remained significantly increased in the 
rHuEPO400 and rHuEPO600 groups, a reduction in 
reticulocytes and RPI from the 1st to the 3rd week 
was found. Throughout the study, a significant in-
crease in MCV, and a reduction in MCHC were 
found in the rHuEPO200, rHuEPO400 and 
rHuEPO600 groups, together with an increase in 
RDW, when compared to the control group. At the 
end of the protocol, both rHuEPO400 and 
rHuEPO600 groups showed a significant reduction 
in platelet count, versus the other groups (Table 2). 
Serum EPO levels were significantly reduced in the 
rHuEPO100 group, when compared to the control 
and to the other rHuEPO-treated groups, in both 
follow-up times. At the end of protocol, the 
rHuEPO200 group presented significantly increased 
serum EPO levels, compared to the control and the 
other rHuEPO-treated groups. 
 
3.2. Extramedullary erythropoiesis  
No signs of liver extramedullary erythropoiesis 
were found; however, spleen extramedullary eryth-
ropoiesis was found in the rHuEPO600 group, as 
shown by the up-regulation of spleen EPOR mRNA 
levels (Fig. 1A). In addition, the histopathological 
analysis of spleen showed that the red pulp area was 
larger, compared to that observed in the other 
groups, and hematopoietic cells were observed only 
in this particular group (Fig. 1B-1D). Relative spleen 
weight (spleen/BW ratio) was also higher in the 
rHuEPO600 group, compared to the other groups 
(Spleen/BW ratio (g/Kg): control - 1.690±0.063; 
rHuEPO100 - 1.611±0.070; rHuEPO200 - 
1.817±0.120; rHuEPO400 - 1.965±0.155 versus 
rHuEPO600 - 2.586±0.172, p<0.05). 
 
3.3. Iron metabolism 
Regarding serum iron metabolism, we found that 
only the rHuEPO100 group showed a significant 
reduction in serum iron when compared to the con-
trol and rHuEPO400 groups (Fig. 2A1). No signifi-
cant changes were found in serum ferritin levels 
(Fig. 2A2). A reduction in serum Tf was observed in 
the rHuEPO100, rHuEPO200 and rHuEPO600 
groups, when compared to the control group (Fig. 
2A3). A significant increase in TSAT was encoun-
tered in the rHuEPO200, rHuEPO400 and 
rHuEPO600 groups, versus the control and the 
rHuEPO100 groups (Fig. 2A4). 
A significant up-regulation in liver TfR1 mRNA 
levels was found in the rHuEPO600 group, when 
compared to the other groups (Fig. 2B1). Liver TfR2 
mRNA levels were significantly overexpressed in 
both the rHuEPO200 and rHuEPO600 groups, ver-
sus the control and the rHuEPO400 groups (Fig. 
2B2). No significant alterations were observed in 
HFE mRNA levels (Fig. 2B3). The rHuEPO200 
group showed a significant up-regulation in HJV 
(Fig. 2B4), BMP6 (Fig. 2B5) and hepcidin (Fig. 
2B6) mRNA levels, and a significant down-
regulation of matriptase-2 (Fig. 2B7), compared to 
the other groups. A significant down-regulation of 
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Table 2 – Hematological data throughout the study (at baseline and after 1 and 3 weeks of treatment) 
Results are presented as mean ± SEM. a p<0.05 vs control group; b p<0.05 vs rHuEPO100 group; c p<0.05 vs rHuEPO200 group; d 
p<0.05 vs rHuEPO400 group (Mann-Whitney test). 0w –start of protocol; 1w – 1 week;  3w – 3 weeks ; EPO – erythropoietin; Hb – 
hemoglobin; Ht – hematocrit; MCH – mean cell hemoglobin; MCHC – mean cell hemoglobin concentration; MCV – mean cell volume; 
PLT – platelets; RBC – red blood cells; Ret – reticulocytes; RPI – reticulocyte production index. 
 
BMP6 and hepcidin (Hamp) mRNA levels were 
observed in the rHuEPO400 and rHuEPO600 
groups, accompanied by an up-regulation of matrip-
tase-2. Duodenal DMT1 mRNA levels were up-
regulated in the rHuEPO200, rHuEPO400 and 
rHuEPO600 groups, when compared to the control 
and the rHuEPO100 groups (Fig. 2B8).  
While a significantly increased liver hepcidin 
protein expression was found in the rHuEPO200-
treated rats, a reduced expression was observed in 
the rHuEPO400 and rHuEPO600 groups (Fig. 3A).  
Liver pSMAD1/5/9:SMAD1/5/9 ratio protein 
was significantly increased in the rHuEPO200 
group, but reduced in the other treated groups, com- 
 Control rHuEPO100 rHuEPO200 rHuEPO400 rHuEPO600 
RBC (x 1012/L)      
0w 7.46±0.07 7.39±0.12 7.55±0.10 7.36±0.11 7.56±0.11 
1w 8.30±0.09 8.69±0.26 8.51±0.08 9.39±0.18ac 9.14±0.12ac 
3w 7.99±0.17 8.20±0.13 9.41±0.12ab 9.85±0.23ab 10.53±0.39abc 
Hb (g/dL)      
0w 14.44±0.18 14.44±0.17 14.31±0.21 14.29±0.17 14.56±0.18 
1w 14.96±0.18 15.99±0.16a 16.00±0.16a 17.09±0.19abc 17.60±0.25abc 
3w 14.47±0.19 14.74±0.30 17.06±0.32ab 18.14±0.40ab 19.60±0.60abc 
Ht (%)      
0w 42.42±0.52 41.17±0.47 43.14±0.66 41.26±0.61 42.49±0.53 
1w 43.69±0.73 45.37±1.30 48.74±0.71a 51.71±0.77abc 54.61±0.85abcd 
3w 43.57±0.85 44.89±1.19 53.21±1.16ab 57.37±1.20abc 66.56±1.03abcd 
Ret (x109/L) 
0w 228.01±13.21 151.84±13.25 243.03±17.41 215.25±29.06 256.93±16.96 
1w 305.32±13.32 566.05±30.32a 505.97±30.64a 959.73±44.64abc 1022.43±77.42abc 
3w 205.68±16.16 215.01±26.67 179.34±26.07 535.60±52.38abc 469.55±31.74abc 
RPI      
0w 2.93±0.13 2.04±0.19 2.90±0.07 2.86±0.17 3.12±0.23 
1w 3.65±0.13 6.81±0.43a 6.53±30.44a 12.05±0.58abc 14.67±0.91abc 
3w 1.80±0.27 2.43±0.26 2.30±0.35 7.07±0.63abc 6.40±0.50abc 
MCV (fL)      
0w 56.70±0.37 56.25±0.31 56.63±0.68 56.25±0.53 56.88±0.95 
1w 52.80±0.42 52.71±0.29 57.43±0.57ab 55.71±0.36abc 59.75±0.84abcd 
3w 54.50±0.48 54.88±0.35 57.14±0.59ab 58.29±0.71ab 59.86±1.03abc 
MCH (pg)      
0w 19.46±0.17 19.36±0.17 19.00±0.20 19.46±0.30 19.30±0.33 
1w 18.11±0.12 18.19±0.22 19.03±0.23 18.23±0.31 19.50±0.27 
3w 18.11±0.19 18.10±0.25 18.24±0.19 18.46±0.28 18.64±0.35 
MCHC (g/dL)      
0w 34.18±0.19 34.60±0.33 33.68±0.18 34.68±0.35 33.88±0.26 
1w 34.36±0.27 34.36±0.39 33.24±0.28a 33.04±0.29ab 32.24±0.14abcd 
3w 33.27±0.35 32.90±0.33 32.10±0.21a 31.63±0.11abc 31.14±0.36ab 
RDW (%)      
0w 12.22±0.11 12.74±0.16 12.39±0.18 12.61±0.13 12.30±0.21 
1w 13.50±0.23 15.20±0.11a 15.31±0.20a 17.41±0.20abc 16.93±0.25abc 
3w 13.34±0.06 14.21±0.23a 15.71±0.09ab 17.51±0.21abc 19.23±0.28abc 
PLT (x 109/L)      
0w 670.63±17.09 681.25±18.27 700.43±24.70 661.57±13.34 702.00±18.81 
1w 650.10±22.29 631.38±32.26 626.83±15.15 614.38±23.84 576.75±33.36 
3w 688.20±19.68 679.17±28.91 642.38±61.01 428.43±22.04abc 482.00±30.76abc 
Serum EPO (mIU/mL) 
0w 3.93±0.46 2.98±0.55 3.35±0.25 4.35±0.74 3.98±0.43 
1w 3.63±0.26 2.39±0.44a 5.11±0.86b 4.25±0.41b 3.40±0.19b 
3w 3.84±0.37 2.62±0.17a 6.61±0.58ab 3.47±0.39bc 3.38±0.26bc 
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pared to the control group (Fig. 3B). 
 
Discussion 
The synthesis of hepcidin is known to be con-
trolled by different factors; however the crosstalk 
between them in specific physiological and patho-
logical conditions is poorly understood. rHuEPO is 
widely used due to its stimulating effect on erythro-
poiesis and to its pleiotropic actions, but to achieve 
the desired non-hematopoietic actions, high rHuEPO 
doses are needed. The stimulating effect on erythro-
poiesis is also illicitly used in sports doping to in-
crease RBC mass, improving sports performance. 
Our aim was to clarify the impact of a stimulated 
erythropoiesis triggered by increasing rHuEPO dos-
es, in case of normal tissue oxygen levels.          
We found that the administration of increasing 
rHuEPO doses to healthy rats induced erythropoiesis 
in a dose-dependent manner, as showed by the in-
crease in RBC, Hb and Ht. The highest dose 
(rHuEPO600) was also able to induce spleen ex-
tramedullary erythropoiesis, and the analysis of the 
blood smears showed the presence of Howell-Jolly 
bodies in the RBC, compatible with an altered splen-
ic function [15]. The increase in MCV and the re-
duction in MCHC, observed in the rHuEPO200, 
rHuEPO400 and rHuEPO600 groups, are the result 
of a higher number of reticulocytes caused by stimu-
lated erythropoiesis, which are larger than mature 
RBC and with lower Hb concentration. The in-
creased RDW confirmed the anisocytosis due to the 
increased reticulocytes. The reduced platelet count 
observed, at the end of the protocol, in the 
rHuEPO400 and rHuEPO600 groups, might be due 
to competition between erythroid and megakaryo-
cytic cells that have common progenitors cells [16]. 
Another possible explanation is that the hemoreolog-
ical disturbances, due to increased RBC concentra-
tion, lead to platelet sequestration in the spleen, 
reducing its circulating number. 
The increasing rHuEPO stimulus promoted an 
increase in iron absorption and mobilization, as 
suggested by the increase in TSAT and duodenal 
DMT1 mRNA levels, in order to face the increased 
iron demands for stimulated erythropoiesis, main-
taining serum iron and ferritin levels (Fig. 2). Tf is 
responsible for iron transport to its target cells, car-
rying each molecule two iron (Fe3+) ions. Tf-bound 
Fe (Tf-Fe) can be uptaked by the cells through two 
types of Tf receptors (TfR), TfR1 and TfR2; TfR1 is 
expressed ubiquitously and presents higher affinity 
for Tf-Fe; increased TfR1 levels can be found in 
accelerated erythropoiesis to compensate the high 
rate of iron demand for RBC production; TfR2 is 
mainly expressed on hepatocytes and presents other 
iron regulatory functions [17]. In conditions of nor-
mal TSAT, a sensor for systemic iron availability, 
Tf-Fe and the hemochromatosis protein (HFE) com-
pete for binding to TfR1; in conditions of increased 
TSAT, Tf-Fe displaces HFE from TfR1 that binds to 
TfR2, activating the recruitment of hemojuvelin 
(HJV), a co-receptor of bone morphogenetic protein 
6 (BMP6) [18]. HJV can be regulated by matriptase-
2, which promotes its cleavage producing a soluble 
form that blunts the action of BMP6 [19]. The link-
age of HJV to BMP6 leads to the phosphorylation of 
SMAD1, SMAD5 and SMAD9, activating the re-
cruitment of SMAD4, forming a complex that will 
translocate into the nucleus and activate the tran-
scription of the hepcidin gene [20]. The increase in 
hepcidin synthesis will lead to a reduction in iron 
absorption and mobilization, in order to control iron 
body levels. However, TSAT is not the only regula-
tor of hepcidin synthesis. Erythropoiesis acts as an 
inhibitor of hepcidin synthesis, in order to stimulate 
iron absorption and mobilization for an efficient Hb 
synthesis by the erythroid cells. Regardless of the 
progresses achieved on hepcidin regulation, during 
the last years, the exact mechanisms by which eryth-
ropoiesis inhibits hepcidin synthesis are not fully 
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Fig. 1 – Extramedullary erythropoiesis in the spleen. 
A) Relative mRNA expression of erythropoietin 
receptor (EPOR) in spleen; B) Representative image 
of the white and red pulp area in the spleen of the 
control group (100x); C) Representative image of 
the enlarged red pulp area in the spleen of the 
rHuEPO600 group (100x); D) Representative image 
of erythroid cells and megakaryocyte (arrow) in the 
red pulp of the rHuEPO600 group spleen (400x). 
understood. It was reported that EPO itself can be an 
inhibitor factor [21], but recent studies showed that 
in conditions of high EPO levels, without erythro-
poiesis, no inhibition of hepcidin synthesis occurs 
[22,23]. It appears that erythropoiesis inhibits hep-
cidin synthesis through some factors produced by 
the hematopoietic cells in the bone marrow, such as 
the growth differentiation factor 15 [24], the twisted 
gastrulation factor-1 [25] and,  the erythroferrone 
[26,27].  
In the rHuEPO200 group, the erythropoiesis 
stimuli triggered by rHuEPO seems to overwhelm 
the bone marrow response capacity, as suggested by 
the increase (two fold) in reticulocyte count and RPI 
at the 1st week that was followed by a decrease to 
basal values at the 3rd week of treatment. The signif-
icantly high serum EPO levels in the rHuEPO200 
group (Table 2) and the up-regulation of liver EPO 
mRNA levels (data not shown) are consistent with a 
reduction in the bone marrow erythropoietic activity. 
Indeed, it was reported that serum EPO levels in-
creases, in response to a reduction in erythroid pro-
genitors in the bone marrow, independently of 
changes in tissue oxygenation [28]. Moreover, in 
line with this, the higher rHuEPO stimuli 
(rHuEPO400 and rHuEPO600) seem to trigger ex-
tramedullary erythropoiesis, already evident in the 
spleen, for the highest rHuEPO doses.  In the 
rHuEPO200 group, we also found an up-regulation 
of liver TfR2, HJV and BMP6 levels, an activation 
of the SMAD1/5/9 pathway and a down-regulation 
of matriptase-2 that, altogether, contribute to in-
crease hepcidin synthesis. It seems that in the dy-
namic balance, erythropoiesis-iron-hepcidin, the 
increased TSAT prevails over the inhibitory effect of 
erythropoiesis, increasing hepcidin synthesis to 
avoid iron overload. We found that while increased 
TSAT was a common feature in rHuEPO200, 
rHuEPO400 and rHuEPO600 groups, hepcidin syn-
thesis was only increased in the rHuEPO200 group, 
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Fig. 3 – Evaluation of liver proteins by western blot and representative images of western blot for the differ-
ent groups. A – Hepcidin; B – pSMAD1/5/9:SMAD1/5/9 ratio. Results are presented as mean ± SEM: aa p<0.01 vs 
Control group; b p<0.05 vs rHuEPO100 group; c p<0.05, cc p<0.01 vs rHuEPO200 group (Mann-Whitney test). 
 
suggesting that other(s) factor(s) prevailed over 
TSAT in the modulation of hepcidin synthesis. The 
rHuEPO400 and rHuEPO600 groups showed a 
down-regulation in BPM6 and HJV mRNA levels, 
as compared to rHuEPO200 group, which translates 
in no activation of the SMAD1/5/9 pathway. In 
accordance, the rHuEPO400 and rHuEPO600 
groups showed hepcidin mRNA levels and protein 
synthesis repressed. Although, TfR2 levels were not 
repressed, as they are regulated by TSAT, it appears 
that the increase in matriptase-2 is the main respon-
sible for the inhibition of hepcidin transcription. In 
fact, matriptase-2 can be regulated directly by iron 
levels in order to prevent excessive hepcidin produc-
tion [17]. We must also consider that the increase in 
blood viscosity, due to the increase in RBC, by in-
ducing hemorheological disturbances may create a 
hypoxic environment in the microvasculature of the 
kidney and liver, also contributing to the switch in 
hepcidin synthesis. Moreover, given the high rate of 
erythropoiesis, showed by the high RPI and reticulo-
cytes in the rHuEPO400 and rHuEPO600 groups, 
this could be another factor explaining the inhibition 
of hepcidin synthesis to face the high iron demands 
for such a high rate of normal and extramedullary 
erythropoiesis.  
This dynamic balance between erythropoiesis 
and iron metabolism is frequently observed in pa-
tients with β-thalassemia, where the presence of 
increased erythropoiesis (but ineffective) results in 
inappropriate low hepcidin levels despite iron over-
load, showing the predominance of erythroid over 
iron as hepcidin regulator [27,29,30].  
In conclusion, our study showed that when a 
high erythropoietic stimuli occurs, independent of 
tissue oxygenation, the hepcidin synthesis is mainly 
regulated by TSAT, through the TfR2/HJV/BMP6 
complex that activates the SMAD1/5/9 pathway; 
however, when the erythropoiesis rate reaches a 
specific threshold, the extramedullary hematopoiesis 
is also triggered, and the control of hepcidin synthe-
sis is switched to matriptase-2 that by inactivating 
HJV, blunts the TfR2/HJV/BMP6 complex and, 
thus, inhibits hepcidin synthesis.  
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General discussion 
Anemia is a common complication in CKD patients that often develops early in the 
course of the pathology, being associated with the progression of the renal disease [22, 40, 
41]. The first treatment available for anemia correction in CKD patients was RBC 
transfusion, but the introduction of rHuEPO in the late 80’s revolutionized the treatment 
of anemia in CKD patients. The search for new and better formulations amplified the 
number of ESA available for anemia correction, but until today the treatment of anemia in 
CKD patients is still a challenge. Some of the CKD patients do not properly respond to ESA 
treatment [50] needing higher doses to overcome ESA resistance in order to achieve target 
Hb levels. Reported data showing an increased incidence of cardiovascular events and 
mortality in CKD patients under ESA therapy [243, 321], especially in hyporesponsive 
patients [250-254], raised concerns. In agreement, experts have reviewed, and updated in 
2012, the guidelines for anemia management in CKD patients [48] and the use of more 
conservative ESA doses in clinical practice was recommended. However, the risks/benefits 
for high ESA doses are still poorly clarified, as well as the causes (and mechanisms) 
underlying the associated increased cardiovascular and mortality risk in CKD patients. 
Our experimental work aimed to contribute to clarify the linkage(s) of risk in the 
treatment of anemia with higher therapeutic doses of rHuEPO in CKD patients. 
Animal models can be a valuable tool to study the pathophysiology of CKD anemia, 
the molecular mechanisms underlying the progression of renal disease and the effects of 
rHuEPO therapy beyond the correction of anemia, providing identification of putative new 
targets to improve therapeutic efficacy and reduce the high mortality observed in CKD 
patients. Previous studies conducted by our group showed that the remnant model of CKD 
induced by a ¾ nephrectomy presents a moderate stage of CRF, but without a sustained 
anemia [344]. Furthermore, we also showed that the 5/6 nephrectomy-induced CKD 
model was associated with the development of sustained CRF and anemia along the 9th 
week protocol [313]; however, the development of antibodies against rHuEPO after the 6th 
week of treatment [345] lead us to shorten, in the present study, the protocol time to 3 
weeks of rHuEPO therapy.  
In the work presented herein, after 3 weeks of nephrectomy, the rat model of CRF 
developed a moderate degree of renal failure, as showed by the 2 to 3 fold increase in 
serum creatinine and BUN, the remarkable increase in albumin excretion and the 
consistent reduction in GFR, which are markers of CKD used in clinical practice for the 
classification and stratification of the disease [1]. The development of renal insufficiency 
was associated with a high score of renal lesions (namely glomerular, tubulointerstitial 
and vascular lesions), hypertension, inflammation and anemia. The substantial surgical 
removal of nephrons induced a compensatory hypertrophy of the remnant kidney in the 
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CRF rats, with increased workload of the remaining nephrons that, by affecting other 
kidney structures, lead to the progression of the disease. The development of a moderate 
anemia in the CRF rats, following kidney mass reduction, is due to the reduction of renal 
EPO secretion, as showed by the reduced kidney protein expression of HIF-2α and EPO; 
however, serum EPO was increased, being mostly from hepatic origin. It has been 
reported that in both CKD patients and animal models of CKD, the serum EPO levels are 
within the normal range or even increased [62, 64-66, 313]. The serum EPO levels in CRF 
rats are, probably, not sufficient to overcome renal anemia; actually, anemic patients with 
normal renal function might increase serum EPO levels to 10 to 100 fold the normal value 
[67], depending on the disease severity [62, 63]. The kidney inflammatory features 
observed in the CRF rats (IL-6, IL-1β and NF-κB overexpression) may also contribute to 
reduce renal EPO production. It is known that patients with anemia can switch EPO 
production from kidney to liver [70]. Indeed, the increase in liver HIF-2α, EPO and EPOR, 
supports the contribution of the liver to serum EPO levels observed in CRF rats, as 
reported by others [346, 347] (Paper I).  
The continuous hypoxic stimulation in the CRF rats may perpetuate the 
inflammatory response and the release of pro-fibrotic factors.  Indeed, the sustained 
overexpression of TGF-β1 in CRF rats, known to increase the production and 
accumulation of ECM, thus promoting fibrosis [163], may explain the increased fibrosis 
and glomerulosclerosis and the increased expression of pro-inflammatory cytokines in 
CRF rats, further aggravating renal injury. 
The use of rHuEPO in the CRF rats was able to correct the anemia in a dose-
dependent manner. Comparing all the CRF groups under rHuEPO treatment (Table 12), 
we found that the lower doses tested (CRF100 and CRF200 groups), mimicking those 
usually used to correct anemia in CKD patients, were able to improve (but still present) 
glomerular and tubulointerstitial renal lesions, to reduce renal inflammatory features, but 
not systemic inflammation (CRP levels). The higher rHuEPO doses (CRF400 and 
CRF600), representing those used in the treatment of hyporesponsive CKD patients, 
markedly improved all renal lesions and inflammation (local and systemic). However, no 
differences in GFR were observed between the untreated group and those treated with 
rHuEPO. All the treated groups presented mild tubulointerstitial lesions that could 
explain the absence of renal function improvement. Actually, mild tubular lesions 
correlated significantly and negatively with GFR and positively with serum creatinine, in 
agreement with other studies [26]. Moreover, the histopathological analysis of the 
remnant kidney of rHuEPO-treated rats showed a dysfunctional tissue adjacent to the scar 
areas that may contribute to hamper GFR improvement (Paper I). 
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Hypertension is strictly linked with CKD, being either a cause or a consequence of 
the disease. Indeed, our CRF rats showed a hypertensive state, which was generally 
ameliorated by rHuEPO therapy; however, within treated groups rHuEPO presented a 
pro-hypertensive effect in a dose-dependent manner, which can blunt the beneficial effects 
on renal function (Paper I).  
Several mechanisms have been proposed to explain the hypertension induced by 
ESA therapy [241]. In order to assess the effect of rHuEPO therapy per se, without the 
interference of CRF-induced changes, we treated normal rats with the same doses used in 
the CRF rats. We found that the hematological changes were rHuEPO dose-dependent, as 
occurred in the CRF rHuEPO-treated animals, leading to increased blood viscosity. An 
increase in blood pressure was observed in all treated animals that can result from the 
direct action of rHuEPO on the renal vessels [232, 233] and/or from the increased blood 
viscosity associated with erythrocytosis (Paper IV). 
The increasing RBC, by increasing blood viscosity, cause an increment in vascular 
resistance; however, the observed increase in SBP cannot be only explained by the 
erythrocytosis, as the lower dose used was able to induce an increase in SBP without 
significant changes in RBC, suggesting a direct effect of rHuEPO on renal vessels, 
especially on VSMC, as previously reported by others [232, 233]. Indeed, we found a 
proliferation of the medial layer of the arteries and the presence of arteriolosclerosis and 
arteriosclerosis. The regulation of blood pressure appears to be mainly associated with 
eNOS activity, as the groups with higher blood pressure presented a reduction in eNOS 
activity. After 3 weeks of rHuEPO treatment, the groups with the highest blood pressure 
presented already arteriosclerosis and several tubulointerstitial renal lesions. 
Nevertheless, the markers used in this study to evaluate renal function and injury did not 
detect alterations in renal function (Paper IV).  
These results are in accordance with data from a previous study conducted by our 
group [345], in which the treatment with rHuEPO during 9 weeks (with a dose of 
200IU/Kg BW/week) was associated with an aggravation of advanced lesions. These 
worsening features were accompanied, among others, by a rise in blood pressure, 
regardless of similar hematological values (versus Sham group), suggesting that the higher 
renal damage was mainly due to rHuEPO direct effects on renal vessel and/or to rHuEPO-
induced hypertension, rather than to increased Hb concentration and blood 
hyperviscosity. 
Functional iron deficiency is a common feature observed in CKD patients, mainly in 
patients with resistance to ESA therapy [31, 90, 279], due to the increase in hepcidin 
synthesis stimulated by inflammatory mediators [266]. Usually, CKD patients under HD 
present high levels of inflammatory markers (CRP and IL-6) and disturbances in iron 
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metabolism (lower serum iron and transferrin, and increased TSAT and ferritin) [31]. In 
our study, despite the inflammatory state, no significant changes in serum iron markers 
were observed in untreated CRF rats. It is known that hepcidin transcription is regulated 
by several factors (inflammation, TSAT, liver iron, hypoxia and erythropoiesis) and the 
preponderance of each factor is still unclear for different pathological conditions. In our 
study, the hypoxia associated to anemia in the CRF group and the stimulated 
erythropoiesis with the lowest rHuEPO dose (CRF100), seem to prevail in the down-
regulation of hepcidin mRNA levels. The higher rHuEPO doses (CRF200 and CRF400) 
induced a higher erythropoietic stimulus, increasing iron absorption to maintain iron 
availability to the higher erythropoiesis rate, thus causing hepcidin synthesis repression 
(Table 12). The highest rHuEPO dose (CRF600) endorsed an even higher erythropoietic 
stimulus and iron absorption that lead to liver iron accumulation, which induced liver 
hepcidin transcription, through the SMAD pathway [101], creating a scenario similar to 
functional iron deficiency (Paper II). Our data suggest that the rHuEPO stimulus trigger 
a first wave to achieve correction of the anemia/hypoxia (CRF100), by inhibiting hepcidin 
synthesis, favoring erythropoiesis through an increase in iron absorption. The increasing 
iron absorption seems to lead to increasing liver iron storage (CRF600) that is able to 
switch hepcidin production, triggering hepcidin transcription via BMP6/SMAD pathway. 
Thus, hepatic iron-induced hepcidin synthesis prevails over the other regulator factors.  
This increase in hepcidin is not due to inflammation (CRF600), as CRP levels were 
normal. As reported by others, it appears that in a moderate degree of renal insufficiency 
hepcidin is correlated with iron stores, but not with inflammatory markers [348]. 
Moreover, the increase in hepcidin in the CRF600 group is not due to reduced excretion, 
as GFR was similar to the other CRF groups. 
The dynamic balance between the several factors regulating hepcidin production 
was also studied in healthy rats. Therefore, once CRF is not present is these rats, 
inflammation and hypoxia (induced by anemia) were excluded, becoming erythropoiesis 
and iron the major potential regulators. The treatment with rHuEPO in healthy rats 
stimulated erythropoiesis in a dose-dependent manner, as well as iron absorption 
(rHuEPO200, rHuEPO400 and rHuEPO600), shown by the increase in duodenal DMT1 
transcription and TSAT. Contrasting with the results obtained in the CRF animals, higher 
rHuEPO doses were unable to induce an increased hepcidin synthesis; instead, we found a 
down-regulation of hepcidin transcription with the highest doses, despite the increased 
iron absorption, suggesting the supremacy of erythropoiesis over iron in the regulation of 
hepcidin in the absence of hypoxia, in order to maintain an adequate iron availability for 
Hb synthesis (Paper V). The reduction of erythropoietic activity in the rHuEPO200 
group lead to an increase in liver hepcidin and, as occurred in CRF rats, the SMAD 
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pathway is the major regulator of hepcidin transcription; however, in this case (without 
CRF) no liver iron overload was observed, and the TfR2/HJV complex is responsible for 
inducing BMP6.  
 
Table 12 – Effects of low and high doses of recombinant human erythropoietin therapy in 
chronic renal failure rats compared to untreated animals 
* compared to Sham group; § compared to no rHuEPO treatment; ↑ - increased; ↓ - decreased; ↔ - 
unchanged.  
 
Hyporesponsiveness to ESA therapy has been associated with several causes [255-
258]. In previous studies conducted by our group, we found that ESA resistance in HD 
patients is mainly linked with inflammation and functional iron deficiency [31, 90]. 
Parameters 
No rHuEPO 
treatment* 
Low rHuEPO doses§ High rHuEPO doses§ 
100 200 400 600 
Hematological data 
RBC ↓ ↑ ↑ ↑ ↑ 
Hb ↓ ↑ ↑ ↑ ↑ 
Ht ↓ ↑ ↑ ↑ ↑ 
Ret ↔ ↔ ↔ ↔ ↔ 
Serum EPO ↑ ↓ ↓ ↓ ↓ 
Biochemical data 
Serum CRP ↑ ↔ ↔ ↓ ↓ 
Serum creatinine ↑ ↔ ↔ ↔ ↔ 
CC ↓ ↔ ↔ ↔ ↔ 
GFR ↑ ↔ ↔ ↔ ↔ 
AE ↑ ↓ ↓ ↔ ↔ 
Blood pressure data 
SBP ↑ ↓ ↓ ↓ ↓ 
DBP ↑ ↓ ↓ ↓ ↓ 
MBP ↑ ↓ ↓ ↓ ↓ 
Iron metabolism data 
Iron ↔ ↔ ↔ ↔ ↓ 
Ferritin ↔ ↔ ↔ ↑ ↑ 
Tf ↔ ↔ ↓ ↓ ↓ 
TSAT ↔ ↔ ↑ ↑ ↑ 
Hepcidin ↔ ↔ ↓ ↓ ↑ 
Renal lesions/inflammatory markers 
Glomerular ↑ ↓ ↓ ↓ ↓ 
Tubulointerstitial ↑ ↓ ↓ ↓ ↓ 
Vascular ↑ ↓ ↓ ↓ ↓ 
TGF-β1 ↑ ↔ ↓ ↓ ↓ 
NF-κB ↑ ↓ ↓ ↓ ↓ 
IL-1β ↑ ↔ ↓ ↓ ↓ 
IL-6 ↑ ↓ ↓ ↓ ↓ 
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Several studies reported that ESA hyporesponsiveness is associated with progression of 
renal disease and increased mortality in CKD patients [253, 254].  
In our study, we found that a group of rats receiving the rHuEPO dose of 200IU/Kg 
BW/week (rHuEPO200NR), after an initial correction of anemia, presented a sudden 
reduction in the response to the treatment, developing anemia. As observed in the 
untreated CRF animals, high serum EPO levels were detected, mainly from hepatic origin, 
in order to compensate anemia. Serum CRP levels and renal inflammatory markers (NF-
κB, IL-1β and IL-6) increased, contributing to repress bone marrow erythropoiesis and 
renal EPO synthesis. Despite of the inflammatory features, no disturbances in serum iron 
markers used in this study were observed and a down-regulation of hepcidin expression 
was found, following the development of hypoxia. The increased serum EPO levels and the 
exogenous rHuEPO may also contribute to further inhibit hepcidin synthesis [120] 
(Paper III). 
Our data suggest that inflammation is an important determinant in 
hyporesponsiveness to rHuEPO therapy, blunting the response to both the endogenous 
(hepatic) EPO and to the rHuEPO. This hyporesponse causes the reappearance of anemia 
that contributes to worsening of renal fibrosis and to the progression of CKD, thus 
explaining the poorer outcome of non-responders CKD patients (Paper III). 
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Final remarks 
 
In conclusion, our data give further insights into i) the pathophysiology of CKD 
associated complications, ii) the impact of rHuEPO therapy on renal lesions, 
inflammation, iron metabolism and blood pressure and, iii) the pathophysiology of 
hyporesponsiveness to rHuEPO therapy and of its impact on renal disease progression.  
 
Finally, our data enable us to propose some answers to the starting question:  
 
Anemia and high therapeutic doses of recombinant human erythropoietin in 
chronic kidney disease – a linkage of risk? 
 
• A short-term treatment with high doses, used to overcome an episode of 
hyporesponse to rHuEPO, can present benefits by reducing inflammation, without 
worsening of renal lesions.   
 
• The pro-hypertensive effect during a long-term treatment, particularly with higher 
rHuEPO doses, should be considered, and carefully managed in order to avoid a 
negative cardiorenal impact. This should also be considered in non-hypoxic 
conditions. 
 
• The correction of anemia with high rHuEPO doses, by favoring erythropoiesis and 
iron absorption, can increase iron stores, inducing hepcidin synthesis that might 
contribute to hyporesponsiveness to rHuEPO therapy.  
 
• Hyporesponsiveness to rHuEPO therapy associated with inflammation aggravates 
anemia, favoring hypoxia and renal fibrosis that will further enhance the 
inflammatory response, creating a vicious cycle that promotes renal disease 
progression. 
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Anemia is a common complication in patientswith chronic kidney disease (CKD),mainly due to inadequate renal
production of erythropoietin. In hemodialysis (HD) patients this condition may be aggravated by iron deﬁciency
(absolute or functional). The correction of this anemia is usually achieved by treatment with erythropoiesis
stimulating agents (ESAs) and iron (oral or intravenous). Studies questioning the safety of ESAs (especially at
higher doses) changed the pattern of anemia treatment in CKD patients. According to the new guidelines,
when transferrin saturation is lower than 30% and ferritin lower than 500 ng/mL, a trial with iron should be
started, to avoid therapy with ESAs or at least to reduce the doses needed to treat the anemia. Recent reports
showed increasing ferritin levels, towards values above 800 ng/mL, in CKD patients treated according to the
guidelines. In this review we focus on the risks of the increased iron use to treat CKD anemia, namely, iron
overload and toxicity, increased risk of infections, as well as mortality.
© 2015 Elsevier Ltd. All rights reserved.
1. Iron disturbances in hemodialysis patients
Anemia is a common complication in patients with chronic kidney
disease (CKD). The number of CKD patients with anemia increases
with the progression of renal dysfunction [1]. Themain cause of anemia
is the inadequate production of erythropoietin (EPO), a glycoprotein
mainly produced by the kidney, responsible for the growth, differentia-
tion and reduction of apoptosis of erythroid cells in the bone marrow
[2]. Iron deﬁciency is another common cause of anemia in these patients
[3]. The high frequency of blood analysis, the surgical procedures for
vascular access and the blood loss into the hemodialyser and tubes
during the dialysis procedure contribute to reduce iron stores. A CKD
patient under hemodialysis (HD) therapy loses about 1–2 g of iron per
year through these mechanisms. Inﬂammation is another hallmark of
CKD that may lead to a “functional” iron deﬁcient anemia, as we and
others previously reported [4–10]. Actually, inﬂammation has been
proposed to play an important role in disturbances in iron metabolism.
It is known, as we found, that CKD patients under HD present high
serum levels of hepcidin [6,11], which has been described as a major
regulator of body iron homeostasis. Hepcidin, synthesized by the liver,
acts by inhibiting cellular iron efﬂux from hepatocytes, enterocytes
and iron recycling macrophages, through binding to ferroportin, induc-
ing its degradation [12]. Hepcidin synthesis is regulated by several
proteins (Fig. 1), namely, hemochromatosis protein (Hfe), transferrin
receptor 1 (TfR1), TfR2, hemojuvelin (HJV), bone morphogenic protein
(BMP6), matriptase-2 and transferrin [13–15]. In the liver, diferric
transferrin competes with TfR1 for binding to Hfe; in conditions associ-
ated with increased iron, more Hfe will be available to bind to TfR2; this
complex, TfR2-Hfe, promotes HJV binding to BMP6, triggering hepcidin
synthesis. Moreover, hypoxia and EPO, as well as twisted gastrulation
protein 1 (TWSG1), growth differentiation factor 15 (GDF15) and,
more recently, erythroferrone, all produced by erythroblasts, are also
importantmodulators of hepcidin synthesis, inducing a downregulation
of hepcidin synthesis [16,17]. Thus, HD patients under recombinant
human EPO (rHuEPO) therapy might develop an iron deﬁcient anemia
due to several factors, as blood loss and inﬂammation.
2. Treatment of anemia
Theﬁrst treatment used to correct anemia in CKDpatientswas blood
transfusion. However, the risk of transfusion reactions (immunological
sensitization), transmission of infectious agents and iron overload
triggered the search for a better treatment of anemia [18].
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The introduction of rHuEPO in the late 80s revolutionized the treat-
ment of anemia of CKD, particularly of end stage renal disease patients.
Since then, several erythropoiesis stimulating agents (ESAs) have been
approved to treat the anemia of CKD patients, differing in their half-
life (Table 1),which determines the frequency and route of their admin-
istration. They were, therefore, divided into “short-acting” and “long-
acting” ESAs. Epoetin beta and alpha are “short-acting” ESAs, with iden-
tical amino acid and carbohydrate composition to EPO, that are given 3
times per week. Recently, biosimilar epoetins have been introduced in
the market (epoetin zeta and theta), presenting therapeutic proﬁles
similar to those of epoetin beta and alpha [19].
The need to improve formulations, in order to reduce the frequency
of administration, led to the development of “long-acting” ESAs.
Darbopoetin alpha presents two additional N-linked carbohydrate
chains compared to EPO, which increase its half-life and, therefore,
allow its administration only once per week. In 2007, methoxy polyeth-
ylene glycolepoetin beta, a continuous EPO receptor activator (CERA)
was introduced, presenting a half-life of about 130 h, which reduced
its administration for once per month [20]. Peginesatide, with a longer
half-life, is a pegylated homodimeric peptide with no sequence homol-
ogy to EPO [21]; it was theﬁrst synthetic peptide approved for the treat-
ment of CKD anemia, in 2012; however, due to serious hypersensitivity
associated reactions, the productwas removed from themarket in 2013.
The introduction of ESAs reduced the need for transfusions and
improved the quality of life in CKD patients, as the treatment reduced
the symptoms and the comorbidities associated with anemia [22] and
slowed the progression of renal disease, increasing the time before
replacement therapy [23]. Although the majority of the patients re-
spond to ESA therapy, about 10% of CKD patients are hypo-responsive
[24]. To overcome this reduced response, often referred as resistance,
higher doses of ESAs are needed to achieve the target hemoglobin
(Hb) levels [4–6].
One of the causes for hypo-responsiveness to ESAs is iron deﬁciency
(Fig. 2), either absolute or functional [25]. Serum iron, transferrin and
ferritin concentrations, as well as transferrin saturation (TSAT), are
usually used to assess iron status. Plasma/serum ferritin concentration
is the only non-invasive evaluation to assess iron stores. A ferritin
value lower than 30 ng/mL in men or lower than 15 ng/mL in women
are consistent with absolute iron deﬁciency [26]; a serum ferritin
concentration higher than 300 ng/mL, along with anemia, indicates a
functional iron deﬁciency, as it usually occurs in CKD patients [6].
Serum iron and TSAT are useful to measure circulating iron, available
for delivery to bone marrow erythroid cells, for Hb synthesis. In the case
of anemia, it is important to distinguish between absolute iron deﬁciency
(low levels of iron, ferritin and TSAT), which usually is responsive to iron
therapy, from a functional iron deﬁciency (high levels of ferritin and low
iron and low/normal levels of TSAT) that results from an inﬂammatory
state. Indeed, the inﬂammatory condition triggers the production of
hepcidin, which inhibits iron absorption and mobilization, leading to
the development/worsening of anemia in CKD patients [27].
Nowadays, the gold standard treatment for anemia in CKD patients
is the administration of ESAs, associated with iron supplementation.
When ESA therapy was introduced, the patients were treated to nor-
malize hematocrit (Ht) and Hb levels. However, the ﬁrst clinical trial
evaluating the outcomes of the patients, according to their Ht, showed
that values higher than 42% were associated with increased number of
deaths [28]. The publication of other three studies [29–31] reporting
similar conclusions raised concerns about the risks associated with
normalization of Ht, and about the risks associated with the higher
ESA doses needed to achieve those Ht values. Considering the results
of these studies, the Food and Drug Administration (FDA) launched in
2007 some safety advisories, recommending that patients should not
exceed the Hb level of 12 g/dL [32]. Later, in 2011, the use of more
Fig. 1. Iron absorption and regulation of iron metabolism. Diet iron is present as either heme iron (Fe2+) or nonheme iron (Fe3+). Nonheme iron (Fe3+) must ﬁrst be reduced to Fe2+, by
duodenal cytochrome B (DcytB), before it can be transported by the divalentmetal iron transporter 1 (DMT1). Once inside the enterocyte, the newly absorbed iron enters the intracellular
iron pool. If the iron is not required by the body, it is loaded onto the iron storage protein ferritin. Iron required by the body is transferred across the basolateral membrane by ferroportin
(FPN). The export of iron also requires the ferroxidase hephaestin (HEPH). Iron is transported by transferrin (Tf) to the local where it is needed, as in the bonemarrow to erythropoiesis.
The senescent erythrocytes are phagocyted by macrophages recycling iron. Hepcidin the main regulator of iron metabolism (by blocking FPN action) is synthesized by the liver and reg-
ulated by several stimulator (+) and inhibitor (−) factors, as transferrin saturation (TSAT), inﬂammation, anemia, erythropoiesis and hypoxia. BMP6 — Bone morphogenetic protein 6;
BMP-r— BMP receptor; HFE — hemochromatosis protein; HIF — hypoxia inducible factor; HJV— hemojuvelin; IL6 — Interleukin 6; IL6-r — IL6 receptor; TFR — Transferrin receptor.
Table 1
Erythropoiesis-stimulating agents approved for CKD anemia treatment.
Short-acting Long-acting
Epoetin beta
Epoetin alpha
Epoetin zeta
Epoetin theta
Darbopoetin alpha
Methoxy polyethylene glycolepoetin beta
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conservative ESAs doses was recommended [33]. In accordance, the
Kidney Disease Improving Global Outcomes (KDIGO) and the European
Best Practice Guidelines (EBPG) Work Group made also an update to
their guidelines, recommending that Hb levels should be 11–12 g/dL,
without intentionally exceeding 13 g/dL and that a safer use of ESAs
should be adopted [24,34]. Moreover, the “Clinical Practice Guideline
for Anemia in Chronic Kidney Disease” [24] from KDIGO also stated
that CKD patients with anemia should ﬁrst start iron therapy rather
than ESAs. They suggested that CKD patients should start iron supple-
mentation when TSAT is lower than 30% and ferritin levels lower than
500 ng/mL; however, the upper safe serum ferritin level was not deﬁned.
The use of iron is now a common practice in the treatment of anemia
in CKD patients, in spite of the concerns about the increase in ferritin
levels and tissue iron overload, due to the use of high/continuous iron
supplementation.
3. Oral and intravenous iron
Supplementation of HDpatientswith iron is needed tomaintain iron
available for an adequate erythropoiesis. The decision for oral or
intravenous (IV) iron treatment should balance the beneﬁts and risks
for the patient (Fig. 2).
Oral iron formulations (Table 2) are less expensive; however, the
gastrointestinal side effects experienced by some patients (about 30%)
may reduce the effect and adherence to treatment [35,36]. Some studies
reported that IV iron therapy increases both Hb and ferritin, while oral
iron therapy increases Hb without increasing iron stores [35,36]. More-
over, most of the clinical studies evaluating oral and IV administration
reported that IV iron therapy leads to a higher increase in Hb than oral
iron therapy [36,37].
IV iron therapy is better tolerated than oral iron therapy [35,36], has
more adherence and efﬁcacy, but requires the existence of an IV access.
It has been associated with hypersensitivity reactions that, although
very rare, can be life-threatening [38]. The major risk factors for these
hypersensitivity reactions include a previous reaction to an iron
infusion, a fast iron infusion rate, multiple drug allergies, severe atopy
and systemic inﬂammatory diseases [38].
IV iron therapy is preferred for patients under HD, as they have a
vascular access already available that can be used for iron infusion. In
non-dialysis (ND) CKD patients, oral iron may be preferred to preserve
IV access. However, there is no consensus for the use of oral rather than
IV iron as ﬁrst line treatment in ND-CKD patients. Several studies have
been performed [35,37,39,40] to further clarify the efﬁcacy and safety
of oral versus IV iron supplementation in ND-CKD patients. Stoves
et al. [39], in a follow-up study along 6 months of ND-CKD patients,
found that the Hb response and ESA requirements with IV iron (iron su-
crose) or with oral iron (ferrous sulfate) supplementation were similar.
In accordance, Charytan et al. [35] and Agarwal et al. [41] reported that
both IV and oral iron therapies in ND-CKD patients resulted in similar
Hb responses, but IV iron therapy showed better results in replacing
Fig. 2. Iron deﬁciency and treatment. Iron deﬁciency can be absolute or functional according to transferrin saturation (TSAT) and ferritin values. Oral or intravenous (IV) iron can be used to
correct iron deﬁciency depending on patient characteristics.
Table 2
Iron supplements approved for CKD anemia treatment.
Oral Intravenous
Ferrous sulfate
Ferrous gluconate
Ferrous fumarate
Iron sucrose
Ferumoxytol
Ferric carboxymaltose
Iron dextran
3S. Ribeiro et al. / Blood Reviews xxx (2015) xxx–xxx
Please cite this article as: Ribeiro S, et al, Iron therapy in chronic kidney disease: Recent changes, beneﬁts and risks, Blood Rev (2015), http://
dx.doi.org/10.1016/j.blre.2015.07.006
| 209
iron stores. Conversely, Qunibi et al. [36], Van Wyck et al. [37] and the
recently FIND-CKD study [40] found that IV iron is superior to oral
iron therapy, as ND-CKD patients under IV iron therapy showed higher
Hb levels and iron stores, as well as a higher improvement in their
quality of life.
The efﬁcacy of oral iron therapy can be compromised in CKD, as
these patients usually present a low to mild degree of inﬂammation,
which leads to an increase in hepcidin levels [6,42]. This increase in
hepcidin, by reducing gastrointestinal iron absorption and decreasing
iron release from body storage sites, inhibits the use of iron for erythro-
poiesis and leads to an increase in ferritin (Fig. 1).
One of the concerns in IV iron therapy is that the used iron dose
overcomes the binding capacity of transferrin, leading to an increase
in non-transferrin bound iron (NTBI). Moreover, as transferrin levels
are usually reduced in CKD patients, this effect might be enhanced [6,
43]. The presence of NTBI can lead to the development of oxidative
stress, increasing the pro-oxidant state of these patients. In the case of
co-existence of inﬂammation and cardiovascular (CV) disease, the oxi-
dative stress may be even more enhanced. It has been also suggested
that NTBI might be a source for iron deposition in organs [44–46].
The optimization of iron delivery, given the complications associated
with IV iron therapy and the reduced oral iron adherence and efﬁcacy, is
an actual challenge to search and develop better iron formulations
(Table 2). Recently, a treatment with oral liposomal iron showed to be
a safe and efﬁcacious alternative to IV iron in ND-CKD patients [47].
Iron-carbohydrate complexes (IV formulations), presenting lower
hypersensitivity reactions than iron-dextran complexes and allowing
the gradual release of iron (instead of a cumulative iron dose), have
been developed and approved [48].
3.1. Iron overload
Iron has essential roles in several physiological processes, including
the synthesis of Hb and other hemeproteins. The body iron stores are
tightly controlled, as there is no physiological mechanism of iron excre-
tion. Iron can be stored in the body, as ferritin and hemosiderin. These
forms are found in the macrophages of the reticuloendothelial system
(liver, spleen and bone marrow) and in the parenchymal liver cells.
Serum ferritin, TSAT and reticulocyte count are used to evaluate iron
stores andbonemarrow iron availability. Ferritin levels can be increased
in the case of inﬂammation and do not seem to be correlated with he-
patic iron overload [49]. The ﬁrst test used to evaluate iron availability
to the bone marrow was performed by biopsy; as it is an invasive test,
associated with some risks, it is used only to study speciﬁc iron disor-
ders. The non-invasive techniques, as magnetic resonance imaging
and magnetic susceptometry, are new tools to evaluate iron overload
in CKD patients. However, these techniques do not distinguish between
non-bound iron and iron stored in the macrophages of the reticuloen-
dothelial system. Nowadays, the challenge is to ﬁnd new markers and
better techniques to predict iron overload [50].
The Dialysis Outcomes and Practice Patterns Study (DOPPS) [51]
showed that the number of HD patients with IV iron supplementation in-
creased in most countries; however, and evenmore important, the doses
prescribed to these patients also increased in the past 10–15 years. Over-
all, themean serum ferritin has increased over time, and the proportion of
patients with serum ferritin values ≥800 ng/mL has also increased [51].
The recent KDIGO Controversies Conference on Iron Management
in CKD (San Francisco, 2014) recognized the entity of iron overload in
HD patients. Actually, there are several studies reporting tissue iron
accumulation in HD patients treated with ESAs and IV iron (Table 3)
[49,52–54]. Canavese et al. [52] found that 70% of HDpatients presented
mild-to-severe hepatic iron overload, although the same percentage of
patients presented serum ferritin values below 500 ng/mL. Ferrari
et al. [49] reported that 60% of HD patients presented liver iron concen-
tration N60 μmol/g (above the normal upper limit of 30 μmol/g) and
13% had liver iron concentrations N130 μmol/g, which is usually found
in patients with hemochromatosis; they also found that iron liver accu-
mulation was correlated with cumulative iron dose, but no correlation
was observed with ferritin or TSAT. Recently, two other studies found
similar results [53,54]. Ghoti et al. [53] reported that 90% of HD patients
presented mild to severe hepatic iron deposition and also iron deposi-
tion in the spleen. In the other study, 84% of the HD patients had hepatic
iron overload, and in 30% of them iron overload was severe; moreover,
iron liver content correlated with infused iron [54].
In spite of the widespread use of IV iron supplementation in HD
patients, the safest dosing strategy is still poorly clariﬁed, as well as its
relation with serum ferritin levels, iron overload and mortality risk.
Actually, only few studies addressed these questions, and presented
controversial results (Table 3). Feldman et al. [55] found that HD pa-
tients receiving more than 1000 mg of IV iron in a period of 6 months
presented a higher risk of death and hospitalization, compared to pa-
tients with no iron supplementation. In a follow-up study of 2 years,
the same group evaluated the effect of each 6 months of iron exposure
and did not ﬁnd any association between the iron administrated and
mortality, but found an association between iron dose and mortality at
12 to 18 months of treatment, for iron doses higher than 1800 mg
[56]. In the ﬁrst study of this group [55], only 17% of the HD patients re-
ceived iron dosing above 1000 mg, whereas in the second study [56]
this number rose to 48%. These authors also found an association be-
tween mortality and ferritin levels N800 ng/mL in the 6 months prior
to death, but this ﬁnding could result from confounding factors, such
as inﬂammation and malnutrition [56].
Another observational study evaluating HD patients for a period of
2 years showed that serum ferritin levels in the range of 200–
1200 ng/mL, TSAT between 30 and 50% and IV iron dose b400 mg by
month were associated with improved survival, suggesting that the as-
sociation of high ferritin levels andmortality could also result from con-
founding factors [57]. A recent study [58] evaluated the effect of a bolus
of IV iron (consecutive doses ≥100 mg exceeding 600 mg during one
month) versus maintenance of IV iron therapy (all other iron doses
during the month), and also the effect of high (N200 mg over 1
month) versus low dose of IV iron (≤200 mg over 1 month); after
1 month of iron exposure, the patients were studied for a follow-up
period of 3 months; no signiﬁcant associations of bolus versus mainte-
nance dose or of high versus low dose IV iron with increased short-
term CV morbidity and mortality were found.
Zitt et al. [59] found that increasing ferritin concentrations
(N800 ng/mL) in patients with normal C-reactive protein (CRP) con-
centrations were associated with decreasing mortality, whereas in
patients with high CRP (N0.5 mg/dL) values the increasing ferritin con-
centration was linked with increased mortality, suggesting that serum
ferritin levels above 800 ng/mL are associated with increased mortality
in the case of concomitant inﬂammation. A 2-year follow-up study, by
our group [6], found that HD patients presented several changes in
iron metabolism (increased TSAT, ferritin and hepcidin and a decrease
in iron and transferrin) and inﬂammatory markers (increased interleu-
kin [IL]-6 and CRP). Patients who died during this follow-up period
showed signiﬁcantly lower values for transferrin and TSAT and in-
creased levels of IL-6 and CRP. In the adjusted survival regression
model, CRP was found to be a signiﬁcant predictor of mortality.
The recently published observational DOPPS study [60] showed that
HD patients receiving, along 4 months, 300 mg/month or even a higher
dose of IV iron supplementation, comparedwith patients supplemented
with 100–199 mg/month, presented increased hospitalization risk, all-
cause mortality and CV mortality, regardless of serum ferritin or CRP
concentrations.
Considering the controversial data in literature, there is a clear need
to develop clinical trials with longer follow-up periods of HD patients to
evaluate the effect of long-term cumulative IV iron doses and the impact
of serum ferritin levels on all-cause and CV mortality. In accordance, a
clinical trial, “The Proactive IV irOn Therapy for HaemodiALysis patients
(PIVOTAL)”, has recently started, and the aim is to compare the effect of
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IV iron high-dose versus low-dose regimen on all-cause mortality, and to
evaluate the incidence of non-fatal CV endpoints, in HD patients along 2–
3 year follow-up [61]. Another aimof this study is to compare the effect of
the two regimens on ESA dose requirements, red blood cell transfusions,
complications of HD treatment, and quality of life of the patients.
3.2. Iron toxicity
Data in literature strongly suggest the risk of tissue iron overload in
HD patients, although the underlying pathophysiological mechanisms
are less clear, especially in the case of IV administration of iron. The infu-
sion of iron may overwhelm the capacity of the iron binding proteins,
allowing iron to become free in circulation and/or to increase iron stores.
It is known that free iron can react with hydrogen peroxide leading to
the production of hydroxyl radicals that are able to trigger oxidative
modiﬁcations in lipids, proteins andDNA. Indeed, the literature supports
that after IV iron injection in HD patients a transient increase in oxida-
tive stress occurs, as shown by the increase in plasma lipid peroxidation
[62] and oxidative modiﬁcation of proteins [63]. Actually, different
markers of oxidative stress are signiﬁcantly increased in CKD patients
[64,65] and are involved in the progression of renal disease [66].
Several diseases have been associated with oxidative stress, such as
the CV diseases [67,68], which are the major cause of death in HD pa-
tients. It has been hypothesized that the oxidative stress induced by IV
iron infusion could favor atherosclerosis and endothelial cell damage.
Reis et al. [69] found that in dialysis patients the carotid intima media
thickness correlated with serum ferritin and with the IV iron dose,
corroborating the previous hypothesis. Studies in rabbit models found
that the more extensive atherosclerotic lesions contained a higher
concentration of iron and that the formation of these lesions may be
accelerated by free radical production, caused by increased iron levels
[70,71]. Kuo et al. [72] reported that CKD patients who had received IV
iron sucrose preparation presented increased superoxide production
by circulatingmononuclear cells and increased expression of soluble ad-
hesion molecules and of mononuclear-endothelial adhesion molecules,
when compared with untreated CKD patients or healthy subjects. In the
same study, the authors corroborated their results by showing thatmice
with uninephrectomy treated with IV iron presented increased tissue
superoxide production, increased expression of tissue cell adhesion
molecules, endothelial adhesiveness and exacerbated atherosclerosis
in the aorta. These effects seem to be dependent on IV iron formulation
used, as reported by Toblli et al. [73].
NTBI might be important for extrahepatic iron deposition and toxic-
ity, namely, in the kidney. Progressive tubulointerstitial damage and
renal ﬁbrosis are common pathways in the development of CKD and
iron deposition could favor these lesions. Indeed, iron accumulation is
observed in the proximal tubule in human CKD [74], as well as in
rats with nephropathy [75–78], and seems to be associated with the
progression of CKD. In a study by our group, using a rat model of ne-
phrectomy, we found iron deposition in tubules, along with extensive
tubulointerstitial lesions [78]. Recently, in a similar model, Naito et al.
[76] reported that the animals with renal failure, treated with oral iron
Table 3
Studies evaluating iron overload and mortality risk associated with intravenous iron therapy in dialysis patients.
Year Patients Iron dose/follow-up time Outcome Ref.
Iron overload 2012 HD patients
(n = 119)
100 mg of iron sucrose
(2–3×/w — induction phase; 1×/w every
4 w —maintenance phase)
60 mo follow-up
• 84% of patients with hepatic iron deposition,
30% of them with severe iron overload
• Iron liver content correlates with infused iron
[54]
2012 HD patients
(n = 21)
100 mg (ferric saccharate) 1–3×/w
12 mo follow-up
• 90% of patients with mild-to-severe hepatic iron deposition
• 95% of patients with splenic iron deposition
• 14% patients with pancreatic iron deposition
[53]
2011 CKD patients
(n = 25)
50 to 200 mg/mo for 12 mo • Liver iron concentration: 60% of patients N60 μmol/g;
13% of patients N130 μmol/g (reference value 30 μmol/g)
[49]
2004 HD patients
(n = 40)
31.25 mg ferric gluconate complex
10 patients: maintenance iron at least 6 mo
30 patients: without iron therapy at least 2 mo
(after ferritin N500 μg/L)
• 70% of patients with mild-to-severe hepatic iron overload
• 70% of patients with ferritin b500 ng/mL
[52]
Mortality 2015 HD patients
(n = 32,435)
4 mo-follow up of IV iron dose: b300 mg/mo
versus ≥ 300 mg/mo
• ↑ mortality among patients with higher doses
of IV iron (≥300 mg/mo over 4 mo), regardless
serum ferritin or CRP values
[60]
2014 Dialysis patients
(n = 235)
7.6 year-follow up with continuous maintenance
iron therapy once/w in varying doses: 12.5 mg
(minimum dose) to 62.5 mg (maximum dose)
• ↑ mortality with ferritin levels N800 ng/mL in the
case of concomitant inﬂammation (CRP N 0.5 mg/dL)
[59]
2013 HD patients
(n = 117,050)
3 mo-follow up after 1 mo exposure to:
high dose (N200 mg) versus low dose (1–200 mg)
bolus (consecutive doses ≥100 mg exceeding 600 mg
during one month) versus maintenance dose
• No signiﬁcant associations of bolus versus maintenance
dose or high dose versus low dose IV iron with increased
short-term cardiovascular morbidity and mortality
[58]
2005 HD patients
(n = 58,058)
Iron gluconate effect in a 2 year-follow up,
with different iron dose categories: 0 mg/mo;
1 to 199.9 mg/mo; 200 to 399.9 mg/mo; N400 mg/mo
• Ferritin 200–1200 ng/mL, TSAT 30–50% and IV iron
dose b400 mg/mo associated with improved survival
[57]
2004 HD patients
(n = 27 280)
Effect of iron administration in a 2 year follow-up,
with iron doses categories at each 6 mo: N0 to 700 mg;
N700 to 100 mg; N1000 to 1800 mg; N1800 mg
• No association between iron administrated and mortality
• Association between iron dose and mortality
at 12 to 18 mo of treatment, for doses N1800 mg
• Association between mortality and ferritin N800 ng/mL
in the 6 mo prior to death
[56]
2002 HD patients
(n = 10 169)
Number of 100-mg vials of iron during 6 mo • ↑ risk of death and hospitalization with IV iron N1000 mg [55]
CRP — C reactive protein; HD— hemodialysis; IV— intravenous; mo —month; w —week.
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chelators, showed a reduction in interstitial ﬁbrosis, suggesting that
renal iron accumulation is associated with renal interstitial ﬁbrosis,
promoting the progress of renal disease.
3.3. Association of iron therapy with infection
In vitro studies show a relationship between the availability of iron
and bacterial virulence, as iron is important for bacteria multiplication
in the host. Therefore, clinical conditions associated with iron excess
in the host may increase the risk for infection [79]. Clinical studies
reported different results about the linkage of IV iron therapy with in-
fection. One study observed a signiﬁcantly higher rate of bacterial infec-
tion with higher IV iron saccharate dose, but not with higher frequency
of dosing administration [80]. A one year follow-up study of HD patients
examined the relationship between iron stores, IV iron dosing and
bacteremic risk, and found that patients with higher iron stores had a
signiﬁcantly higher risk of bacteremia; however, they did not ﬁnd an
IV iron dose–response relationship [81]. Brewster et al. [82] reported
that IV iron did not signiﬁcantly increase the rate of microorganism
growth within catheters or the development of blood infections with
iron supplementation. After the recent changes in the pattern of IV
iron treatment [24], Bansal et al. [83] in a 2 year follow-up study of
HD patients treated with IV iron found a signiﬁcant increase in TSAT
and in serum ferritin; however, it was not associated with an increase
in the incidence of infectious complications. In a retrospective cohort
study of HD patients, those receiving bolus versus maintenance iron
therapy were at increased risk of infection-related hospitalization [84].
Recently, Kuragano et al. [85] found that patients with a higher ferritin
level had a higher risk of infectious disease than those with lower
ferritin level. They also found that the risk of infection and hospitaliza-
tion were signiﬁcantly higher among patients who were treated
with high weekly doses of IV iron, compared with no iron. An observa-
tional study that included 14,078 patients reported the possibility of
infection-related mortality with higher iron doses [86].
The type of IV iron formulationmight have also an impact in the rate
of infection, as suggested by Sirken et al. [87], that found a higher bacter-
emia rate with iron sucrose thanwith ferric gluconate; however, a rela-
tionship between IV iron dose and bacteremia was not supported.
Randomized clinical trials are needed to assess the effect of cumulative
IV iron doses and the risk of infection-related mortality.
4. Conclusions
The new protocol for anemia management, in accordance with the
recent published guidelines “Clinical Practice Guideline for Anemia in
Chronic Kidney Disease” from KDIGO [24], contributed to an increase
in the frequency and in the dose of iron used to treat anemia of CKD
patients. Higher values of TSAT and ferritin have been found in dialysis
patients, raising concerns about iron overload. Data reported in litera-
ture alerts to the safety of cumulative higher iron doses in dialysis
patients, as they seem to be associated with increased risk of iron
overload, toxicity and infection, which can lead to an increased risk of
mortality in these patients. Actually, there is a need to clarify the effect
of the actual iron dosing in CKD patients and its effect on mortality.
Practice points
• Iron deﬁciency (absolute or functional) is a common cause of anemia
in CKD patients.
• The number of HD patients with IV iron supplementation and the
prescribed doses increased in the past years.
• The prevalence of HD patients with ferritin levels above 800 ng/mL
has increased.
• Iron overload in HD patients has been reported in several studies;
however, the relationship between iron overload and mortality risk
is not clear.
• Serum ferritin is not always a predictor of iron overload, due to
confounding factors, as inﬂammation and malnutrition.
• Non-invasive techniques, asmagnetic resonance imaging andmagnetic
susceptometry, are new tools to evaluate iron overload in CKD patients.
Research agenda
• Clinical trials to evaluate the association between high iron doses, iron
overload and mortality risk in HD patients.
• Basic and clinical research is still needed to ﬁnd better markers and
assays to evaluate iron overload.
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